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ABSTRACT

Taylor, Sarah E., Ph.D., University of South Alabama, December 2021. The Effect of
Medication on Cognition: Information from a Clinical Sample Using a Semi-Flexible
Battery of Common Neuropsychological Tests. Chair of Committee: Benjamin D. Hill,
Ph.D.
BACKGROUND: Prescription medications are widely used, particularly among older
adults, with 46% of adults overall and 85% of older adults (65 years old and older) using
at least one medication (Martin et al., 2019). Three percent of adults overall and 39% of
older adults use 5 or more medications, constituting polypharmacy (Kantor et al., 2015).
While there are many medications, as well as polypharmacy, that are known to have
cognitive effects, many other widely used medications have been inconsistently
associated with changes in cognition. Additionally, the degree of change, independent of
effects of a possible underlying neurodegenerative process, is unknown. This is
problematic for physicians, specifically neuropsychologists, who are tasked with
evaluating cognition and providing differential diagnoses for potential cognitive change.
OBJECTIVES: The current study sought to evaluate the effects of medication and
polypharmacy on global and domain specific cognitive functioning in a broad clinical
sample of adults using a comprehensive battery of neuropsychological tests. METHODS:
Seven hundred and fifty archival neuropsychological data files were reviewed for
inclusion. Four hundred and ninety-seven cases were ultimately retained for analyses
(mean age = 40.75, SD = 14.61, range = 18-80 years). Most of the sample identified as
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female (52%) and Caucasian (94%). The number of medications used by study
participants ranged from 0 to 14 (M = 2.64, SD = 2.50) and 11.3% reported taking 6 or
more medications. All participants completed a large flexible battery of common
neuropsychological tests, which allowed for calculation of overall test battery
performance and cognitive domain specific performances. RESULTS: Two-way
Analyses of Covariance analyzed the interaction and main effects of specific medication
groups and polypharmacy on global cognitive performance, as measured by the overall
test battery mean and intra-individual variability. Significant main effects of analgesics,
triptan, polypharmacy on IIV were identified. No significant interaction or main effects
were identified for two-way Multivariate Analyses of Covariance evaluating the effects
of medication and polypharmacy across nine cognitive domains. CONCLUSIONS:
Subjects taking analgesic medications, and medications from the triptans drug class,
showed more cognitive variability over the course of a neuropsychological evaluation,
compared to those not taking these medications. Additionally, subjects without
polypharmacy showed more cognitive variability than those taking more than 5
medications and those who were not taking any medications. Study limitations and
clinical implications of these findings are discussed.

xviii

CHAPTER I
INTRODUCTION

The percent of adults and older adults in the population is steadily increasing. By
2030, The United Nations Department of Economic and Social Affairs, Population
Division (UN; 2019) estimates that in the United States (US), 77% of the population will
be over the age of 20 and 37% of the population will be over the age of 50. These are 5%
and 11% increases in the size of these age groups since 1990. The UN estimates that
these US age cohorts will continue to increase in size over the next 20 years to include
78% and 41% of the total US population, respectively, in the year 2050.
One explanation for the increased population of adult and older adult cohorts in
the US is the overall increase in life expectancy, following a reduction in death rates in
late life (Zhaurova, 2008). For example, declines in smoking rates have led to fewer
deaths due to cardiovascular disease (Silverstein et al., 2001; Stewart et al., 2009).
Availability of Medicare coverage for individuals over the age of 65 has improved access
to health interventions for older adults in the US, including access to prescription
medication (Crimmins, & Beltrán-Sánchez, 2010). Additionally, a greater focus on
prevention of disease and evolution of medical treatments have lowered the instances of
fatalities due to heart attack, stroke, and cancer (Baigent et al., 2005; Law et al., 2009).
However, longer life expectancies do not necessarily equate to a healthier population of
adults and older adults.
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For example, rates of obesity have increased drastically since the 1980s across all
age groups (Flegal et al., 2016; Ogden et al., 2006). Similarly, prevalence rates for
arthritis and musculoskeletal problems have been on the rise (Reynolds et al., 1998).
Biomarker trends indicate that individuals between the ages of 40 and 64 are being
diagnosed and treated for hypertension and high cholesterol more than in previous years
(Martin et al., 2010). Additionally, trends of higher C-reactive protein (CRP) levels, an
indicator of body inflammation, in men and glycated hemoglobin levels, an indicator of
excess sugar and possible uncontrolled diabetes, in women between the ages of 40 and 64
are evident (Martin et al., 2010).
These changes are consistent with data from the Center for Disease Control and
Prevention (CDC) showing significant increases in adult obesity since 1999 (Hales et al.,
2017). Moreover, evidence from the National Health Interview Survey generally shows
increases in heart disease, heart attacks, stroke, cancer, and diabetes in men over 30 and
women over 40 (Crimmins & Beltrán-Sánchez, 2010). Further, the rates of comorbidity
as well as the number of comorbid diseases prevalent in older adults are significantly
higher than in previous decades (Crimmins & Saito, 2000). Recent estimates suggest that
most community dwelling older adults are diagnosed with two or more chronic
conditions (Barnett et al., 2012). However, for individuals residing in care facilities, the
number of comorbid conditions is significantly higher. One study conducted in Germany
reported that individuals in residential care facilities averaged 17 chronic conditions
(Akner, 2009).
However, not all prevalence rates are rising. Specifically, over the past decade,
incidents of high cholesterol and hypertension appear to be declining (Crimmins et al.,
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2005; Crimmins et al., 2010). Given the relations between high cholesterol and
hypertension with heart disease and stroke (Johnson et al., 2014), the leading and fifth
leading causes of death in the US (Murphy et al., 2018), respectively, these findings
support a decrease in late life mortality. Yet, in the context of the biomarker trends
described above, it is most likely that these declines are attributable to the use of
prescription drugs to treat or manage these diseases rather than a reduction in diagnoses
of these conditions altogether (Crimmins & Beltrán-Sánchez, 2010).
Thus, while more people are living into older adulthood, disease morbidity
appears to be expanding. This fact is supported by the widespread use of prescription
medications to both prevent and treat conditions plaguing adults and older adults. A
national US survey conducted in 2011 and 2012 indicated that 59% of adults over the age
of 20 reported using one or more prescription medications (Kantor et al., 2015). Fifteen
percent of these adults reported using 5 or more medications (Kantor et al., 2015). For
Americans over the age of 65, 90% reported using one or more prescription medications
and 39% reported using five or more prescription medications (Kantor et al., 2015).
These numbers are generally consistent with international trends of medication
use. Across all age groups, in the United Kingdom (UK), 43% of patients were prescribed
at least one regular prescription medication by their primary care physician and generally
averaged four regular prescription medications (Petty et al., 2014). However, when
focusing specifically on community-dwelling older adults, data from the UK (Clague et
al., 2016; McLean et al., 2017; Petty et al., 2014), Norway (Andersen et al., 2011), and
Spain (del Ser et al., 2019) suggest that 70% to 95% of patients used at least one
prescription medication and on average took between three and four different drugs or
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medications, concurrently. Therefore, most adults and older adults in the US and
internationally regularly use medications.
While the use of these medications in pharmacotherapy are ideally effective, safe,
and selective in their effects, there is no guarantee that any drug will be without
unintended side effects, such as a decline in cognitive functioning (Burchum &
Rosenthal, 2016; Jyrkkä et al., 2011; Maher et al., 2014; Martin et al., 2000). For
example, opioids (Allegri et al., 2019), anticholinergic medications (Risacher et al.,
2016), certain bladder relaxants (Obermann et al., 2013), and various antiepileptic
medications (Nevado-Holgado et al., 2016; Park & Kwon, 2008; Stein & Strickland,
1998), have been associated with cognitive decline. Additionally, polypharmacy (use of
five or more drugs) and excessive polypharmacy (use of 10 or more drugs) have been
associated with changes in cognitive functioning (Jyrkkä et al., 2011; Sordahl et al.,
2019).
In the US, a subset of these side effects is identified in clinical trials, prior to
general use of the drug, as approved by the Food and Drug Administration (FDA).
However, while clinical trials are typically conducted in samples composed of 500 to
5000 patients, patient samples rarely include older adults, patients on multiple regular
medications due to comorbidities, or other cognitively vulnerable populations (Boyd et
al., 2012; Burchum & Rosenthal, 2016; Cho et al., 2011; McMurdo, 2005). Additionally,
only a few hundred patients participating in clinical trials test the prescribed medication
for more than 3 to 6 months (Burchum & Rosenthal, 2016).
Therefore, some variations in pharmacokinetics and pharmacodynamics across
patient populations and long-term effects of many prescription drugs may not be properly
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vetted prior to their widespread use (Katzung, 2018). Further, neither clinical testing nor
FDA approval is required for combination medications prior to their public release (FDA,
2017). Instead, FDA investigations into the safety of a combination medication only
occur after public health concerns are reported (FDA, 2017).
The combination of high use patterns of prescription medications (Andersen et al.,
2011; Clague et al., 2016; del Ser et al., 2019; Denison et al., 2012; Kantor et al., 2015;
Kelly et al., 2005; McLean et al., 2017; Petty et al., 2014; Qato et al., 2008) and the
limitations in evaluations of the effects of these drugs (Burchum & Rosenthal, 2016; Cho
et al., 2011; FDA, 2017) suggests that there are more side effects of using currently
available drugs than we are presently aware. Many of these possible side effects may
directly or indirectly impact cognitive functioning. This creates a challenge for physicians
across professional fields in determining the etiology of changes in a patient’s cognitive
functioning. Neuropsychologists, in particular, who spend over three-fourths of their time
evaluating the cognitive abilities of adults (Rabin et al., 2016), must be able to determine
the effects of specific drugs or interactions between multiple drugs to accurately interpret
results from neuropsychological assessments. Without accurate and thorough studies
evaluating these potential effects on cognitive functioning, implications may include
inappropriate diagnosis, delayed treatment of appropriate diagnosis, use of potentially
inappropriate medications (PIMs), increased or subsequent adverse drug reactions (e.g.,
falls or delirium), financial cost of increased medical care, motor vehicle accidents,
irreversible cognitive impairments, and financial and psychological costs of loss of
employment.
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Therefore, to further the understanding of medication effects in the context of
neuropsychological assessment, this study will examine the effects of medication on
cognition in a clinical sample using a semi-flexible battery of common
neuropsychological tests. The following literature review summarizes relevant concepts
of clinical pharmacology and information on patterns of medication use. Additionally,
this review will explore research regarding the effects of various clinical pharmacology
and polypharmacy on cognition and ways to measure these effects.
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CHAPTER II
LITERATURE REVIEW

Clinical Pharmacology
The field of clinical pharmacology is concerned with all aspects of how drugs
function in humans, where a drug is defined as any chemical that impacts life (Burchum
& Rosenthal, 2016). This includes the study of drugs and drug interactions across clinical
and non-clinical (i.e., healthy) populations. Therefore, the basic principles of clinical
pharmacology apply to the development and testing of new drugs, as well as to the use of
established drugs to prevent or treat disease (Katzung, 2018). Theoretically, these basic
principles are grounded in a shared goal: to develop and use a drug/drugs to safely and
reliably create desired responses, without side effects or unintended interactions.
However, the innumerable complexities of the interactions between biophysiology,
biochemistry, genetics, psychology, and other processes that contribute to human
functioning all but preclude the possibility of ever developing a “perfect drug.”
Consequently, the primary objective in the medical use of drugs is to maximize the
benefits of therapeutics while minimizing harm (Burchum & Rosenthal, 2016; Katzung,
2018).
Ultimately, therapeutic outcomes depend on many different factors that can be
related to the patient, the drug, the treating physician, or the surrounding environment.
Although, the drug response within the human body is arguably the factor of greatest
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consequence, given the primary objective of pharmacotherapy. Specifically, if the
response is too high, the drug will accumulate throughout the body, leading to toxicity
(Burchum & Rosenthal, 2016). Conversely, if the response is too low, concentrations of
the drug in the bloodstream will decrease, leading to possible treatment failure.
In each of these cases, the harm created by the inappropriate intensity of the drug
reaction outweighs the benefits. When the strength of the drug is too low, there is no
benefit of pharmacotherapeutics. Additionally, given the possibility that drug exposure,
and subsequent treatment failure, increases drug-resistance of the disease or diagnosis, a
low intensity drug reaction may cause more than minimal harm (Martinez et al., 2012).
On the other hand, severe adverse effects have been associated with drug toxicity, such as
the development of delirium, dementia, and even death (Moore & O’Keeffe, 1999).
Therefore, when a drug is administered, ensuring that the intensity of response will be
appropriate is essential to achieving the primary therapeutic objective in clinical
pharmacology. Several factors that contribute to variations in the intensity of a drug
response, which may lead to overall harmful or negative drug effects, are explored below.

Factors Related to Drug Intensity
Drug Administration.
First, variables related to drug administration can significantly affect the strength
of a drug. Specifically, dosage, route of administration, and frequency or timing of an
administered medication could lead to very high or very low concentrations of a drug in
the bloodstream (Burchum & Rosenthal, 2016; Katzung, 2018). Therefore, specific drug
dose regimens that dictate these factors (e.g., 30 mg, once daily, at bedtime, taken orally)
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are designed to achieve steady-state drug concentrations that provide the most benefit
from therapeutic drug intervention while minimizing drug toxicity (Brandt, 2013;
Martinez et al., 2012). However, medication errors contribute to variability in drug
dosage, route of administration, and timing that affect the intensity of the drug reaction.
Pharmacokinetics.
Pharmacokinetics, which determine how drugs move into, through, and out of the
body in four basic processes (i.e., absorption, distribution, metabolism, and excretion),
also plays a role in determining drug reaction intensity (Stahl, 2013). Absorption is the
process by which a drug moves from the administration site into the blood (Burchum &
Rosenthal, 2016). Distribution is the process by which a drug moves throughout the body,
from the blood and into cells. Metabolism is the process by which drugs are altered or
transformed by enzymes (i.e., enzymatic alterations) to promote excretion. Excretion is
the process by which drugs are removed from the body. Ultimately, these processes work
collaboratively to determine the how much of a drug arrives to the sites of action and how
long the drug remains at its sites of action (Katzung, 2018). However, factors related to
absorption and elimination (i.e., metabolism and excretion) have unique roles throughout
this process that impact the intensity of a drug response.
Specifically, the amount of drug that is absorbed following drug administration
and how quickly the drug is absorbed are the first factors that contribute to the strength of
a drug response. Essentially, higher and more quick absorption leads to greater
accumulation of the drug in the body, whereas lower and slower absorption leads to a
smaller accumulation of the drug in the body (Burchum & Rosenthal, 2016; Katzung,
2018). The concentration of the drug in the body can be altered again based on the
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outcomes of the metabolism. In addition to altering drug compounds to improve
excretion, the results of enzymatic alterations can include activation or deactivation of
compounds or enhanced effects of an administered drug (Burchum & Rosenthal, 2016).
Enzymatic alterations that activate previously inactive compounds (i.e., prodrug) or
enhance the effect of the drug may increase the concentration of the drug in the body,
potentially to toxic levels (Katzung, 2018). Enzymatic alterations that deactivate drugs,
on the other hand, reduce the concentration of the active drug in the bloodstream
(Burchum & Rosenthal, 2016).
The pharmacokinetic variables that impact the intensity of a drug response
described up to this point are generally inherent to pharmacokinetic processes. However,
additional variables that depend on the individual, the drug, and circumstance of
pharmacotherapeutics may also impact pharmacokinetic processes and thus, the intensity
of a drug response. For instance, age, genetics, frailty, and malnutrition have all been
associated with reductions in drug metabolism (Katzung, 2018; Kinirons & O'Mahony,
2004). Therefore, rather than maintaining the concentration of the drug through
converting the drug to an inactive form and excreting it at a regular rate, the active drug
accumulates. This leads to an increase in the concentration of the drug in the system.
Similarly, the process of excretion slows dramatically for individuals with chronic kidney
disease and those diagnosed with renal failure, conditions that are most common among
individuals over the age of 65 (CDC, 2019). Since excretion primarily occurs in the
kidneys, slowed excretion of the drug increases the intensity of the drug response
(Burchum & Rosenthal, 2016).
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Additionally, specific properties of a drug may allow it to induce or inhibit drugmetabolizing enzymes during the process of metabolism, which in turn impact the drug
reaction. If drug-metabolizing enzymes are induced, the concentration of the drug will
decline and reduce the intensity of the drug reaction (Burchum & Rosenthal, 2016).
Conversely, if drug-metabolizing enzymes are inhibited, then the concentration of the
drug will rise and increase the intensity of the drug reaction. Finally, competition for
metabolism may occur if two or more drugs utilize the same metabolic pathway
(Katzung, 2018). This competition could result in reduced metabolism for one or both/all
of the drugs involved, thereby allowing for the drug(s) to accumulate in the system.
Pharmacodynamics.
While pharmacokinetics determine how much of an administered dose gets to its
sites of action and how long the drug remains active there, pharmacodynamics dictate the
intensity and type of reaction a drug has when it is at its sites of action (Burchum &
Rosenthal, 2016). To initiate this process, a drug interacts with either a drug binding
receptor or other small molecules. This interaction produces a series of events that lead to
the drug response. At this stage, much of the intensity of a drug response is due to the
dose-response relationship, which is a drug-specific relationship between the size of the
administered dose and the intensity of the drug’s response (Katzung, 2018). However,
this relationship is moderated by factors such as the functional state of the patient, drug
tolerance or sensitivity, and placebo effects (Burchum & Rosenthal, 2016).
Individual Differences.
Patient-specific factors involved in determining the intensity of a drug response
explain differences in drug responses between individual patients (Burchum & Rosenthal,
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2016). Although some of these factors were discussed above in terms of their
relationships with pharmacokinetic processes, individual differences can impact
pharmacokinetics and pharmacodynamics more broadly to alter the intensity of a drug
response. Generally, these factors are categorized in three domains: physiological
variables, pathological variables, and genetic variables.
Physiological variables that moderate the intensity of drug responses include age,
gender, weight, hormonal status, diet, and oxidative stress (Bailey, 1983; Burchum &
Rosenthal, 2016; Deavall et al., 2012; Katzung, 2018). Pathological variables that
moderate the intensity of drug responses include impairment of the liver, impairment of
the kidneys, frailty, and chronic brain pathology (Katzung, 2018; Kinirons & O'Mahony,
2004; Moore & O’Keeffe, 1999). Genetic predispositions to drug reactions also moderate
the intensity of drug responses (Katzung, 2018). While these individual difference
variables do not constitute a comprehensive list of patient characteristics, individual
variation must be considered both in terms of individual contributions to drug intensity,
as well as with regard to interactions between these differences and pharmacokinetic and
pharmacodynamic processes in order to maximize the benefits while minimizing harm in
pharmacotherapeutics.
Drug Interactions
A further consideration in pharmacotherapeutics involves drug interactions. This
can include interactions among two prescribed drugs. Although an administered drug
may also interact with food, tobacco, caffeine, or other substances in the body. When
drugs interact, there are three possible outcomes: the effects of one drug intensifies
(potentiative), the effect of one drug reduces (inhibitory), or the interactive/combined
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effect is a new reaction that is not seen when either drug is used individually (Burchum &
Rosenthal, 2016). This is similar to the concept of agonists and antagonists for specific
substances but refers specifically to drug interactions. Potentiative and inhibitory
outcomes may influence therapeutic effects positively by both increasing therapeutic
effects and decreasing adverse effects, respectively (Burchum & Rosenthal, 2016).
However, potentiative and inhibitory outcomes could also negatively impact therapeutic
effects. Specifically, potentiative interactions may increase adverse effects and inhibitory
interactions may reduce therapeutic effects (Burchum & Rosenthal, 2016). Not much is
known about the implications of interactions in which a new response, not produced
when either drug is used independently, occurs as this outcome is rare (Burchum &
Rosenthal, 2016).
Mechanisms of Interaction.
There are four mechanisms in which drugs interact: direct interactions, combined
toxicity, pharmacokinetic interactions, and pharmacodynamic interactions (Burchum &
Rosenthal, 2016). Direct interactions occur due to the physical or chemical properties of
the drugs involved and generally result in both drugs becoming inactive (Burchum &
Rosenthal, 2016). Although direct reactions can occur inside the body, water inside the
body dilutes a drug following administration, so this is less likely to occur (Burchum &
Rosenthal, 2016). Combined toxicity occurs when two drugs that are toxic to the same
organ are administered (Burchum & Rosenthal, 2016). This results in greater toxic effects
and more injury to the patient than if the drugs were not combined in
pharmacotherapeutic treatment.
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Pharmacokinetic interactions, on the other hand, can affect any of the four basic
pharmacokinetic processes (Burchum & Rosenthal, 2016), although only alterations in
metabolism will be specified here given its complexity. All pharmacokinetic interactions
either enhance or reduce the primary process for the other drug (see pharmacokinetics
section above) and oftentimes have implications for drug treatment. Specifically, in terms
of metabolism, some drugs induce or increase the metabolism of other drugs by
increasing enzymes that process the other drug (i.e., synthesizing; Katzung, 2018).
Ultimately, this can increase the rate of metabolism of the other drug by a factor or two or
three in a week-long period (Burchum & Rosenthal, 2016). After an increase in
metabolism, the rate of metabolism will not return to normal until after the inducing
agent is removed. Conversely, some drugs may decrease metabolism of another drug by
inhibiting enzymes that would metabolize the other drug (Katzung, 2018). In some cases,
inhibition of drug metabolism can be beneficial, however, generally there are many
adverse effects (Burchum & Rosenthal, 2016).
Pharmacodynamic interactions can either occur at the same receptor or at separate
receptors and can be potentiative or inhibitory (Burchum & Rosenthal, 2016). Although
Burchum and Rosenthal (2016) note that interactions occurring at the same receptor are
almost always inhibitory. These types of interactions can have significant implications for
drug treatment. For example, interactions occurring at the same receptor may serve to
reduce beneficial therapeutic effects or reduce toxicity. Interactions occurring from drugs
acting at separate sites can also be potentiative or inhibitory, but only if both drugs
influence the same physiological process (Burchum & Rosenthal, 2016).
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Clinical Significance.
Overall, drug interaction is another factor in which drug intensity may be altered.
However, the specific responses that may occur for any particular interaction are
dependent on the therapeutic response and mechanisms of action for each drug involved.
Nevertheless, any drug interaction has the potential to impact therapeutic effects. In some
circumstances, this can be beneficial, such as when an interaction increases the
therapeutic effect of a drug or reduces toxicity. Although, in other circumstances,
interactions can be detrimental due to reduced therapeutic effects or increased toxicity.
Awareness of these potential outcomes are particularly important for drugs with a
narrow therapeutic range. These drugs are particularly sensitive to interactions, with
slight increases in the concentration of the drug leading to drug toxicity and slight
reductions in the drug concentration leading to treatment failure (Burchum & Rosenthal,
2016). Additionally, the risk of harmful interactions increases as the number of drugs
administered increases. While a large number of important interactions have been
identified, allowing for some detrimental effects to be reduced, many more have not been
identified (Burchum & Rosenthal, 2016). Therefore, significant risk of harmful effects
remains when large numbers of drugs are prescribed and interact.
Regulation of Drugs
Some of the risk of a potential harmful effect is evaluated through assessments of
a drug’s basic properties, such as pharmacokinetics (i.e., absorption, distribution,
metabolism, excretion), drug functioning in healthy participants, and drug functioning in
clinical samples, per FDA guidelines (Burchum & Rosenthal, 2016). However, even after
a drug is considered “safe” and “effective” by FDA standards (see FDA, 2017) and
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approved for general use, questions remain regarding the potential for various side effects
(Katzung, 2018). This is particularly true for adults with co-morbidities and older adults,
who may be more sensitive to cognitive effects and who are often excluded from
participation in clinical trials (Boyd et al., 2012; Cho et al., 2011; McMurdo, 2005).
Additionally, the subtlety with which many cognitive effects may occur suggests that it is
unlikely for most cognitive changes to be identified during the clinical trial phase of drug
testing.
Given these limitations in the regulation of drugs and the sizeable potential for
previously undetected cognitive effects accompanying their use, it would follow that
many patients and physicians alike would be wary of the widespread use of medications.
However, current estimates suggest that this may not be the case (Kantor et al., 2015;
Martin et al., 2019). In an effort to elucidate the magnitude of potential risk for cognitive
effects of prescription medication, the following section will review patterns of
medication use and characteristics of persons who use prescription medications.

Patterns of Medication Use

Prescription Medications Over Time
Despite the need for further testing after FDA approval to fully understand the
effects of many commonly used medications, specifically with regard to cognitive sideeffects, the use of prescription medications has steadily risen until recent years. In an
analysis of data from National Health and Nutrition Examination Survey (NHANES),
Kantor and colleagues (2015) found that 51% of adults in the US population were
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prescribed one or more medications between 1999 and 2000. Two years later, the
proportion of individuals over the age of 20 prescribed at least one medication rose to
54% (Kantor et al., 2015). By 2005 and 2006, Kantor and colleagues found that the
prevalence of using any prescription medication for adults in the US was 55%. These
estimates are generally consistent with data from Che and colleagues’ (2014) survey of
prescription medication use in Wisconsinites from 2008 to 2010, in which 54% of
Americans between the ages of 21 and 74 reported using at least one prescription
medication. The most recent data analyzed from Kantor et al. (2015) was from 2011 and
2012. At that time, 59% of Americans over the age of 20 were prescribed at least one
medication (Kantor et al., 2015).
However, there is significant variability in reported rates of medication use across
studies. For example, data collected from 2009 to 2011 examining the rates of medication
use in community-dwelling adults over the age of 50 found that 69% of participants used
one or more prescription medications (Peklar et al., 2014). Contrarily, in a 2010 to 2011
study of medication use in community-dwelling adults between the ages of 62 and 85,
approximately 88% used prescription medications (Qato et al., 2016). A third study
analyzing data from 2011 found that 75% of adults over the age of 60 were prescribed at
least one long-term medication (Petty et al., 2014). While these differences are likely due
to a combination of methodological differences and sample specific factors, described in
more detail below, the extent of variability in these estimates demonstrates the challenges
in comparing rates of medication use across studies.
To date, no known studies examine the rates of prescription medication use
combining adult and older adult age groups in the most recent decade to directly compare
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with Kantor and colleagues’ (2015) previous work. However, a US National Center for
Health Statistics (NCHS) brief noted that between 2015 and 2016, 47% of adults between
the ages of 20 and 59 reported using one or more prescription drugs (Martin et al., 2019).
Alternatively, 85% of adults over the age of 60 reported using one or more prescription
drugs (Martin et al., 2019). Overall, the rates of prescription drug use across all ages were
lower than rates from nearly a decade prior in 2007-2008 (rates of 46% and 48%,
respectively; Martin et al., 2019). When examining adult (20-59) and older adult (60+)
age groups separately, slight declines were observed for both adults and older adults
(Martin et al., 2019). Although neither of these reductions in prescription drug use from
2007-2008 to 2015-2016 were statistically significant. Therefore, it is possible that rates
of prescription medication use are leveling or even declining for adults. Nevertheless, use
of prescription medications continues to be very high.
Differences in Use of Medications by Age.
Literature has consistently shown that use of prescription medication increases
with age (Che et al., 2014; Kantor et al., 2015; Martin et al., 2019; Petty et al., 2014; Qato
et al., 2008). In the US, Qato and colleagues (2008) found that 90% of older adults
between the ages of 75 and 85 reported using one or more prescription medications
compared to 74% of the youngest group, aged 57 to 64. This is consistent with Gurwitz
and colleagues’ (2003) findings that older adults are the largest group of purchasers of
prescriptions, OTC medications, and dietary supplements.
In a broader sample of adults, Che et al. (2014) found a similar pattern. Only a
third of adults aged 21 to 39 reported using at least one prescription medication regularly
between 2008 and 2010 compared to almost three-fourths of adults aged 60 to 74. A

18

subsequent study of data collected in 2011 and 2012 found that 35% of adults between
the ages of 20 and 39 used one or more prescription medications, compared to 65% of
those between the ages of 40 and 64 and 90% of those over the age of 65 (Kantor et al.,
2015). Different rates of prescription drug use were identified in a 2015 to 2016 US
NCHS brief, although the pattern remained the same. Specifically, 47% of people
between the ages of 20 and 59 reported prescription drug use compared to 80% of people
over the age of 60 (Martin et al., 2019). This relationship between age and prescription
medication use was also evident in comparisons of medication use by sex and race
(Martin et al., 2019).
Differences in Use of Medications by Gender.
For younger adults, between the ages of 20 and 59, prescription medication use
was higher among women than men, 56% compared to 37%, according to a NCHS study
conducted in 2015 and 2016 (Martin et al., 2019). Women (86%) also showed a higher
use of prescription medications than men (77%) in a study conducted in 2005 and 2006
of older adults ranging from 57 to 85 years old (Qato et al., 2008). However, a more
recent study found that for adults over the age of 60, there was no difference between
men and women in their use of prescription drugs (Martin et al., 2019). When examined
across all age groups, this NCHS study found prescription medication use to be higher in
women (50%) than men (42%; Martin et al., 2019).
Differences in Use of Medications by Race.
In addition to differences in prescription medication use across age and gender,
prescription medication use also varies across race. Overall, use of prescription
medication is highest among persons who identified as White (50%), followed by persons
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who identified as Black (45%), according to the most recent data from NCHS (Martin et
al., 2019). Use of prescription medications is lowest among those who identified as
Hispanic (37%) or Asian (33%; Martin et al., 2019). When examining older and younger
adults separately, adults between the ages of 20 and 59 showed the same pattern of
prescription drug use as the overall sample: 52.4% White, 45.3% Black, 33.6% Hispanic,
and 30.2% Asian (Martin et al., 2019). However, no difference in use of prescription
medication was observed across racial or ethnic groups for older adults (e.g., people over
the age of 60; Martin et al., 2019).
Other Factors Contributing to Differences in Use of Medications.
In addition to age, gender, and race, several other factors have also been
associated with differential uses of medications. For example, rates of prescription
medication use differed across various levels of education, income, insurance coverage,
and Body Mass Index (BMI) in a broad sample of adults over the age of 20 (Kantor et al.,
2015). Specifically, of adults reporting “college” as their highest level of education, 61%
reported using at least one prescription medication. In contrast, only 57% of adults who
reported having less than 12 years of education and adults who reported completing only
“some college” reported using one or more medication. Prevalence of medication use
also increased with reported family income (Kantor et al., 2015). Of individuals with a
family income below the federal poverty level, 49% reported using one or more
prescription medications compared to 65% of adults who reported the highest level of
family income (above 88,000). Regarding insurance coverage, not surprisingly, only 31%
of adults who did not have insurance reported taking prescription medications compared
to 57% of adults who had private insurance and 64% of adults who had insurance through

20

the government (Kantor et al., 2015). However, differences in medication use by
insurance coverage was only calculated for individuals under the age of 65 since nearly
all adults over the age of 65 participating in this study reported having some form of
health insurance.
Lastly, when evaluating medication use based on BMI, Kantor and colleagues
(2015) found that 59% of adults with a BMI below 18.5, 52% of adults with a BMI
between 18 and 25, and 57% of adults with a BMI between 25 and 30 reported using one
or more prescription medications. Additionally, 62% of adults with a BMI between 30
and 35, 68% of adults with a BMI between 35 and 40, and 73% of adults with a BMI
over 40 used one or more prescription medications. Based on the CDC recommended
classifications for BMI, which indicate normal BMI as BMI between 18.5 and 24.9
(CDC, 2017), findings from Kantor et al. (2015) indicate that adults with a BMI in the
obese category were significantly more likely to use medications than individuals with
BMIs in the normal range.
Similar results were identified by Qato and colleagues (2008) in their study of
medication and dietary supplement use in older adults. Specifically, older adults with
more co-morbid conditions, who classified themselves as “nonpoor”, and who reported
higher levels of education were more likely to use one or more medications. Although,
this included use of any combination of prescription, OTC medications, and dietary
supplements.
Common Medications
Despite differences in use of medications across demographic variables, Kantor et
al. (2015) identified several of the most common prescription medications used by adults

21

in 2011 and 2012. Overall, antihypertensives (27%), antihyperlipidemic agents (18%),
antidepressants (13%), prescription analgesics (11%), antidiabetic agents (8.2%), proton
pump inhibitors (7.8%), and thyroid hormones (6.4%) were the most common therapeutic
groups of medications prescribed for individuals over the age of 20. Specifically,
simvastatin, a lipid modifying agent used to treat high cholesterol (WHO Collaborating
Centre for Drug Statistics Methodology [WHO], 2021), was the most commonly reported
prescription medication, taken by 7.9% of the sample (Kantor et al., 2015). Lisinopril,
levothyroxine, metoprolol, metformin, hydrochlorothiazide, omeprazole, amlodipine,
atorvastatin, and albuterol were also among the top 10 medications reported by Kantor et
al. study participants.
Qato and colleagues (2016) found that the most common medications for older
adults between the ages of 62 and 85 in 2010 and 2011, were nearly identical to those
reported by Kantor et al. (2015) for their broader sample of adults. Antihypertensives was
the most common therapeutic group of prescription medications, reported by 65.1% of
older adults (Qato et al., 2016). Analgesics (54.3%), antihyperlipidemics (50.1%),
coagulation modifiers (47.6%), respiratory agents (19.6%), proton pump inhibitors
(18.5%), antidiabetic agents (17.8), and thyroid hormones (15.8%) were also among the
most common therapeutic groups of medications prescribed to older adults. In terms of
specific medications, simvastatin (22.5%), lisinopril (19.9%), hydrochlorothiazide
(19.3%), levothyroxine sodium (15.4%), metoprolol (14.9%), amlodipine (13.4%),
metformin (12.6%), atorvastatin calcium (9.7%), atenolol (8.5%), and furosemide (8.2%)
were most commonly reported (Qato et al., 2016).
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However, when Martin et al. (2019) directly compared older and younger adults
in the most recent MCHS data from 2015 and 2016, the most common therapeutic group
of prescription medication differed. For younger adults, aged 20 to 59, antidepressants
were the most commonly reported therapeutic group of prescription medications (Martin
et al., 2019). In contrast, the most common therapeutic group of prescription medications
for adults over the age of 60 was lipid-lowering drugs (Martin et al., 2019). These
differences are not unusual given that different health conditions are more prominent at
different stages of life.
Overall, the use of prescription medications is extensive and more prevalent than
in previous decades (Kantor et al., 2015; Martin et al., 2019; Qato et al., 2016). While
various demographic variables have been associated with medication use, age appears to
be the most significant, with older adults reporting higher consumption of prescription
medications than younger adults (Che et al., 2014; Kantor et al., 2015; Martin et al.,
2019; Petty et al., 2014; Qato et al., 2008). However, many adults use more than one
medication (Che et al., 2014; Denison et al., 2012; Freund et al., 2013; Gahche et al.,
2017; Kantor et al., 2015; Qato et al., 2016), which as described above, can impact the
pharmacokinetics and pharmacodynamics of the prescriptions and potentially lead to
detrimental side effects. Therefore, the literature below describes polypharmacy and its
prevalence in prescription medication use.
Polypharmacy
Polypharmacy has featured prominently in studies of pharmacology, nursing
practice, and treatment of diagnoses and diseases across fields (e.g., neurology,
psychiatry, gerontology, endocrinology, and cardiology) given its relationship with drug
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related problems (DRPs) that can interfere with treatment or recovery (Viktil et al.,
2007). However, no formal definition of polypharmacy has been identified. Some studies
define polypharmacy as the use of two or more medications (Frazier, 2005; Fulton &
Allen, 2005). Others define polypharmacy as the use of more drugs than appropriate
given a patient presentation (Fulton & Allen, 2005; Tjia et al., 2013). Additionally,
polypharmacy has been termed the concurrent use of two or more medications that treat
the same symptom, illness, or disease, or treatment with two drugs from the same drug
class (Brager & Sloand, 2005). The benchmark of five or more medications has also been
used in an effort to standardize definitions of polypharmacy with a customary cutoff
value (Viktil et al., 2007).
Through an investigation of the cutoff of five or more medications and DRPs in
patients admitted to the hospital, Viktil et al. (2007) revealed a linear relationship
between number of medications used prior to admittance and number of DRPs. With
every increase in number of medications, there was a nearly 9% increase in DRPs.
Further, individuals admitted to the hospital with five or more regular medications
experienced significantly more DRPs than patients admitted to the hospital with less than
five regular medications (Viktil et al., 2007). However, there is no evidence to suggest
that this relationship is due to the cutoff of 5 or more medications to identify
polypharmacy rather than a function of the linear relationship between number of
medications and DRP. This suggests that indicating polypharmacy with a cut off of 5 or
more medications may be entirely arbitrary and not serve as an adequate value to
differentiate risk for DRPs in research or clinical practice as it was intended. Despite this
explanation, many researchers continue to use the cutoff of 5 or more medications to
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indicate polypharmacy when discerning high risk patients and in describing various
qualities of the samples that fall in this category (e.g., Che et al., 2014; Jyrkkä et al.,
2011; Kantor et al., 2015; Qato et al., 2008, Qato et al., 2016).
For example, an investigation into medication use in older adults, Qato et al.
(2008) found that over 50% of adults between the ages of 57 and 85 took 5 or more
prescription medications, OTC medications, or dietary supplements. Additionally, of
those older adults using prescription medications, nearly 70% reported also using OTC
medications, dietary supplements, or both (Qato et al., 2008). A follow-up study
conducted five years later from 2010 to 2011 examined the use of medication in older
Americans between the ages of 62 and 85 (Qato et al., 2016). Rates of polypharmacy for
any combination of medications increased from 50% to 67% of older adults who used 5
or more prescription or OTC medications or dietary supplements (Qato et al., 2016).
Prescription Medications
When specifically considering the relationship between prescription medication
and polypharmacy, Qato et al. (2008) found that 29% of older Americans between 57 and
85 years old reported using five or more medications. In a follow-up study examining the
use of medication in adults between the ages of 62 and 85, Qato et al., (2016) found the
rate of polypharmacy for prescription medications increased to approximately 36%.
Conversely, in an investigation of prescription medication use in a broader sample of
adults over the age of 20, Kantor and colleagues (2015) found that only 15% of adults
reported using five or more medications. The variation in these prevalence rates, like that
observed for use of at least one prescription medication, is likely due to the differences in
the age of the participants across studies.
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When stratified by age, prevalence rates for polypharmacy become more
consistent across studies. In fact, when Kantor and colleagues’ (2015) sample is stratified
by age cohorts, older adults over the age of 65 reported the most instances of
polypharmacy, with 39% of this group reporting use of five or more prescription
medications. Conversely, only 3% of individuals aged 20 to 39 reported using five or
more prescription medications (Kantor et al., 2015).
This concept is further exemplified in a study that reviewed instances of
prescription drugs recorded in an electronic medical record of adult patients seen in
primary care settings (Freund et al., 2013). Patients aged 18-23, 25-34, 35-44, and 45-54
years old were found to have the following rates of polypharmacy: 20%, 29%, 40%, and
55%, respectively. While these rates are slightly higher than those obtained by Kantor et
al. (2015), Qato et al. (2008), and Qato et al. (2016), likely due to the number of
prescriptions being determined by a medical record system rather than through in-person
interviews, the rates of polypharmacy still appear to increase with age much like that of
individual medication use.
Like age, gender was also associated rates of polypharmacy. Overall, women
between the ages of 21 and 74 were more likely to experience polypharmacy than men,
according to data collected between 2008 and 2010 (Che et al., 2014). Specifically, 16%
of women reported using five or more prescription medications compared to almost 11%
of men (Che et al., 2014). These results are nearly identical to Kantor and colleagues’
(2015) report that 16% of women and 13% of men used five or more prescription
medications in 2011 and 2012. Similar patterns are observed in older adults in the 57 to
64 and 65 to 74 age groups (Qato et al., 2008). However, individuals from the oldest age
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group, composed of individuals between 75 and 85 years old, did not show any
differences in polypharmacy across gender (Qato et al., 2008).
Associations between race, BMI, smoking history and rates of polypharmacy have
also been identified (Che et al., 2014; Kantor et al., 2015). In a broad study of adults over
the age of 20, 17% of adults who identified as white reported taking five or more
medications compared to 14% of adults who identified as black (Kantor et al., 2015).
When evaluating use of five or more medications based on BMI, Kantor and colleagues
found that 18% of adults with a BMI below 18.5, 8.4% of adults with a BMI between 18
and 25, and 12% of adults with a BMI between 25 and 30 reported using five or more
prescription medications. Additionally, 17% of adults with a BMI between 30 and 35,
24% of adults with a BMI between 35 and 40, and 29% of adults with a BMI over 40
used five or more prescription medications. Based on the CDC (2017) recommended
classifications for BMI, which indicate normal BMI as between 18.5 and 24.9, adults
classified as obese were significantly more likely to use medications than individuals
with BMIs in the normal range (Kantor et al., 2015). Further, adults who reported a
history of smoking were nearly twice as likely to use five or more prescription
medications than adults without a history of smoking (Che et al., 2014).
Not surprisingly, family income, health insurance coverage, and being able to
identify a regular source of care were also linked with greater use of polypharmacy in
prescription medications (Che et al., 2014; Kantor et al., 2015). Family income was
negatively related to polypharmacy; meaning that adults reporting lower family incomes
were more likely to report taking five or more medications than adults who reported
higher incomes (Che et al., 2014; Kantor et al., 2015). Additionally, adults who reported
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having insurance through the government (Medicaid or Medicare), having prescription
drug coverage, and who identified a location where they typically receive healthcare were
more likely to use five or more medications (Che et al., 2014; Kantor et al., 2015).
Overall, use of prescription medication is extensive, and frequently occurs
alongside four or more other medications, as is the case in polypharmacy. While these
medications are evaluated by the FDA prior to widespread use, that does not mean they
are without side effects, particularly with regard to cognition. Additionally, given the
limits in assessment of medication side effects prior to FDA approval and release, it is
likely that additional side effects are present, including those that affect cognition. The
following section details the cognitive effects that have been observed following the use
of various medications.

Cognitive Effects of Medications
Ultimately, any medication may cause cognitive effects, such as confusion
associated with delirium, if the drug concentration reaches a toxic level (Moore &
O’Keeffe, 1999). Although, delirium-like events are not necessary in order for
medications to impact cognitive functioning. Many medications have been associated
with more subtle changes in cognition, even in studies of relatively young and healthy
samples (see Allegri et al., 2019; Nevado-Holgado et al., 2016; Prado & Crowe, 2019;
and Prado et al., 2018). However, for individuals who are cognitively vulnerable due to
stroke, traumatic brain injury, or advanced age, these effects may cause more significant
changes or chronic cognitive impairment (Moore & O’Keeffe, 1999). Further, for
individuals who have already been diagnosed with cognitive impairment, this could mean
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worsening impairment or a significant enough decline to warrant a diagnosis of dementia
(Campbell et al., 2009).
The American Geriatrics Society (AGS) Beers Criteria for Potentially
Inappropriate Medication Use in Older Adults (AGS Beers Criteria) provides a specific
list of medications that are typically best to avoid in older adults with the goal of reducing
their exposure to PIMs that may increase risk of negative effects (Fick et al., 2019).
However, decisions regarding pharmacological treatment are not always clear cut, and
depending on various situational factors, may still lead to the use of PIMs that increase
the risk of drug toxicity or negative drug interactions in older individuals. This, in turn,
may produce cognitive impairment. This is of particular concern in cognitively
vulnerable populations who may be at a higher risk of using PIMs (Gnjidic et al., 2018;
Miller et al., 2017).
Medications of primary concern for both researchers and clinicians are those
known to have sedative or anticholinergic effects due to their effect on the central
nervous system (CNS). Specifically, anticholinergic effects have consistently been
related to the development of cognitive impairment, delirium, and dementia (Campbell et
al., 2009; Marvanova, 2016; Moore & O’Keeffe, 1999). The 2019 AGS Beers Criteria
provides a strong recommendation to avoid prescribing drugs with strong anticholinergic
properties, such as first-generation antihistamines, antispasmodics, and certain
antiparkinsonian agents.
Anticholinergics
Cholinergic pathways have long been associated with cognitive functioning, and
memory in particular (Campbell et al., 2009; Stein & Strickland, 1998). Therefore, when
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this pathway is interrupted, as is the case in the use of anticholinergic drugs, impairments
in cognitive functioning may occur. Many explanations have been provided for this
relationship, such as increased brain cell death (Del Pino et al., 2016) or synaptic pruning
and degeneration (Geula, 1998) at the sites of action for anticholinergic drugs. Although,
an anticholinergic drug, or a drug with a strong anticholinergic effect, functions in much
the same way as Alzheimer disease pathology. Specifically, these drugs act as antagonists
and block muscarinic receptors (Katzung, 2018; Lam, 2017; Lepkowsky, 2016). As a
result of this antagonist effect, reactions that are essential to the communication between
neurons for adequate attention, memory, and learning are significantly reduced, leading
to functional impairments in these cognitive domains (Lam, 2017; Lepkowsky, 2016;
Tannenbaum et al., 2012).
Risacher and colleagues’ (2016) demonstrated this in a study of anticholinergic
medication use, cognitive functioning, and brain atrophy in cognitively normal older
adults. Overall cognitive functioning and performance on tasks of immediate memory
and executive functioning were significantly lower for patients taking anticholinergic
medications compared to patients who were not taking anticholinergic medications
(Risacher et al., 2016). Additionally, structural magnetic resonance imaging (MRI)
reviled greater brain atrophy in patients taking anticholinergic medications than patients
not taking anticholinergic medications, as evidenced by reduced overall cortical volume
and enlargement of the lateral ventricles. Further, patients in this study using
anticholinergic medications showed reduced cortical thickness in the medial temporal
lobe (Risacher et al., 2016), an area known for its involvement in episodic memory and
learning (Squire, 2004).

30

Anticholinergic effects have been documented for amitriptyline, clomipramine,
amoxapine, hydroxyzine, digoxin, furosemide, codeine, and chlorpheniramine among
others (Marvanova, 2016; Sordahl et al., 2019; see Table 1 for a list of the drug families
and therapeutic uses of a subset of common medications that act on anticholinergic
pathways). However, use of one anticholinergic drug will not necessarily lead to negative
cognitive effects. Rather, it is the collective potency of the anticholinergic effect of the
drug/drugs used, or anticholinergic burden, that leads to impairment (Lam, 2017). For
example, in Risacher and colleagues’ (2016) study, anticholinergic burden was negatively
related to overall cognitive function, as well as immediate recall and executive
functioning performance. This effect is often more pronounced in older adults, given the
reduced number of cholinergic neurons or receptors, in conjunction with various other
pharmacokinetic and pharmacodynamic factors compared to younger adults (Campbell et
al., 2009).
While medications with strong anticholinergic effects contribute to a large portion
of negative cognitive side effects, there are many other ways that medications may
impact cognitive functioning. For example, reduced cerebral blood flow (Marvanova,
2016), the creation of neurotoxic metabolites (Kornitzer et al., 2006; Marvanova, 2016),
and imbalances in fluids or electrolytes (Marvanova, 2016) have been suggested as
possible mechanisms of cognitive dysfunction following the use of certain medications.
Although, the potential for cognitive effects of medication depends on the specific
pharmacodynamic effect of the drug itself, which can vary as a function of therapeutic
use and drug families. Therefore, the cognitive effects of medications from a selection of
therapeutic use categories will be reviewed below.
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Table 1
Common Medications with Anticholinergic Properties
Therapeutic Use
Drug Family
Drug Name (generic)
Anxiolytic
Benzodiazepine
Alprazolam
Antihistamine
First-Generation H1 Antagonist
Diphenhydramine
Movement Disorder
Central Muscarinic Antagonist
Benztropine
Antidepressant
MRI
Amitriptyline
Antidepressant
SSRI
Paroxetine
Antipsychotic
Atypical Antipsychotics
Quetiapine
Antidepressant
MRI
Clomipramine
Cardiovascular
Antiarrhythmic
Disopyramide
Cardiovascular
Diuretic
Furosemide
Urological
Antispasmodic
Oxybutynin
Note. Adapted from Sordahl et al. (2019) and Marvanova, (2016). MRI = Monoamine
Reuptake Inhibitors, SSRI = Selective Serotonin Reuptake Inhibitor. Medication
classifications based on the ACT Classification Index from the (WHO Collaborating
Centre for Drug Statistics Methodology, 2021).

Antidepressants
The cognitive effects of antidepressants are varied across drug classes or families.
Tricyclic antidepressants (TCAs) are widely known for their negative cognitive effects,
likely due to the combination of sedative and anticholinergic effects of drugs in this
family (Sordahl et al., 2019; Stein & Strickland, 1998). In terms of cognitive effects,
TCAs have been associated with impairments in sustained attention, speed of information
processing, memory, and psychomotor functioning (Horst & Preskorn 1998; Stein &
Strickland, 1998; Tannenbaum et al., 2012). However, in a recent meta-analysis
analyzing cognitive effects of antidepressants in depressed and non-depressed samples,
TCAs did not significantly impact performance in any cognitive domain for which it was
assessed (i.e., sustained and divided attention, immediate and delayed memory,
processing speed, and psychomotor functioning; Prado et al., 2018). Given that TCAs
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were only assessed in depressed patients, this finding is complicated by the cognitive
benefits resulting from the remittance of symptoms of depression.
In the same meta-analysis, selective serotonin reuptake inhibitors (SSRIs),
serotonin and norepinephrine reuptake inhibitors (SNRIs), and serotonin modulator and
stimulators (SMSs), all showed significant positive effects in several cognitive domains
(Prado et al., 2018). Although, the magnitudes of the identified effects were small and
only significant in the depressed sample. Therefore, it is possible that these effects are
due to the resolution of symptoms of depression and thus, only speak to the cognitive
effects of depression. Additionally, in many of Prado and colleagues’ analyses, only two
or three studies were included, significantly reducing the likelihood of identifying an
effect if one is present.
Nonetheless, results from Prado et al. (2018) were significant for small, positive
effects of SSRI use on tasks of divided attention, executive functioning, immediate and
delayed memory, and processing speed. SNRI use also showed small, positive effects on
tasks of divided attention, executive functioning, and delayed memory. SMS use showed
small, positive effects for divided attention, processing speed, and delayed memory. No
significant effects were observed for selective serotonin reuptake enhancers (SSREs) in
the depressed samples. In non-depressed patients, only SSRIs and SNRIs were analyzed,
and no significant effects were observed in any cognitive domain (i.e., sustained and
divided attention, immediate and delayed memory, expressive language, visual
spatial/construction skills, working memory, processing speed, and psychomotor
functioning; Prado et al., 2018).
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The cognitive effects of trazodone, a serotonin receptor antagonists and reuptake
inhibitor (SARI) often used for sleep initiation, have also been evaluated in recent
studies. However, the literature is mixed. Following seven days of use, Roth and
colleagues (2011) found small but significant declines in performance on tests of shortterm memory, verbal learning, and motor functioning in a sample of young adults
diagnosed with insomnia. Conversely, Rush et al. (1997) found acute performance on
measures of learning and recall for 50 mg, 100 mg, and 200 mg of trazodone did not
differ from participants who were administered a placebo, when assessed six-hours
following drug administration. In a third study, Camargos et al. (2015) found no changes
in overall cognitive functioning, attention, working memory, and processing speed after
two-weeks of trazodone use in older adults diagnosed with Alzheimer’s disease.
However, the participants were significantly cognitively impaired prior to inclusion in the
study (mean Mini-Mental State Exam [MMSE] = 11.2/30, where 25 or more indicates
cognitive functioning is within normal limits). Due to this impairment, the participants
were unable to complete assessments of verbal learning and memory, which significantly
limited the possibility of detecting further decline (Camargos et al., 2015).
Overall, most evidence suggests that use of TCAs leads to poorer cognitive
functioning (Horst & Preskorn 1998; Stein & Strickland, 1998). Trazadone may
negatively impact various aspects of cognitive functioning. However, more literature is
needed on the various acute and long-term effects of trazodone use and the potential for
cognitive effects in both clinical and non-clinical samples. While there is no clear
evidence of a negative effect of other antidepressant medications (i.e., SSRIs, SNRIs,
SMSs, SSREs), and some literature suggests SSRIs and SNRIs may have a positive effect

34

on cognition in depressed samples, more evidence is required to unequivocally make
claims regarding the cognitive effects of these drug classes given the limitations of the
presently available literature.
Anxiolytics
In terms of anxiolytics, the use of benzodiazepines has often been associated with
changes in cognitive functioning across domains, consistent with known sedative and
anticholinergic effects (del Ser et al., 2019; Koelega, 1989; Picton et al., 2018; Stein &
Strickland, 1998; Tannenbaum et al., 2012). Specifically, reductions in sustained
attention, psychomotor speed, speed of information processing, and memory
performances have been observed (del Ser et al., 2019; Stein & Strickland, 1998;
Tannenbaum et al., 2012). While impairments in memory and attention domains appear
to be dose-dependent, they appear to persist over time (Moore & O’Keeffe, 1999; Stein &
Strickland, 1998). However, psychomotor slowing appears to return to normal following
sustained use due to increased tolerance of sedation effects (Koelega, 1989).
Additionally, a recent longitudinal study of cognitively normal older adults found
statistically significant reductions in processing speed at a two-year follow-up (del Ser et
al., 2019). Although, the effect of this finding was small.
Despite frequent findings of cognitive impairment across a variety of cognitive
domains following benzodiazepine use, there continues to be variability in findings of
impairment, and discrepancies regarding which domains are affected. Nader and Gowing
(2020) demonstrated this in their recent review of literature examining the association
between long-term exposure to benzodiazepines and risk of cognitive decline in adults.
Of the 14 studies reviewed, only three supported an association between long-term
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benzodiazepine use and cognitive impairment with small to medium effect sizes.
However, there was no consistency with regard to affected domains across all three
studies. Additionally, definitions of long-term use, cognitive domains assessed, cognitive
tests within domains, scoring of cognitive tests, and statistical analyses differed across all
included studies, likely contributing to the inconsistent results.
In terms of global cognitive functioning, recent studies of the effects of
benzodiazepines in elderly populations were also mixed (Nader & Gowing, 2020; Picton
et al., 2018). For example, in reviews of studies examining benzodiazepine use in the
elderly, only three of nine prospective clinical trials and five of seven case-control studies
found significant differences in overall cognitive functioning between individuals
prescribed benzodiazepines and controls (Picton et al., 2018). However, of the studies
that did not find impairments in global cognitive functioning in individuals using
benzodiazepines, many had smaller sample sizes and shorter follow-up periods. A more
recent longitudinal study evaluating benzodiazepine use and the risk of cognitive
impairment in older adults found that while benzodiazepine use did not increase the risk
of the development of dementia, it did increase the risk of milder cognitive impairment
(Nafti et al., 2020). Additionally, literature examining the effects of longer acting
benzodiazepines indicates that they are more strongly related to cognitive decline in older
adults, compared to shorter acting benzodiazepines (Picton et al., 2018). For example, del
Ser et al. (2019) found that bromazepam, in particular, was associated with a higher rate
of transition to mild cognitive impairment (MCI) from normal cognition compared to
other drugs.
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The AGS Beers Criteria (2019) note that there is moderate evidence that
benzodiazepines increase the risk of cognitive impairment and delirium in older adults
and strongly recommend they are avoided. Despite this recommendation, benzodiazepine
use remains common in older adults, particularly women, making them especially
susceptible to negative cognitive effects of these prescriptions (Olfson et al., 2015; Maust
et al., 2016). There is very little evidence regarding the effects of other anxiolytics on
cognitive functioning. Although, in a comparison of buspirone, an atypical anxiolytic and
a benzodiazepine, buspirone did not show a statistically significant effect on cognitive
functioning (Stein & Strickland, 1998). Therefore, no strong conclusions can be drawn
regarding the effect of anxiolytics on cognitive functioning.
Analgesics
Overall, use of analgesics, and opioids in particular, have been associated with
cognitive deficits across a range of cognitive domains. In some cases, these negative
effects have been associated with anticholinergic or neurotoxic effects of drug
metabolites, however, that is not always the case (Kornitzer et al., 2006). With the use of
opioids, Ersek and colleagues (2004) noted that reductions in psychomotor speed, poor
attention, and impairments in memory were commonly cited in the literature. However, a
more recent meta-analytic review found impairments in the domains of verbal working
memory, cognitive impulsivity, and cognitive flexibility for individuals using opioids
compared to healthy controls (Baldacchino et al., 2012). Conversely, Allegri and
colleagues’ (2019) meta-analytic review of the long-term effects of opioid use on
cognition only identified differential performances in the attention domain, with
individuals taking opioid medications having a significantly poorer performance than
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those taking non-CNS acting medications. In both Baldacchino et al. (2012) and Allegri
et al. (2019), the magnitudes of the effects were medium. Additionally, one longitudinal
study of opioid use in older adults found that opioid use was associated with global
cognitive decline, although this effect was only evident in participants over the age of 75
and did not control for the effect of pain (Puustinen et al., 2011).
Therefore, opioids appear to have a significant effect of cognition, although the
specific domains affected may vary. One possible reason for this may be due to the
heterogeneity in chemical structures, pharmacokinetics, and pharmacodynamics of the
opioids used in these studies. For instance, morphine has been associated with reduced
psychomotor speed, verbal processing, and attention, whereas oxycodone has been
associated with reduced attention, verbal learning, working memory, and reaction time
(Allegri et al., 2019).
Apart from the cognitive effects associated with opioids, little is known about the
cognitive effects of other types of analgesics. One study found that beginning naproxen
was associated with improved processing speed from a baseline assessment (Obermann et
al., 2013). However, given that pain was not controlled for in this study, this
improvement may be due to the resolution of pain rather than an effect of the drug
specifically. Overall, opioids appear to significantly affect cognitive functioning,
particularly in working memory, psychomotor speed, and attention. However, more
research into specific medications within this therapeutic group is necessary in order to
clarify the domains affected.
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Antiepileptics
Impairments in a broad range of cognitive domains have been observed across a
variety of antiepileptic medications (Stein & Strickland, 1998). Broadly, long-term use of
antiepileptic drugs (AEDs) has been associated with poor performance on tests of
attention and concentration, psychomotor functioning, and verbal fluency (Park & Kwon,
2008; Stein & Strickland,1998). Although short term use of AEDs shows less consistent
effects on cognitive functioning, likely due to various methodological problems in these
studies (Park & Kwon, 2008).
In general, older antiepileptic medications appear to show more diffuse and
intense effects than newer medications (Park & Kwon, 2008; Stein & Strickland, 1998).
For example, the negative neuropsychological effects of phenobarbital include sedativeand dose-dependent impairments in measured intelligence quotient (IQ; Calandre et al.,
1990; Farwell et al., 1992), attention and concentration (see Smith, 1991 for a review), as
well as memory and psychomotor speed (MacLeod et al., 1978). Additionally, phenytoin
and carbamazepine use are generally associated with impairment in psychomotor speed
and slowed verbal responding, respectively (Stein & Strickland, 1998). Yet, there is
evidence to suggest topiramate and levetiracetam, two newer AEDs, produce greater
reductions in cognitive functioning than any other AEDs. Specifically, Nevado-Holgado
and colleagues (2016) found that use of topiramate was associated with the worst
reasoning and memory performances of individuals using active CNS medications. Use
of levetiracetam, on the other hand, was associated with memory performances that were
only slightly better than that of topiramate but poorer than other AEDs and worse
reaction time compared to other AEDs (Nevado-Holgado et al., 2016). Therefore, long-
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term use of AEDs is consistently related to reduced cognitive functioning across many
cognitive domains, although measures of attention and psychomotor speed may be most
sensitive to these effects.
Cardiovascular
Overall, findings of cognitive effects of cardiovascular medications across studies
are variable, likely suggesting differential effects of specific medications or drug families
used in cardiovascular treatments. Specifically, one meta-analysis studying the effect of
various antihypertensive medications on cognitive functioning in patients without a
history of cerebrovascular disease (e.g., stroke, stenosis, and aneurysm) found a
significant positive effect of antihypertensive medication use on overall cognitive
functioning (Marpillat et al., 2013). Although the effect size for this finding was small in
magnitude and only significant for the first 6 months of therapeutic treatment. In terms of
specific cognitive domains, significant positive effects following use of antihypertensive
medications were identified for executive functioning, processing speed, attention, and
immediate and delayed memory, with effect sizes ranging from .20 to .40 (Marpillat et
al., 2013). When analyzed by drug class/drug family, angiotensin II receptor blockers
(ARBs) showed the largest benefit compared to a placebo on overall cognition, with a
large, adjusted effect size of .6. Angiotensin-converting enzyme (ACE) inhibitor, betablockers, and diuretics also showed significant positive effects on overall cognitive
functioning, with effect sizes ranging from medium to large (Marpillat et al., 2013).
These results are consistent with results from Nevado-Holgado et al. (2016) that
individuals prescribed ACE inhibitors, such as perindopril performed better on a test of
reasoning compared to individuals prescribed other antihypertensive medications.

40

However, poorer reasoning and slowed reaction times were associated with the use of
calcium channel blockers (CCBs) and diuretics, such as amlodipine and furosemide,
respectively (Nevado-Holgado et al., 2016). Additionally, in a study of medication use in
older adults, Obermann et al. (2013) found negative cognitive effects in processing speed
and memory domains for starting furosemide between the baseline and one-year followup. Despite these findings, del Ser and colleagues (2019) identified significant reductions
in the conversion to MCI with the use of angiotensin II antagonists, and Losartan in
particular, as well as with the use of hydrochlorothiazide, a diuretic.
One factor that may contribute to the variability in findings across cardiovascular
drug families and specific medications is the anticholinergic properties of some of these
medications. For instance, some diuretics, antiarrhythmics, vasodilators, CCBs, and betablockers (e.g., furosemide, chlorthalidone, hydrochlorothiazide, disopyramide, quinidine,
atenolol, captopril, hydralazine, metoprolol, nifedipine, and timolol maleate) have been
rated as having possible anticholinergic activity that may contribute to overall
anticholinergic cognitive burden (Marvanova, 2016). Further, many drugs (e.g.,
reserpine, methyldopa, clonidine, prazosin, and digoxin) within this therapeutic group
have been associated with the development of delirium and worsening cognitive
functions for individuals diagnosed with mild cognitive impairments or dementia
secondary to neurotoxicity, imbalance of neurotransmitters in the CNS, fluid and
electrolyte imbalances, and decreased cerebral blood flow (Marvanova, 2016). However,
these effects are complicated by the improvement in cognitive symptoms or slowing of
progressive cognitive dysfunction that results from hypertension and other cardiac-related
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diseases. Therefore, further study of the cognitive effects of antihypertensive medications
is warranted.
Overall, many medications have been associated with changes in cognitive
functioning. Although, these effects do not occur in a vacuum. Rather, these cognitive
effects co-occur and interact with factors that contribute to drug intensity and therefore
increase the risk of negative therapeutic effects. Older adults, in particular, are at a high
risk of these negative cognitive effects. This is due in part to differences in
pharmacokinetic processes and pharmacodynamics in older and younger adults (Fulton &
Allen, 2005). Specifically, higher rates of liver and kidneys impairments, frailty,
malnutrition, and chronic brain pathology in older adults compared to younger adults
play a role in elevating this risk for older adults (Burchum & Rosenthal, 2016; Kinirons
& O'Mahony, 2004; Moore & O’Keeffe, 1999). Furthermore, older adults have greater
rates of comorbidities, and thus, polypharmacy, than younger adults (Barnett et al., 2012;
Kantor et al., 2015), which may also contribute to findings of greater cognitive side
effects from medication use.

Cognitive Effects of Polypharmacy
Polypharmacy, defined as the concurrent use of two or more or the concurrent use
of five or more medications, and excessive polypharmacy, defined as the concurrent use
of 10 or more medications (Jyrkkä et al., 2011), have consistently been associated with
greater impairment in cognitive functioning (Jyrkkä et al., 2011; Maher et al., 2014;
Moore & O’Keefe, 1999; Sordahl et al., 2019). Although most analyses of these effects
focus exclusively on the effects of opioids and polypharmacy in older adults.
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Specifically, Wright et al. (2009) found that a combined daily dose of medications greater
than three standard doses, across various CNS acting medications, was strongly related to
overall cognitive decline in older adults. Similarly, the combined use of opioids and any
other CNS acting medication (e.g., benzodiazepines and related drugs, antipsychotics,
antidepressants, opioids, anticholinergics, and antiepileptics) in cognitively intact older
adults was significantly related to global cognitive decline, even after controlling for
other factors related to reduced cognitive functioning, such as age, sex, education, and
various medical conditions (Puustinen et al., 2011).
A recent meta-analysis evaluating the effects of opioid use found that the
combined effects of opioid therapeutic treatment, antidepressants, and/or anticonvulsants
was associated with worse performance on measures of attention compared to patients
not taking CNS active medications (Allegri et al., 2019). Effect size estimates for this
result were in the medium range (SMD: -.62; Allegri et al., 2019). With regard to
anticholinergic medications, increased cognitive burden of anticholinergic medications,
through the use of multiple anticholinergic medications, significantly increased the risk of
negative cognitive effects, such as delirium and dementia (Agar et al., 2009; Boustani et
al., 2008; Campbell et al., 2009; Marvanova, 2016; Moore & O’Keefe, 1999; Sordahl et
al., 2019).
While it is clear that there is an effect of polypharmacy on cognition, particularly
in older adults who are taking multiple CNS active medications, more literature on this
phenomenon in younger adults and for non-opioid medications is necessary.
Additionally, in most of the studies described above, cognitive ability is evaluated based
on a brief, screening measure of global cognition or single brief measures of specific
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cognitive domains (e.g., digit-symbol substitution to assess psychomotor speed or digit
span to assess working memory). This practice is problematic in that cognitive screening
measures are narrow in scope, have relatively low sensitivity, and are generally designed
to identify those who may need a more extensive evaluation (Roebuck-Spencer et al.,
2017). Given these limitations, the use of the brief screening measures significantly limits
the ability to identify possible effects across the full breadth of cognitive domains,
particularly if the effects are subtle. Unfortunately, this limitation in the assessment of
cognitive functioning is not restricted to the evaluation of cognitive effects with respect
to polypharmacy. Rather, this practice appears to be consistent across studies of
medication and cognition. Most studies, even those evaluated within meta-analyses,
utilize brief screening measures to evaluate overall cognitive functioning. Although, that
is not the only measure of cognition available or used by researchers or physicians in the
measurement of cognition. The following section will review some of the other measures
of cognitive functioning used by researchers and physicians.

Measuring Cognitive Dysfunction

Global Cognition
While most models of cognitive functioning recognize a general, latent factor of
cognition, g, the most current framework, termed Cattell-Horn-Carroll (CHC; Flanagan
& McGrew, 1997), primarily focuses on the assessment of many first order factors,
narrow cognitive abilities, that are subsumed by second order factors, or broad cognitive
abilities, which are then subsumed by the third order, overall factor. The CHC model has
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been extensively evaluated and is widely accepted in its modeling of cognitive abilities,
likely due to its foundation in factor analysis (Ackerman & Heggestad, 1997; McGrew,
2009; Schneider & McGrew, 2012; Stankov, 2000). Therefore, the CHC model supports
the guiding principles of cognitive assessment.
The structure of the CHC model is hierarchical in nature and assumes that each
factor is somewhat independent, suggesting that there is unique variance attributed to
each factor, not accounted for by the remaining factors in that order (Flanagan &
McGrew, 1997; Strauss et al., 2006). Therefore, given the multifaceted nature of
cognition, the most accurate assessment of cognitive functioning should include
multifaceted measures and techniques. However, given limitations in available tests, the
ability of patients, the time allotted for the assessment constrain evaluations of cognitive
functioning, this is not always possible, and therefore brief screening measures are
heavily relied upon in research regarding cognition.
One specific measure that has often been used in the assessment of overall
cognitive functioning, is the Mini-Mental State Exam (MMSE; Folstein et al., 1975),
particularly in relation to medication effects (e.g., Camargos et al., 2015; del Ser et al.,
2019; Jyrkkä et al., 2011; Marpillat et al., 2013; Ng et al., 2014; Puustinen et al., 2011;
Sordahl et al., 2019; Wright et al., 2009). While various factor structures for this brief,
screening measure of cognitive impairment have been identified, including both
unidimensional and multidimensional structures, orientation, attention, and memory
factors appear to be the most stable (Banos & Franklin, 2002; Jones & Gallo, 2000).
However, factors containing items attributed to language functioning, and construction
are less stable, and may be sample specific (Strauss et al., 2006).
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Therefore, in terms of measurement of second order factors, or broad cognitive
domains consistent with models of cognitive functioning, this measure is very limited.
Additionally, given the development of this scale to assess cognitive impairment, there is
a large ceiling effect for cognitively normal and mildly impaired patients (de Jager et al.,
2009; Hoops et al., 2009). Consequently, it may be nearly impossible to accurately detect
small to moderate effects of various prescription medications on global cognitive
functioning based on the use of this measure. Given the limitation of the MMSE, two
additional measures of global cognitive functioning will be reviewed below, which may
more accurately capture changes in cognitive functioning due to medication effects.
Overall Test Battery Mean
An Overall Test Battery Mean (OTBM) serves as a demographically corrected
overall index of an individual’s performance across a battery of neuropsychological tests
(Heaton et al., 2001; Miller & Rohling, 2001; Rohling et al., 2003). This is calculated by
first converting all raw test scores to standardized scores either through the use of conormative data or through the use of independently normed data. Scores must then be
converted to a common metric (e.g., T-scores, Z-scores, or standardized scores) and
subsequently averaged.
Analysis of this index suggests that it is analogous to the Halstead Impairment
Index (HII) derived from the standardized Halstead-Reitan Battery (HRB; Reitan &
Wolfson, 1993; Rohling et al., 2003). Reliability estimates of this global index in samples
with schizophrenia and normal controls suggest that the OTBM is stable over time and
generally consistent with Full-Scale IQ (FSIQ) from the Wechsler Adult Intelligence
Scale, third edition (WAIS-III; Heaton et al., 2001). Additionally, the OTBM is sensitive
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to differential overall cognitive performances by individuals with various classifications
of brain injury, groups diagnosed with general medical conditions, groups diagnosed with
depression, and poor effort groups (Green et al., 2001). Therefore, the OTBM appears to
be a sufficiently valid and reliable measure of global cognitive dysfunction. Given that
the calculation of this measure is based on performance across cognitive domains
assessed and is not limited to the domains provided within a single test, this index would
likely reflect the general ability (g) described in the CHC model given adequate
measurement of cognitive domains by individual test selection.
However, there are some limitations to this measurement. Specifically, with
regard to individuals who may demonstrate impairments in only select cognitive
domains. Since the OTBM only provides an index of central tendency for an individual’s
overall performance, individuals who are highly consistent in their performance across
domains would receive the same index score as those who are highly variable, and likely
show deficits in select domains. Therefore, cognitive intra-individual variability (e.g.
Hilborn et al., 2009) may serve as another measure of global cognitive functioning that is
particularly sensitive to subtle cognitive impairments.
Intra-Individual Variability
Cognitive intra-individual variability (IIV) serves as a measure of spread or
dispersion for an individual’s performance either within a single measure across time
(i.e., consistency) or across multiple measures that are in the same metric unit from a
single assessment (i.e., dispersion; Hill et al., 2013; MacDonald et al., 2009). Therefore,
it can be calculated in many different ways. The method most relevant to the present
study is that of dispersion. IIV is calculated by taking the standard deviation (SD) around
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an individual’s OTBM. Thus, greater IIV indicates greater differences in performance
across tasks and domains of a neuropsychological assessment, whereas smaller IIV
indicates more similar performances across tasks and domains of a neuropsychological
assessment.
Several studies of cognitive IIV suggest that this measure is one of CNS
dysfunction (Hill et al., 2013; Hultsch & MacDonald, 2004). Specifically, greater IIV has
been associated with frontal lobe impairment (Stuss et al., 2003), various dementing
illnesses (Ballard et al., 2001; Hultsch et al., 2000; Murtha et al., 2002; Walker et al.,
2000), and HIV status (Morgan et al., 2011). Additionally, cognitive IIV has been found
to be positively associated with TBI severity (Hill et al., 2013) and experiences of
cognitive decline in cognitively normal older adults (Hilborn et al., 2009). Thus, IIV may
serve as a sensitive indicator of cognitive integrity when evaluating the potential effects
of prescription medication use.

48

CHAPTER III
STATEMENT OF THE PROBLEM

The use of prescription medications in treating disease, relieving symptoms, and
preventing future physical or mental health events is extensive. Particularly, in adults and
older adults, who make up a considerable proportion of the population and are at the
highest risk of health-related problems. Despite evaluations of most prescription
medications prior to FDA approval and general use, risk of additional side effects
remains. This is particularly relevant in the case of relatively subtle and long-term effects
of prescription drug use in cognitively vulnerable populations, who are often excluded
from clinical trials (Boyd et al., 2012; Cho et al., 2011; McMurdo, 2005). Therefore, the
potential for patients to experience meaningful changes in cognitive functioning
following prescription medication use is very high, particularly for patients who use
multiple drugs.
This issue is highly relevant for physicians, specifically neurologists and
neuropsychologists. Without a clear understanding of the effects of medication groups
and specific medications, these physicians are unable to adequately clarify diagnoses,
make treatment recommendations, and inform prognoses of patients reporting cognitive
changes due to their reliance on patterns of performance on cognitive testing (Schoenberg
& Scott, 2011). Moreover, while the cognitive effects of some of these commonly
prescribed medications have been elucidated in recent years in both cross sectional and
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longitudinal studies, several limitations to the existing body of literature remain.
First, few studies examine cognitive effects of medication or polypharmacy in
broad clinical samples, limiting the generalizability of results. Second, across studies of
the effects of medication on cognitive functioning, many psychiatric, neurological, and
general medical diagnoses were inconsistently controlled for (e.g., del Ser et al., 2019 and
Obermann et al., 2013). By not adequately controlling for these potential confounding
variables, it is impossible to tease out the effects of pharmacotherapeutics from
disease/diagnosis effects in these studies. Third, the existing literature on the effects of
medication on cognition has generally avoided evaluations of a potential interaction
effect with polypharmacy by statistically controlling for possible effects by entering the
number of medications prescribed as a covariate in analyses (e.g., del Ser et al., 2019;
Nevado-Holgado et al., 2016; Wright et al., 2009). While these types of analyses provide
valuable information regarding the individual effects of medication and polypharmacy to
cognitive performance, the results are not necessarily generalizable to a significant
proportion of the population who use multiple medications concurrently.
Lastly, studies of medication effects on cognition generally restrict investigations
to a few screening tests of overall functioning or evaluation of limited domains of
cognitive functioning (e.g., del Ser et al., 2019; Jyrkka et al, 2011; Nevado-Holgado et
al., 2016; Obermann et al., 2013; Wright et al., 2009). Though these narrow
investigations have identified effects for some variables, a more thorough measurement
of cognition may detect more subtle effects of altered cognitive functioning.
Additionally, questions remain regarding the effects of medications and polypharmacy on
common neuropsychological measures of global and domain-specific functioning across
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a variety of cognitive domains.

The Present Study
The present study sought to add to and extend the literature regarding effects of
medications and polypharmacy on cognition in a broad clinical sample (e.g., TBI,
vascular/cerebrovascular accident [CVA], encephalitis, mental health diagnoses, etc.).
Specifically, the present study consisted of a thorough evaluation of the independent and
collaborative effects of medications and polypharmacy on cognitive functioning in both
global and specific domains, as measured by a standardized battery of common
neuropsychological tests. Given this objective, three primary aims were explored: (1) the
effects of medications and polypharmacy on global cognitive functioning, as assessed by
the OTBM; (2) the effects of medications and polypharmacy on global cognitive
functioning, as assessed by variability in performance across cognitive domains (IIV);
and (3) the effects of medications and polypharmacy on performance in specific cognitive
domains.
Hypotheses
The purpose of this dissertation is to address the following aims/hypotheses:
Aim One.
To examine the effects of medication use and polypharmacy on global cognitive
functioning, as assessed by OTBM, two-way Analyses of Covariance (ANCOVAs) were
used to evaluate the interaction and main effects of medication use and polypharmacy on
the OTBM. Specifically, these analyses were used to determine if there was an
interaction between medication use and polypharmacy level on OTBM, if there were
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differential effects of medication use on the OTBM, and if there were differential effects
of levels of polypharmacy on OTBM. To isolate the effects of medication use, levels of
polypharmacy, and their potential interaction, psychiatric, neurological, and general
medical diagnoses, as well as estimated premorbid functioning were each entered as
covariates. Given this objective the following hypotheses were tested:
1.1 There is a significant interaction between medication use and level of
polypharmacy on OTBM.
1.2 The OTBM of individuals using a medication is significantly different from
the OTBM of those not using the medication.
1.3 The OTBM of at least one polypharmacy level is significantly different from
the other polypharmacy levels.
Aim Two.
To examine the effects of medication use and polypharmacy on global cognitive
functioning, as assessed by IIV (see the Calculation of IIV section below), two-way
ANCOVAs were used to evaluate the interaction and main effects of medication use and
polypharmacy on IIV. Specifically, these analyses were used to determine if there was an
interaction between therapeutic group and polypharmacy on IIV, if there were differential
effects of medication use on IIV, and if there were differential effects of polypharmacy
on IIV. To isolate the effects of medication use, levels of polypharmacy, and their
potential interaction, psychiatric, neurological, and general medical diagnoses, as well as
estimated premorbid functioning were each entered as covariates. Given this objective the
following hypotheses were tested:
2.1 There is a significant interaction between medication use and level of
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polypharmacy on IIV.
2.2 The IIV of individuals using a medication is significantly different from the
IIV of those not using the medication.
2.3 The IIV of at least one polypharmacy level is significantly different from the
other polypharmacy levels.
Aim Three.
To examine the effects of medication use and polypharmacy on domain-specific
cognitive functioning, two-way Multivariate Analyses of Covariance (MANCOVA) were
used to evaluate the interaction and main effects of medication use and polypharmacy on
the following cognitive domain means: Attention/Working Memory, Processing Speed,
Verbal Reasoning, Visual Reasoning, Verbal Memory, Visual Memory, Executive
Functioning, Dominant Motor and Sensory Functioning, and Non-Dominant Motor and
Sensory Functioning. Specifically, these analyses were used to determine if there was an
interaction between medications and polypharmacy on each cognitive domain mean, if
there were differential effects of medication use on each cognitive domain, and if there
were differential effects of polypharmacy on each cognitive domain mean. Given this
objective the following hypotheses were tested:
3.1 There is a significant interaction between medication use and polypharmacy
on a domain-specific performance (e.g., domain mean).
3.2 The domain mean of individuals using a medication is significantly different
from the domain mean of those not using the medication.
3.3 The domain mean of at least one polypharmacy level is significantly different
from the other polypharmacy levels.
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CHAPTER IV
METHODOLOGY

Prior to data collection, this study was approved by the University of South
Alabama Institutional Review Board (IRB; see Appendix A). Archival data from two
practicing neuropsychologists, located in the Midwestern and Southeastern US, who
utilized the Meyers Neuropsychological System (MNS; Meyers, 2013) were utilized in
this study. Given that the study was retrospective nature and there was no foreseeable
risk, informed consent was not necessary from study participants.
All patients were evaluated between 1990 and 2020. At the time of their
assessment, participants completed a clinical interview and a comprehensive flexible
battery of neuropsychological tests, which included tests from the Meyers
Neuropsychological Battery (MNB; Meyers & Rohling, 2004): subtests from the WAISIII (Wechsler, 1997) or Wechsler Adult Intelligence Scale IV (WAIS-IV; Wechsler,
2008); Trail Making Test (TMT; Reitan & Wolfson, 1985); Judgement of Line
Orientation (JLO; Benton et al., 1983a); Finger Tapping (FTT; Reitan & Wolfson, 1985);
Finger Localization Test (FLT; Benton et al., 1983b); Token Test (TT; Spreen & Strauss,
1998); North American Adult Reading Test (NAART; Spreen & Strauss, 1998); Sentence
Repetition (SR; Spreen & Strauss, 1991); Controlled Oral Word Association Test (FAS;
Spreen & Strauss, 1998); Animal Naming (Animals; Spreen & Strauss, 1998); Boston
Naming (BNT; Spreen & Strauss, 1998); Dichotic Listening (DLT; Meyers et al., 2002;
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Roberts et al., 1994); Auditory Verbal Learning Test (AVLT; Spreen & Strauss, 1998);
Rey Complex Figure Test (RCFT; Meyers & Meyers, 1995); The Category Test Victoria Revision (VCT; Spreen & Strauss, 1991); and Forced Choice (FC; Brandt et al.,
1985).

Inclusion and Exclusion Criteria
Cases were only included in the study if participants were over the age of 18, if
medication information was included in the record, and the record contained sufficient
(e.g., at least 20%) of the study variables. Given the likelihood that follow-up or reevaluation data could unintentionally overly influence statistical analyses, these cases
were excluded from the study. Further, due to the distinct lower limit of standardized
measurement on neuropsychological tests, subjects with premorbid estimations or an
OTBM below the second percentile were not included in the study. Lastly, cases were
excluded from the study on the basis of failed validity tests or if they had a diagnosis of
malingering.
With regard to validity testing, the generally accepted standard indicating invalid
test performance is two or more failed validity measures over the course of a
neuropsychological evaluation (Larrabee, 2008; Meyers & Volbrecht, 2003; Meyers et
al., 2011). However, more recent literature indicates that many commonly used cut-offs
for performance validity tests (PVTs) may not be appropriate for use in cognitively
impaired samples due to high false-positive rates (McGuire et al., 2019; Martin et al.,
2020). Instead, a standard of three or more failed PVTs over the course of a
neuropsychological evaluation has been suggested as a more appropriate indicator of
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invalid performance in cognitively impaired samples (Martin et al., 2020). Therefore, if a
subject was not diagnosed with cognitive impairment and failed two or more validity
tests, they were excluded from the study. Contrarily, if the subject was diagnosed with
cognitive impairment and the patient failed three or more PVTs, they were excluded from
the study.

Participants
Seven hundred and fifty archived data files were reviewed for inclusion in this
study. Of these cases, 110 subjects were under the age of 18 and were excluded. Of the
remaining cases, two did not contain medication information, one did not include any
cognitive test data, five cases were re-evaluations, and five cases were duplicate entries
and therefore were excluded. An additional 35 cases were excluded due to containing
insufficient cognitive data to calculate at least 20% of the study outcome variables.
Of the remaining 592 cases, 22 cases were excluded due to having an OTBM
below the second percentile (e.g., T < 30). Further, one case file listed a diagnosis of
“malingering” and was excluded. Seventy-two additional cases were excluded due to
concerns for performance validity as described above. The remaining 497 cases were
retained for inclusion in the study. See Figure 1 for a visual representation of the
screening process.
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Figure 1
Screening Process and Exclusion Criteria for Archival Case Review

750 Cases

110 Under 18

640 Cases

2 No Medication
Information

638 Cases

1 No Cognitive
Test Data

637 Cases

5 Re-evaluation

632 Cases

5 Duplicate

627 Cases

35 Insufficient
Cognitive Data

592 Cases

22 OTBM < 30

570 Cases

1 Malingering
Diagnosis

569 Cases

72 Performance
Validity Concern

497 Cases
Note. OTBM = Overall Test Battery Mean.
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Table 2 presents characteristics of the final sample. As can be seen, the final
sample had a mean age of 40.75 (SD = 14.61, range = 18-80 years old). Average years of
education was 12.93 (SD = 2.36). Fifty-two percent of the sample identified as female. A
majority of the sample identified as Caucasian (n = 468, 94.0%). Number of medications
used by each subject ranged from 0 to 14 medications (M = 2.64, SD = 2.50).
Approximately 11% of cases had polypharmacy, as defined as using six or more
medications. Table B.1 and Table B.2 detail the diagnoses and medications for sample
participants, respectively. Additionally, given that medications with strong
anticholinergic properties come from a variety of therapeutic use categories and
medication families, medications with strong anticholinergic properties used by sample
participants are also provided in table B.3. Table 3 details overall cognitive performance
for the sample.
Of note, 47 subjects (9.5%) in this sample were considered “older adults,” as
defined as age at or above 65 years, at the time of the evaluation. Given the generally
small subsample of older adults, these groups were combined for all analyses. However,
much like the literature on medication use, medication use significantly differed across
these stages of life [c2(2, 497) = 17.75, p < .001). Specifically, 17.8 % of adults reported
not taking any medications, 72.4% of adults reported taking 1-5 medications, and 9.8% of
adults reported taking six or more medications (e.g., polypharmacy). For older adults on
the other hand, all subjects were taking at least one medication. Approximately 75% of
older adult subjects reported taking 1-5 medications. The remaining 25.5% of older adult
subjects reported taking 6 or more medications (e.g., polypharmacy). Performance on
cognitive measures did not differ between adults and older adults in the sample
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[tOTBM(495)=0.30, p=.384; tattention(492)=0.97, p=.166; tprocessing speed (491)=-0.18, p=.430;
tverbal reasoning(493)=1.03, p=.1.52; tvisual reasoning(494)=1.27, p=.102; tverbal memory(488)=-0.92,
p=.179; tvisual memory(479)=0.12, p=.451; texecutive functions(495)=0.43, p=.333; tdominant
motor(461)=-0.69,

p=.246; tnon-dominant motor(460)=-1.0, p=.150; tIIV(473)=-0.40, p=.345].

Table 2
Characteristics of the Final Sample
Total Sample
M (SD)
40.8 (14.6)
12.9 (2.4)
n (Valid %)
237 (47.7%)
259 (52.1%)

Adult
M (SD)
37.9 (12.1)
12.9 (2.3)
n (Valid %)
212 (47.1%)
237 (52.7%)

Older Adult
M (SD)
67.8 (6.5)
13.4 (3.1)
n (Valid %)
25 (53.2%)
22 (46.8%)

Variable
Age
Education
Gender
Male
Female
Ethnicity
Asian/Asian American
3 (0.6%)
3 (0.7%)
0 (0.0%)
Black/African American
13 (2.6%
12 (2.7%)
1 (2.1%)
Caucasian
467 (94.0%)
421 (93.6%)
46 (97.9%)
Other
13 (2.6%)
13 (2.9%)
0 (0.0%)
Medication Use
No Medications
80 (16.1%)
80 (17.6%)
0 (0.0%)
1-5 Medications
361 (72.6%)
326 (72.4%)
35 (74.5%)
Polypharmacy (6+)
56 (11.3)
44 (9.8%)
12 (25.5%)
Forensic Evaluation
120 (24.1%)
114 (25.3%)
6 (12.8%)
PVT Failures
0
263 (52.9%)
233 (51.8%)
30 (63.8%)
1
208 (41.9%)
194 (43.1%)
14 (29.8%)
2
26 (5.2%)
23 (5.1%)
3 (6.4%)
Neuropsychology Practice
Midwestern
434 (87.3%)
393 (87.3%)
41 (87.2%)
Southeastern
63 (12.7%)
57 (12.7%)
3 (12.8%)
Note. n = 497. M = mean. SD = Standard Deviation. n = frequency. Due to missing data
across variables, frequencies of variables may not add up to the total sample size. PVT
= Performance Validity Test.
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Table 3
Summary of Cognitive Performance for Sample
n
M
SD
Premorbid Estimate
485
46.5
4.3
OTBM
497
44.5
5.5
IIV
475
9.7
2.4
Attention/Working Memory
494
44.3
6.9
Processing Speed
493
45.1
7.7
Verbal Reasoning
495
45.6
7.0
Visual Reasoning
496
45.1
6.9
Verbal Memory
490
42.1
10.7
Visual Memory
481
43.8
10.5
Executive Functioning
497
45.3
7.0
Dominant Motor Function
463
46.8
8.3
Non-Dominant Motor Function
462
46.3
7.7
Note. N = 497. Sample sizes differ across variables due to missing values. n =
sample size. M = mean. SD = Standard Deviation. OTBM = Overall Test Battery
Mean. IIV = Intra-Individual Variability. OTBM and domain means are presented
as T Score values.

Measures

Meyers Neuropsychological Battery
All study participants completed the MNB (Meyers & Rohling, 2004) at the time
of their assessment. The MNB, is a semi-flexible battery of common neuropsychological
tests that are presented in a standard order. The tests that make up the core of this battery
have been shown to be sensitive to brain injury (Meyers & Rohling, 2009; Meyers &
Rohling, 2004; Volbrecht et al., 2000) and they rank among the most common tests used
by clinical neuropsychologists overall (Rabin et al., 2016).
The following tests are part of the MNB core measures: Block Design,
Similarities, Digit Span, Arithmetic, Information, Coding, and Picture Completion from
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the WAIS-III/IV (Meyers et al., 2013; Pilgrim et al., 1999), TMT (Reitan & Wolfson,
1985), JLO (Benton et al., 1983a), FTT (Reitan & Wolfson, 1985), FLT (Benton et al.,
1983b), TT (Spreen & Strauss, 1998), NAART (Spreen & Strauss, 1998), SR (Spreen &
Strauss, 1991), FAS (Spreen & Strauss, 1998), Animals (Spreen & Strauss, 1998), BNT
(Spreen & Strauss, 1998), DLT (Meyers et al., 2002; Roberts et al., 1994), AVLT
(Spreen & Strauss, 1998), RCFT (Meyers & Meyers, 1995), VCT (Spreen & Strauss,
1991), and FC (Brandt et al., 1985). Scores derived from performance on these tests
assess the following cognitive domains: Attention/Working Memory, Processing Speed,
Verbal Reasoning, Visual Reasoning, Verbal Memory, Visual Memory, Executive
Functioning, and Dominant and Non-Dominant Motor and Sensory Functioning (Lezak
et al., 2012; Meyers & Rohling, 2009; Strauss et al., 2006).
Given the semi-flexible nature of the MNB, other tests were added to the core
MNB and/or were substituted for a core test at the discretion of the supervising
neuropsychologist at the time of the assessment and, subsequently, factored into the
calculation of study variables (e.g., OTBM, IIV, and cognitive domain means). Eleven
additional neuropsychological tests were used across the sample. However, each of these
tests was used for ≤ 5% of sample participants. Given this, for concision, only MNB core
tests are described below. However, all tests (core and supplemental) used for sample
participants and to which cognitive domain they assessed when administered are listed in
Table B.4.
Wechsler Adult Intelligence Scale.
The Wechsler Adult Intelligence Scale (WAIS) is a measure of intellectual
functioning in older adolescents and adults. The two most recent versions, WAIS III and
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WAIS IV, are composed of 10 core subtests that allow for the calculation of a FSIQ and
four index scores: verbal ability (VCI), perceptual ability (POI or PRI), working memory
(WMI), and processing speed (PSI; Wechsler, 1997; Wechsler, 2008). Internal
consistency reliability is very high for the FSIQ, index scores, and core subtests. Further,
subtest specificity is adequate across core subtests, an indication of the proportion of
subtest variance that is reliable and unique to the subtest (Strauss et al., 2006).
A short form of each version of the WAIS (III or IV) was used as part of the
MNB, which includes the Block Design, Similarities, Digit Span, Arithmetic,
Information, Coding, and Picture Completion subtests (Meyers et al., 2013). Each of the
subtest comprising the short version is known to be sensitive to various forms of brain
dysfunction (see Strauss et al., 2006). Additionally, index scores and FSIQ calculated
from this abbreviated version correlate highly with the full-length scores, correlations
range from .92 to .99 (Meyers et al., 2013; Pilgrim et al., 1999). Effect sizes calculated
from comparisons of scores from the short form to the original are negligible (Meyers et
al., 2013). Therefore, the short form of the WAIS III/IV appears to adequately assess IQ
and index performances.
With regard to the specific subtests, block design is a measure of perceptual
reasoning and visual spatial construction, in which patients are asked to arrange blocks to
match a picture. Similarities is a measure of verbal abstraction, in which the participant is
asked to describe how two words are alike. Digit Span and Arithmetic are measures of
basic attention and working memory in which patients are asked to sequence
progressively longer strings of digits and quickly solve mathematics-based word
problems, respectively. Digit Symbol/Coding is a measure of visual attention, learning,
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and processing speed, in which the patient decodes numbers based on a key. Information
is a measure of crystallized knowledge, attention, and long-term verbal recall, in which
patients are asked to answer questions of general knowledge. Picture completion is a
measure of visual perception, in which the patient is asked to quickly identify what piece
of various pictures was removed.
As can be seen from Table B.4, block design was part of the visual
reasoning/perceptual organization MNB domain (Meyers & Rohling, 2009; Volbrecht et
al., 2000; Wechsler, 1997; Wechsler, 2008). Similarities was part of the verbal
reasoning/verbal comprehension MNB domain (Meyers & Rohling, 2009; Volbrecht et
al., 2000; Wechsler, 1997; Wechsler, 2008). Digit Span and Arithmetic were part of the
attention/working memory MNB domain (Meyers & Rohling, 2009; Volbrecht et al.,
2000; Wechsler, 1997; Wechsler, 2008). Digit Symbol/Coding was part of the processing
speed MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler, 1997;
Wechsler, 2008). Information was part of the verbal reasoning/verbal comprehension
MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler, 1997;
Wechsler, 2008). Picture completion was part of the visual reasoning/perceptual
organization MNB domain (Meyers & Rohling, 2009; Volbrecht et al., 2000; Wechsler,
1997; Wechsler, 2008).
Trail Making Test.
TMT is a two-part, timed task that first involves drawing a line to connect a
sequence of numbers in ascending order (Part A), then drawing a line connecting both
numbers and letters in ascending order by switching between connecting numbers and
letters (i.e., 1-A-2-B; Part B; Reitan & Wolfson, 1985). TMT Part A serves as a measure
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of attention and concentration, whereas Part B serves as a measure of sequencing and
mental set shifting (Volbrecht et al., 2000). Each part of the TMT is highly sensitive to
cognitive dysfunction across a range of populations, particularly those with deficits in
attention and frontal lobe functions (Greenlief et al., 1985; Hervey et al., 2004; Mathias
& Wheaton, 2007; Mitrushina et al., 2005; Reitan, 1958; Roca et al., 2013; Ruffolo et al.,
2000; Segalowitz et al., 1992). As indicated in Table B.4, TMT A was part of the
processing speed MNB domain, whereas TMT B was part of the executive functioning
MNB domain (Meyers & Rohling, 2009; Strauss et al., 2006).
Judgement of Line Orientation.
JLO is a 30-item measure of visual perception in which patients compare and
identify identically oriented lines from lines that have been shortened (Benton et al.,
1983a). Split-half reliability for the JLO is high, ranging from .84 to .91, and test-retest
reliability is .90 (Strauss et al., 2006). JLO performance is highly related to performance
on visual-spatial subtests of the WAIS (Strauss et al., 2006). Impairments on this test are
associated with lesions in the right posterior parietal region (Benton et al., 1983a; Tranel
et al., 2009). As indicated in Table B.4, JLO was part of the visual reasoning/perceptual
organization MNB domain (Meyers et al., 2009).
Finger Tapping.
FT, also known as the finger oscillation test, is a measure of psychomotor speed
and persistence in which a patient rapidly taps their index finger on their dominant hand
for 10 seconds (Reitan & Wolfson, 1985). The same procedure is subsequently used on
the non-dominant hand. Reliability coefficients across studies is variable, with some
coefficients as low as .58 (Strauss et al., 2006). Although, most reliability appears to
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generally be between .77 and .94 (Lezak et al., 2012). FTT demonstrates strong
convergent and discriminant validity, as evidenced by high correlations with performance
on the Purdue Pegboard Test, another measure of psychomotor functioning requiring
precise finger movements, and low correlations with grip strength and the processing
speed index from the WAIS III (Strauss et al., 2006). As can be seen in Table B.4, FTT
performance for the dominant hand was part of the dominant motor and sensory MNB
domain, whereas FTT performance for the non-dominant hand was part of the nondominant motor and sensory MNB domain (Meyers, 2013).
Finger Localization Test.
The FLT is a measure of tactile identification in which a patient identifies and
names the finger indicated by the examiner (Benton et al., 1983b). This test is composed
of three parts, in which the patient identifies the fingers touched by the examiner, then
identifies the fingers touched by the examiner when their hand is hidden from view, then
identifies pairs of fingers touched by the examiner simultaneously. Bilateral impairments
on the FLT have been associated with lesions in the left posterior perisylvian region
(Benton et al., 1983b). However, unilateral and contralateral impairments have been more
associated with right hemisphere lesions (Gainotti & Tiacci, 1973). As indicated in Table
B.4, FLT performance for the dominant hand were part of the dominant motor and
sensory MNB domain, whereas FLT performance for the non-dominant hand were part of
the non-dominant motor and sensory MNB domain (Meyers, 2013).
Token Test.
The TT assesses receptive language and comprehension of instructions through
the administration of 39 increasingly complex commands (Spreen & Strauss, 1998).
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Internal reliability for the TT is high, coefficients ranging from .90 to .92 (Spellacy &
Spreen, 1969). The TT correlates highly with other measures of receptive language,
correlation of .71 with the Peabody Picture Vocabulary Test (Lass & Golden, 1975),
suggesting high construct validity. The token test is sensitive to language disorders and
focal left-hemisphere lesions (Strauss et al., 2006). As can be seen in Table B.4, TT was
part of the verbal reasoning/verbal comprehension MNB domain (Meyers & Rohling,
2009).
North American Adult Reading Test.
The NAART is a 35-item measure of premorbid intellectual ability, in which a
patient reads printed words (Spreen & Strauss, 1998). Reliability estimates are above .90
(Raguet et al., 1996; Uttl, 2002) and predictive validity FSIQ and verbal comprehension
is high, correlations range from .40 to .80 (Strauss et al., 2006). In the MNB the NAART
was used in conjunction with demographic data to estimate pre-morbid IQ (Meyers,
2013). Due to the role of this measure in determining estimated premorbid functioning, it
was not included in the calculation of participant’s OTBM or IIV.
Sentence Repetition.
SR is a 22-item test of verbal attention, expressive language, and receptive
language in which patients repeat increasingly long sentences (Spreen & Strauss, 1991).
Test-retest reliability after 1 year was .84, indicating that SR performance is generally
stable over time (Klonoff et al., 1970). SR correlates highly with other tests of repetition,
with correlation coefficients ranging from .75 to .88 (Lawriw, 1976; Shewan & Kertesz,
1980). SR correlates moderately with the Wechsler Memory Scale overall memory
quotient (.38; Vargo & Black, 1984). Further, SR appears to be sensitive to left
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hemisphere impairment (Meyers et al., 2000). As indicated in Table B.4, SR was part of
the attention/working memory MNB domain (Meyers & Rohling, 2009).
Controlled Oral Word Association Test.
FAS is an assessment of word fluency and mental flexibility during which
patients produce as many words as they can that begin with a specific letter in one minute
(Spreen & Strauss, 1998). FAS consists of three trials with three different letters,
typically F, A, and S. Internal consistency among F, A, and S and test-retest reliability is
high, .83 and .74, respectively (Tombaugh et al., 1999). Correlations across different
fluency tasks is high, with correlations ranging from .85 to .94 (Cohen & Stanczak, 2000;
Lacy et al., 1996; Troyer, 2000). As indicated in Table B.4, FAS was part of the verbal
reasoning/verbal comprehension MNB domain (Meyers & Rohling, 2009).
Animal Naming.
Animals is an assessment of word fluency and mental flexibility in which patients
produce as many words as they can in one minute that are within a specific semantic
cluster (i.e., animals; Spreen & Strauss, 1998). Correlations between semantic fluency
tests with various target categories are moderately high, with correlations ranging from
.66 to .71 (Delis et al., 2001; Riva et al., 2000). FAS generally correlates moderately with
animals, with correlation coefficients ranging from .31 to .47, suggesting that each test
provides reliable and unique variance (Johnson-Selfridge et al., 1998; Riva et al., 2000;
Strauss et al., 2006; Tombaugh et al., 1999). Semantic fluency also correlates moderately
to tests of naming, with correlation coefficients ranging from .57 to .68 (Strauss et al.,
2006). As indicated in Table B.4, animals was part of the attention/working memory
MNB domain (Meyers & Rohling, 2009).
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Boston Naming Test.
The BNT is a 60-item measure of confrontation naming in which a patient
generates the common name of objects displayed (Spreen & Strauss, 1998). If the patient
misperceives an object, a semantic cue is given. If the patient generates the correct name
at that point, they are still awarded full points for the item. Measures of internal
consistency reliability of the BNT range from .78 to .96 (Strauss et al., 2006). Flanagan
and Jackson (1997) demonstrated adequate reliability over one to two-week periods in
older adults, with performances correlated at .91. BNT correlates highly with other
measures of confrontation naming, such as the Multilingual Aphasia Examination Visual
Naming Test (Axelrod et al., 1994; Schefft et al., 2003). As indicated in Table B.4, BNT
was part of the verbal reasoning/verbal comprehension MNB domain (Meyers &
Rohling, 2009).
Dichotic Listening.
DL is a 30-item test that involves listening to words produced in either the right or
left ear or two words presented simultaneously in both ears and repeating the word(s) that
were presented (Meyers et al., 2002; Roberts et al., 1994). This test measures both
hemispheric speech dominance and central auditory processing via three index scores:
left index, right index, and both ear index (Strauss et al., 2006). Test-retest reliability
showed no significant differences in scores after six-weeks, suggesting adequate stability
over time (Springer et al., 1991). DL scores are sensitive to both localized and diffuse
brain injuries that affect the deep cerebral white matter pathways (Meyers et al., 2002;
Roberts et al., 1994). As indicated in Table B.4, DL left and right index scores were part
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of the verbal reasoning/verbal comprehension MNB domain, whereas the DL both ear
index was part of the executive functioning MNB domain (Meyers & Rohling, 2009).
Auditory Verbal Learning Test.
The AVLT, or the Rey Auditory Verbal Learning Test, is a measure of verbal
learning and memory, which assesses immediate recall memory, learning over trials,
susceptibility to interference, delayed recall memory, and recognition memory for 15
target words (Spreen & Strauss, 1998). Internal reliability of the AVLT total score is .90
(Van den Burg & Kingma, 1999), whereas test-retest reliability ranged from .60 to .70
(Strauss et al., 2006). The AVLT delayed recall score correlates highly with the AVLT
total score (Van den Burg & Kingma, 1999) suggesting strong construct validity. AVLT
scores also correlate moderately well with other measures of learning and memory,
suggesting that while the AVLT is similar to these other measures of learning and
memory, it also provides reliable and unique variance compared to other measures
(Crossen & Wiens, 1994; Johnstone et al., 2000; Stallings et al., 1995). This uniqueness
may be derived from the non-contextualized nature of the word lists compared to other
measures of list-learning memory and story memory. As indicated in Table B.4, AVLT
trial 1 total was part of the attention/working memory MNB domain (Meyers & Rohling,
2009). AVLT learning, immediate recall, delayed recall, and recognition were all part of
the verbal memory/auditory memory and learning MNB domain (Meyers & Rohling,
2009).
Rey Complex Figure Test.
The RCFT is a measure of visual-spatial construction and visual memory, which
assesses perceptual organization in the copy, as well as immediate and delayed recall and
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recognition for a non-verbal stimulus (Meyers & Meyers, 1995). Split-half reliability,
computed for the details of the figure, are above .60 for the figure copy and above .80 for
both immediate and delayed recall conditions (Berry et al., 1991; Fasteneau et al., 1996).
This suggests that the details from the figure are fairly consistent with regards to their
saliency and the underlying processes involved in their perception and recreation of the
stimulus. Further, test-retest reliability ranges from .76 to .89 for immediate recall,
delayed recall, and recognition scores (Meyers & Meyers, 1995).
Correlational and factor analytic studies support the validity of the RCFT as a
measure of visual-spatial construction and memory (Strauss et al., 2006). For example,
RCFT copy scores are only moderately correlated with immediate and delayed recall
scores, coefficients of .33 and .38, respectively (Meyers & Meyers, 1995). Additionally,
immediate and delayed recall scores are correlated at .88, yet recognition scores are
correlated with recall at .15 (Meyers & Meyers, 1995). This suggests that recall and
recognition memory as assessed with the RCFT, are two distinct aspects of memory. In
terms of convergent and discriminant validity, RCFT scores are significantly related to
other tasks of memory and construction ability but are not related to measures of
language (Meyers & Meyers, 1995). As indicated in Table B.4, RCFT copy was part of
the visual reasoning/perceptual organization domain (Meyers & Rohling, 2009), and
RCFT immediate recall, delayed recall, and recognition performance scores were all part
of the visual memory/nonverbal memory and learning MNB domain (Meyers & Rohling,
2009).
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The Category Test- Victoria Revision.
VCT is an 81-item test measure of reasoning and problem solving which consists
of deducing a classification principle by using feedback from the administrator (Spreen &
Strauss, 1991). The original Category Test shows strong psychometric properties, such as
internal consistency above .95 and moderate correlations with FSIQ and performance
subtests of the Wechsler tests (Strauss et al., 2006). The VCT appears to preform
similarly, as evidenced by cross-validation studies (Kozel & Meyers, 1998; Sherrill,
1985). As can be seen in Table B.4, VCT was part of the executive functioning MNB
domain (Lezak et al., 2012; Strauss et al., 2006).
Forced Choice.
FC is a measure of attention in which a patient recalls as many items as they can
from a list of 20 words presented verbally (Brandt et al., 1985). Subsequently, the patient
chooses which word was on the 20-item list from pairs of words. This test differentiates
amnesia malingering simulators, normal controls, and clinical groups, with individuals
malingering amnesia performing significantly worse than individuals with organic
amnesia on the forced-choice portion of this measure (Brandt et al., 1985). Similar
measures of forced-choice performance validity measures have shown satisfactory
internal consistency scores with malingered head injury simulators (Inman et al., 1998).
Additionally, Arnett and Franzen (1997) found that the free-recall portion of a similar
memory test correlates moderately to the Wechsler Memory Scale delayed recall index.
This suggests that the free recall portion may indeed serve as a measure of impairment.
As indicated in Table B.4, FC is part of the attention/working memory domain (Meyers
& Rohling, 2009).
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Imbedded Performance Validity.
In addition to performance scores on the above tests, nine imbedded measures of
performance validity are calculated within the MNB. These validity measures are derived
from FC, RCFT, JLO, TT, DLT, SR, AVLT recognition, FTT, and Block Design, Digit
Span, and Digit Symbol/Coding from the WAIS III/IV (Meyers & Rohling, 2004; Meyers
& Volbrecht, 2003). Each of the nine measure relies on patterns of performance that are
statistically improbable. For example, inconsistent patterns of functioning or impairments
within and across tests, unusually poor performances on specific “easy” items, and
significantly more errors across tests than would be expected for given observed patient
characteristics each factor into a person’s performance on these validity scales. Failure on
any one measure of performance validity is defined as follows: FC performance £ 10;
attention, encoding, and storage memory error patterns (MEPs) in independently
functioning individuals; Reliable Digit Span £ 6; JLO £ 12; TT Orientation £ 150; DLT £
9; SR £ 9; AVLT recognition £ 9; or FTT speed > 10 points above an estimated FTT
speed calculated based on Block Design, Digit Symbol/Coding, and the RCFT copy
(Meyers & Rohling, 2004; see Meyers & Volbercht, 2003 for detailed explanations of
each performance validity measure).

Procedure
Before the archival data was provided to the principal investigator, raw data were
either normed using their respective manual (e.g., WAIS III/IV) and entered into the
MNS, or they were entered into the MNS to be normed using a “smoothed” norming
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system. Once standardized using the “smoothed” normative data, all standardized scores
were converted to a common metric (T-scores) using the following formula:
%% − 10
! = #$
* ∗ 10, + 50
3
where T is the normed ss minus the arbitrary mean used for ss, divided by the arbitrary
SD of ss, multiplied by the arbitrary SD used for T-scores, and finally added to the
arbitrary mean used for T-scores (Miller & Rohling, 2001). Data were then integrated
into a modified Rohling Interpretive Method approach (RIM; Meyers, 2013).
The Rohling Interpretive Method
RMI (Miller & Rohling, 2001) provides a statistical method of evaluation and
interpretation of standardized scores from flexible batteries that is similar to summaries
provided through co-normed fixed batteries, such as the HII (Reitan & Wolfson, 1985).
The basis of this methodology is derived from recommended practices for conducting
meta-analytic reviews and allows for examination of performance at global, domainspecific, or test-specific levels (see Miller & Rohling, 2001 for the specific steps to using
RIM).
This method of statistical evaluation and calculations of indices of
neuropsychological performance minimizes common problems associated with cognitive
assessment using flexible batteries, such as issues related to co-variation of instruments
and weighting decision (Miller & Rohling, 2001). Additionally, the RIM within the MNS
harnesses the statistical power associated with evaluating cognitive performance using
multiple measures through calculated global (OTBM) and domain indices (Miller &
Rohling, 2001), above and beyond that of any one measure used independently and
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screening measures of cognitive functioning. These features, when used together, are
thought to reduced Type II error and improve diagnostic accuracy. Thus, use of the
modified RIM within the MNS may be particularly effective in detecting subtle deficits
and strengths across and within cognitive domains.
Data Cleaning Procedures
Once test data were scored, normed, and integrated into a modified RIM
approach, data were extracted from the MNS, deidentified, and provided to the principal
investigator along with the neuropsychological report, if available. Necessary
information, including demographic variables, such as age, sex, race, level of education,
and occupation; current medications; substance use; psychiatric diagnoses; neurological
diagnoses; medical diagnoses; and number of performance validity test failures were
entered into a password protected database.
Each medication listed for study participants was assigned three classifications:
(1) therapeutic use, (2) drug family, and (3) drug name (generic; See table B.2). While
many medications can be used for various therapeutic uses, information that would aid in
illuminating the intended therapeutic use of the prescription medication was not typically
available. For example, medications were not associated with specific diagnoses.
Additionally, information regarding dosage, duration of use, and frequency of use, as
well as when the medication was last administered in relation to the neuropsychological
testing session, which could impact their effects on cognition (Burchum & Rosenthal,
2016; Katzung, 2018), were not available in the data. Thus, all prescription medications
reported by study participants were evaluated and the subsequent classifications were
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based on their pharmaceutical composition, ACT code (WHO, 2021), and consultation
with a pharmacology expert.
The levels of medication classification were hierarchical in nature, with
therapeutic use being the largest classification. Each therapeutic use group generally
contained several different drug classes. Each drug class generally contained several
specific drug names. Drug names were the most specific identification of medications
used in this study. Participants who denied use of any medications at the time of their
neuropsychological evaluation were entered into a “no medication” group at each of the
three classification levels and served as a control group for the analyses.
The number of medications reported at the time of the neuropsychological
evaluation were used to categorize cases into three polypharmacy groups. Participants
who reported using one to five medications at the time of their neuropsychological
evaluation were assigned to the “no polypharmacy” group. Participants who reported
using six or more medications at the time of their neuropsychological evaluation were
assigned to the “polypharmacy” group. Participants who denied using any medications at
the time of their neuropsychological evaluation were again assigned into the “no
medication” group and served as a control group for the analyses.
Raw and standardized scores (T-scores corrected for age, education, gender,
handedness, and ethnicity, where appropriate, according to MNS normative data or the
WAIS III/IV manual) for all tests and MNB calculated domains were also entered into
the database when available. If not already present in the archival data, OTBM, domain
means, and IIV were calculated for each participant as follows.
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Calculation of OTBM and Domain Means.
The OTBM and domain means were calculated for each participant with missing
data based on the battery of tests administered to that patient and, if valid, standardized
T-scores were available according to the modified RIM (see Miller & Rohling, 2001).
Specifically, additional tests were assigned to the MNB domains described in Table B.4
with guidance from Miller and Rohling (2001), Lezak et al. (2012), and Strauss et al.
(2006). Domain means were calculated by summing T-scores for a participant’s cognitive
performance across all scores within the domain and dividing by the number of data
points available for that patient. The OTBM was calculated by summing T-scores for a
participant’s cognitive performance across all scores within the neuropsychological
battery and dividing by the number of data points available for that patient.
Calculation of IIV.
If not already present in the archival data, IIV was calculated for each participant
with valid, standardized data (T-scores) for performance measures of cognitive
functioning according to the modified RIM (see Miller & Rohling, 2001). This was
accomplished by taking the square root of the variance within one person’s standardized
score (T-score) performance on all MNB measures of cognitive function. The resulting
overall test battery SD (OTBM SD) for each participant around their own OTBM serves
as an index of variability within each participant’s performance on measures across the
test battery, IIV.
Plan of Analysis
To address Aim One, to evaluate the effects of medication use and polypharmacy
on global cognitive functioning, as assessed by OTBM, a two-way ANCOVA was

76

planned. Similarly, a two-way ANCOVA was planned to address Aim Two and evaluate
the effects of medication use and polypharmacy on global cognitive functioning, as
assessed by IIV. To address Aim Three, two-way MANCOVAs were planned to evaluate
the effects of medication use and polypharmacy on domain specific cognitive
functioning.
Given the wide variety of medications reported by study participants, with some
medications used by only one or two study participants, a deductive approach was taken
to evaluate the effects of medication and polypharmacy on cognition using the
medication classifications described above. For example, the initial evaluation of each
aim was conducted using medications classified by therapeutic use. When a significant
interaction or main effect was identified and subsequent simple effects/post-hoc analyses
indicated that the OTBM, IIV, or cognitive domain means of subjects using medications
from a specific therapeutic group differed significantly from subjects who were not
taking medications from the therapeutic group and/or subjects who were not taking any
medications, subsequent analyses were performed with the drug families categorized
within the significant therapeutic use group.
Only drug families classified within the hierarchy of the therapeutic use
categories which produced significant results were included in subsequent analyses. For
those drug families, the same procedure was employed. Only when a significant
interaction or main effect, and subsequent simple effects/post-hoc analyses, indicated that
the OTBM, IIV, or cognitive domain mean of subjects using medications within the drug
family was significantly different from subjects who were not taking medications from
the drug family and/or subjects who were not taking any medications, were the drug
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names within the medication group evaluated. Use of specific medications (medication
name) were only included in analyses if both of the superordinate classifications were
significant.
The rational for this deductive approach is twofold. First, use of this deductive
approach aided in controlling family-wise error and the inflated risk of Type I error
associated with completing multiple analyses. Second, by evaluating the superordinate
medication category first (e.g., therapeutic use), we ensured that the analyses had the
highest number of reported users, and therefore the highest possible power to find mean
differences, before exploring the effects of medications with individual drug names. This
later point was particularly important because there was significant variability across use
of specific medications. For example, while many of the specific medications used by
study participants fell into the same therapeutic use or drug family groups, many of the
individual medications were only used by a few subjects each (e.g., < 5 subjects). Thus, if
analyses were initially run with drug names, the extremely small sample sizes across drug
names would not have had sufficient power to identify significant results.
A Priori Power Analysis
Another way power was optimized in this study was by limiting analyses to
groups with a sufficient number of medication users. To determine the optimal sample
size for the primary analyses, an a priori power analysis was conducted using G*Power
(Faul et al., 2008) anticipating a medium effect size and a Bonferroni alpha correcting for
10 analyses. Results from this analysis indicated that a sample size of 476 was required to
achieve a power of .80 given an effect size of .20 (medium effect size), a Bonferroni
corrected alpha of .005, and a numerator df of 4, for 7 groups, with covariates. Therefore,
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the sample size of 497 was determined to be sufficiently powered to carry out the primary
analyses. However, considering this overall sample size across groups, medication use
categories needed at least 68 subjects to adequately power the analysis. Therefore,
medication use categories with less than 68 subjects were not evaluated.
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CHAPTER V
RESULTS

Preliminary Analyses
Prior to conducting the primary analyses, all variables were assessed for coding
errors, missing values, univariate and multivariate outliers, and assumptions of normality
using SPSS, Version 28 (IBM Corp., 2021). Coding errors were corrected based on the
available raw scores and T-scores. Coding errors that were unable to be corrected were
coded as missing.
With regard to missing data, for the 497 cases, the proportion of missing data was
minimal across most study variables. Data were missing across these variables as
follows: diagnosis (19.5%); medication (0%); polypharmacy (0%); premorbid estimate
(2.4%); OTBM (0%); IIV (4.4%); Attention and Working Memory (0.6%); Processing
Speed (0.8%); Verbal Reasoning (0.4%); Visual Reasoning (0.2%); Verbal Memory
(1.4%), Visual Memory (3.2%); Executive Functioning (0%); Dominant Motor
Functioning (6.8%); and Non-Dominant Motor Functioning (7.0%). Analyses of these
variables indicated that 49 subjects (9.9%) were missing data on any one variable.
A series of one-way ANOVAs indicated that cases with missing values were
systematically related to the sequence of data entry (a randomly constructed variable), the
neuropsychologist who evaluated the patient, total PVT failures, processing speed, and
executive functioning. This pattern of missingness is consistent with data that is missing

80

at random (MAR). While it is possible that the pattern of missingness is systematically
related to another variable not measured in the data set, indicating that the data is not
missing at random (NMAR), there is no obvious theoretical reason to suspect this in the
present data.
Given that cases with missing data were minimal across most variables, in most
instances constituting less than 5% of the total sample, and the data are likely MAR,
participants with missing data were retained in the sample. Subsequent analyses were
completed on the sample of 497 cases. Pairwise deletion was used to address the minimal
amount of missing data in primary analyses (Schlomer et al., 2010).
Univariate outliers, defined as observations having z-scores > |3|, were found for
3 cases (0.6%) on premorbid estimate, 6 cases (1.2%) on IIV, 2 cases (0.4%) on
processing speed, 7 cases (1.4%) on verbal reasoning, 1 case (0.2%) on visual reasoning,
1 case on executive functioning (0.2%), 8 cases (1.6%) on dominant motor functioning,
and 4 cases (0.8%) on non-dominant motor functioning. Of these, only one value, on nondominant motor functioning, was extreme in nature (e.g., z-score > 5.0) and was replaced
with the next closest value. Mahalanobis distances greater than 32.91 was identified for
10 cases (2%), suggesting they may be possible multivariate outliers. Given the relatively
small percentage of possible univariate and multivariate outliers, the relatively large
sample size, and the fact that only one univariate outlier was extreme in magnitude
requiring replacement, no other cases were deleted or modified, as recommended by
Meyers et al. (2017).
With regard to the distributions of variables, IIV and dominant motor functioning
exhibited slight deviations from normality as evidenced by skew and kurtosis values, and
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visual inspection of Q-Q plots and histograms. Specifically, IIV was slightly positively
skewed (1.09) and dominant motor functioning was slightly negatively skewed (-1.37).
Distributions for both IIV and dominant motor functioning were leptokurtic (kurtosis =
1.62 and 3.53, respectively). However, according to Kim (2013), these values do not
represent substantial deviations from normality given the large sample size. Distributions
of all other variables were within normal limits with regard to skewness, kurtosis, and
visual examination of QQ-plots and histograms. Therefore, no data transformations were
deemed necessary. Linearity assumptions were deemed satisfactory by visual inspection
of bivariate scatterplots and significant bivariate correlations (see Tables B.5 through
B.11 for correlations between study variables).
Given that only two variables showed slight deviations from normality and
simulation analyses indicate that ANOVA modes are robust to deviations from nonnormality, particularly in larger samples (Khan & Rayner, 2003), the data were judged to
be appropriate for further analyses of variance. However, due to sample size limitations
only medications within the following therapeutic use categories were able to be
evaluated in the primary analyses: anticholinergics, antidepressants, anxiolytics,
analgesics, antiepileptics, cardiovascular, anti-inflammatory, and hormones using the
deductive approach described above. Given the reduction in analyses performed, the
Bonferroni corrected alpha value was adjusted accordingly.
Additionally, given the significant relationships identified across the outcome
variables, medication’s therapeutic use categories, diagnoses, and additional cognitive
and demographic related variables (e.g., estimated premorbid functioning, age, location
of evaluation), as can be seen in tables B.5 through B.11, these variables were evaluated
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for potential use as covariates in the primary analyses. Estimated premorbid functioning,
subject age, location of evaluation; use of antidepressants, anxiolytics, antipsychotics,
analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and
hormones; and diagnoses of internalizing disorders, substance abuse, severe mental
illness (SMI), learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory
disorders, and pain conformed to the assumptions of linearity of regression and
homogeneity of regression at both the univariate and the multivariate levels. Therefore,
these variables were used as covariates in all primary analyses, except for when the
corresponding or subordinate medication variable was used as an independent variable.

Primary Analyses Aims One and Two
To examine the effects of medication use and polypharmacy on global cognitive
functioning, as assessed by OTBM and IIV, (use of medication) X 3 (polypharmacy)
between subjects ANCOVAs were used to determine if there was an interaction between
medication use and polypharmacy level on OTBM or IIV, if there were differential
effects of medication use on the OTBM or IIV, and if there were differential effects of
levels of polypharmacy on OTBM or IIV. See tables C.1-C.20 in Appendices for detailed
results for Aims One and Two, as analyzed by two-way ANCOVA on global cognition as
measured by the OTBM and IIV, respectively.
Anticholinergic Medications
To address Aim One, a 3 (use of anticholinergic medication) X 3 (polypharmacy)
between subjects ANCOVA evaluated the interaction and main effects of the use of

83

anticholinergic medication and polypharmacy on the OTBM. Levene’s test was not
statistically significant, F(4, 383) = 2.40 p = .05. Therefore, the data did not violate the
assumption of homogeneity of variance, and it was deemed appropriate for further
analysis.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 364) = 27.10, p < .001], estimated premorbid functioning [F(1, 364) = 167.38 p <
.001], neurocognitive disorder [F(1, 364) = 15.94, p < .001], moderate to severe TBI
[F(1, 364) = 13.18, p < .001], and cardiovascular diagnoses [F(1, 364) = 21.622, p <
.001] were statistically significant. However, there was not a statistically significant
interaction between the effects of using anticholinergic medication and polypharmacy,
F(1, 364) = 3.65, p = .05, nor were there significant main effects of use of anticholinergic
medications, F(1, 364) = 0.45, p = .50, or polypharmacy, F(1, 364) = .25, p = .61, on
OTBM. Therefore, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no interaction between the use of anticholinergic
medication and polypharmacy on overall cognitive functioning as assessed by the
OTBM. There also were not independent effects of use of anticholinergic medications or
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of anticholinergic medication) X 3 (polypharmacy)
between subjects ANCOVA evaluated the interaction and main effects of the use of
anticholinergic medication and polypharmacy on IIV. Levene’s test was not statistically
significant, F(4, 373) = 1.62, p = .17. Therefore, the data did not violate the assumption
of homogeneity of variance, and it was deemed appropriate for further analysis.
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In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 354) = 45.03, p < .001], moderate to severe TBI [F(1, 354) = 8.85, p = .003], and
cardiovascular diagnoses [F(1, 354) = 15.33, p < .001] were statistically significant.
There was not a statistically significant interaction between the effects of using
anticholinergic medication and polypharmacy, F(1, 354) = 3.82, p = .05. There were also
no significant main effects of use of anticholinergic medications, F(1, 354) = 0.65, p =
.42 or polypharmacy on IIV, F(1, 354) = 0.88, p = .35. Overall, despite adjusting for
relevant variables, such as the neuropsychologist conducting the evaluation, estimated
premorbid functioning, age, use of other medications, and diagnoses, there was no
interaction between use of anticholinergic medications and polypharmacy on overall
cognitive functioning as assessed by IIV. There also were not independent effects of use
of anticholinergic medications or polypharmacy on overall cognitive functioning as
assessed by IIV.
Antidepressant Medications
To address Aim One, a 3 (use of antidepressant) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of antidepressant
medication and polypharmacy on the OTBM. Levene’s test was not statistically
significant, F(4, 383) = 1.69, p = .15, indicating that the data did not violate the
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for
further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 363) = 23.93, p < .001], estimated premorbid functioning [F(1, 363) = 160.82, p <
.001], neurocognitive disorder diagnosis [F(1, 363) = 16.89, p < .001], moderate to
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severe TBI [F(1, 363) = 14.94, p < .001], and cardiovascular diagnoses [F(1, 363) =
22.07, p < .001] were statistically significant. There was not a statistically significant
interaction between the effects of using antidepressant medication and polypharmacy,
F(1, 363) = 0.09, p = .77, nor were there significant main effects for the use of
antidepressant medications, F(1, 363) = 0.80, p = .37 on OTBM, or polypharmacy on
OTBM, F(1, 363) = .04, p = .85. Therefore, despite adjusting for relevant variables, such
as the neuropsychologist conducting the evaluation, estimated premorbid functioning,
age, use of other medications, and diagnoses, there was no interaction between use of
antidepressant medications and polypharmacy on overall cognitive functioning as
assessed by the OTBM. There also were not independent effects of use of antidepressant
medications or polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of antidepressant) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of antidepressant
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 1.10, p = .36, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,353) = 24.37, p < .001), use of analgesics [F(1,353) = 8.50, p = .004], moderate to
severe TBI [F(1,353) = 11.83, p < .001], and cardiovascular diagnoses [F(1,353) = 16.53,
p < .001] were statistically significant. There was not a statistically significant interaction
between the effects of using antidepressant medication and polypharmacy, F(1, 353) =
0.01, p = .93, nor was there significant main effect of use of antidepressant medications,
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F(1, 353) = 0.18, p = .68 on IIV. There was a significant main effect of polypharmacy on
IIV at the .05 alpha level, F(1, 353) = 5.29, p = .02. However, when the more stringent
alpha level of .006 (.05/8) was employed to reduce the risk of Type I error, this main
effect was no longer considered significant. Overall, despite adjusting for relevant
variables, such as the neuropsychologist conducting the evaluation, estimated premorbid
functioning, age, use of other medications, and diagnoses, there was no significant
interaction between the use of antidepressant medication and polypharmacy on overall
cognitive functioning, as assessed by IIV. There also were not significant independent
effects of use of antidepressant medications or polypharmacy on overall cognitive
functioning as assessed by IIV at the alpha level of .006.
Anxiolytic Medications
To address Aim One, a 3 (use of anxiolytics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of anxiolytic
medication and polypharmacy on the OTBM. Levene’s test was statistically significant,
F(4, 383) = 3.29, p = .01, indicating that the data violated the assumption of homogeneity
of variance. Therefore, a more stringent alpha value was used when determining whether
the univariate tests were statistically significant. Given that a Bonferroni corrected alpha
of .006 was employed due to the large number of statistical analyses being conducted, an
alpha value of .001 was used for this analysis to further reduce the risk of Type I error.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 25.66, p < .001], estimated premorbid functioning [F(1, 362) = 162.02, p <
.001], use of anti-inflammatory medications [F(1, 362) = 4.34, p = 0.04], neurocognitive
disorder diagnosis [F(1, 362) = 17.02, p < .001], moderate to severe TBI [F(1, 362) =
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13.90, p < .001], cardiovascular diagnoses [F(1, 362) = 25.41, p < .001], and respiratory
diagnoses [F(1, 362) = 4.17, p = .04] were statistically significant. There was a
statistically significant interaction between the effects of using anxiolytic medications
and polypharmacy, F(1, 362) = 6.48, p = .01. However, when the more stringent
corrected alpha of .001 is used, this interaction is not considered statistically significant.
Neither the main effects for the use of anxiolytic medications, F(1, 362) = 2.00, p = .16,
nor polypharmacy, F(1, 362) = .03, p = .88, on OTBM were statistically significant.
Therefore, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant interaction between use of
anxiolytic medications and polypharmacy on overall cognitive functioning as assessed by
the OTBM at the Bonferroni corrected alpha value of .001. There also were not
significant independent effects of use of anxiolytic medications or polypharmacy on
overall cognitive functioning as assessed by the OTBM at the Bonferroni corrected alpha
value of .001.
To address Aim Two, a 3 (use of anxiolytics) X 3 (polypharmacy) between
subjects ANCOVAs evaluated the interaction and main effects of the use of anxiolytic
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 1.21, p = .31, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 44.49, p < .001], use of analgesics [F(1,352) = 7.09, p = .008], diagnosis of a
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neurodevelopmental disorder [F(1, 352) = 4.08, p = .04], moderate to severe TBI [F(1,
352) = 9.85, p = .002], and cardiovascular diagnoses [F(1, 352) = 18.80, p < .001] were
statistically significant. There was a statistically significant interaction between the
effects of using anxiolytic medication and polypharmacy, F(1, 352) = 4.76, p = .03.
However, when a more stringent corrected alpha of .006 is used, this interaction is not
considered statistically significant. Similarly, there was a significant main effect of
polypharmacy on IIV, F(1, 352) = 4.47, p = .04, but when compared to the more stringent
alpha of .006, this main effect was no longer significant. No main effect of use of
anxiolytic medication was identified, F(1, 352) = 1.79, p = .18. Overall, despite adjusting
for relevant variables, such as the neuropsychologist conducting the evaluation, estimated
premorbid functioning, age, use of other medications, and diagnoses, there was no
interaction between anxiolytic medication use and polypharmacy on overall cognitive
functioning as assessed by IIV at p < .006. There also were not independent effects of use
of anxiolytic medications or polypharmacy on overall cognitive functioning as assessed
by IIV at the alpha level of .006.
Analgesic Medications
To address Aim One, a 3 (use of analgesics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of analgesic
medication and polypharmacy on the OTBM. Levene’s test was statistically significant,
F(4, 383) = 2.59, p = .04, indicating that the data violated the assumption of homogeneity
of variance. Therefore, a more stringent alpha value was used when determining whether
the univariate tests were statistically significant. Given that a Bonferroni corrected alpha
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of .006 was employed due to the large number of statistical analyses conducted, an alpha
value of .001 was used for this analysis to further reduce the risk of Type I error.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 25.13, p < .001], estimated premorbid functioning [F(1, 362) = 157.84, p <
.001], neurocognitive disorder diagnosis [F(1, 362) = 15.00, p < .001], moderate to
severe TBI [F(1, 362) = 14.35, p < .001], and cardiovascular diagnoses [F(1, 362) =
22.70, p < .001] were statistically significant. The interaction between the effects of using
analgesic medications and polypharmacy was not significant, F(1, 362) = 2.00, p = .16.
The main effect of polypharmacy on the OTBM also was not significant, F(1, 362) =
0.01, p = .93. The main effect for the use of analgesic medications was significant at the
.05 alpha level, F(1, 362) = 3.97, p < .05. However, when the main effect of use of
analgesic medications was compared to the more stringent alpha of .001, the effect was
no longer significant. Therefore, despite adjusting for relevant variables, such as the
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use
of other medications, and diagnoses, there was no interaction between analgesic
medication use and polypharmacy on overall cognitive functioning as assessed by the
OTBM at the alpha value of .001. There also were not independent effects of analgesic
medication use or polypharmacy on overall cognitive functioning as assessed by the
OTBM at the alpha value of .001.
To address Aim Two, a 3 (use of analgesics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of analgesic
medication and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 1.59, p = .18, indicating that the data did not violate the assumption of
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homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 45.89, p < .001], moderate to severe TBI [F(1, 352) = 10.25, p = .001], and
cardiovascular diagnoses [F(1, 352) = 16.58, p < .001] were statistically significant. The
interaction between the effects of using analgesic medication and polypharmacy was not
significant, F(1, 352) = 2.89, p = .09. However, both the main effect of analgesic
medication use and the main effect of polypharmacy on IIV were significant, F(1, 352) =
11.29, p = < .001, η2 = .02, and F(1, 352) = 4.65, p = .03, respectively. Only the main
effect of analgesic medication on IIV remained significant when applying the more
stringent Bonferroni corrected alpha of .006. This result indicates that subjects taking
analgesic medications showed more cognitive variability (M = 10.51, SD = 2.72) than
those not taking analgesic medication (M = 9.99, SD = 2.37) and those not taking any
prescription medications (M = 9.43, SD = 2.73).
Analgesic Drug Families.
Triptans. Given this finding, and to further evaluate Aim Two with regard to analgesic
medication families, four subsequent 3 (Analgesic group) X 3 (polypharmacy) between
subjects ANCOVAs were used to evaluate the interaction and main effects of the use of
medication in analgesic families and polypharmacy on IIV. The first two-way ANCOVA
evaluated the interaction and main effects of the use of triptans and polypharmacy on IIV.
Levene’s test was not statistically significant, F(4, 373) = 1.72, p = .15, indicating that
the data did not violate the assumption of homogeneity of variance. Therefore, the data
was deemed appropriate for further analyses of variance.
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In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 352) = 44.03, p < .001], neurocognitive disorders [F(1, 352) = 3.98, p = .05],
moderate to severe TBI [F(1, 352) = 9.78, p = .002], and cardiovascular diagnoses [F(1,
352) = 17.47, p < .001] were statistically significant. The interaction between the effects
of using triptans and polypharmacy was not significant, F(1, 352) = 0.44, p = .51.
Additionally, the main effect of polypharmacy on IIV was not significant, F(1, 352) =
2.79, p = .10. However, the main effect of triptan use on IIV was significant, F(1, 352) =
12.91, p = < .001, η2 = .03. This result indicates that subjects using triptan medications
showed more cognitive variability (M = 13.08, SD = 3.96) than those not taking analgesic
medication (M = 9.24, SD = 2.40) and those not taking any prescription medications (M =
9.26, SD = 2.73).
This significant difference between subjects using triptan medications and
subjects who do not use triptan medications suggests that further exploration with regard
to specific drug names is warranted. However, these analyses were unable to be
conducted due to the significantly low frequencies of almotriptan, eletriptan, rizatriptan,
and sumatriptan use in the sample. Specifically, only one participant each reported using
almotriptan and eletriptan, and two participants each reported using rizatriptan and
sumatriptan.
Opioids. The next two-way ANCOVA evaluated the interaction and main effects of the
use of opioids and polypharmacy on IIV. Levene’s test was not statistically significant,
F(4, 373) = 2.32, p = .06, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
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In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 352) = 44.03, p < .001], neurocognitive disorders [F(1, 352) = 4.42, p = .04],
moderate to severe TBI [F(1, 352) = 8.85, p = .003], and cardiovascular diagnoses [F(1,
352) = 15.70, p < .001] were statistically significant. There was not a statistically
significant interaction between the effects of using opioid medication and polypharmacy,
F(1, 352) = 0.07, p = .80, nor were there significant main effects of the use of opioids,
F(1, 352) = 0.10, p = .75, or polypharmacy on IIV, F(1, 352) = 0.10, p = .75. Overall,
despite adjusting for relevant variables, such as the neuropsychologist conducting the
evaluation, estimated premorbid functioning, age, use of other medications, and
diagnoses, there was no interaction between opioid medication use and polypharmacy on
overall cognitive functioning as assessed by IIV at the Bonferroni corrected alpha value
of .006. There also were not independent effects of the use of opioid medications or
polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni
corrected alpha value of .006.
Opioid Combinations. The next two-way ANCOVA evaluated the interaction and main
effects of the use of opioid combination medications and polypharmacy on IIV. Levene’s
test was not statistically significant, F(4, 373) = 1.65, p = .16, indicating that the data did
not violate the assumption of homogeneity of variance. Therefore, the data was deemed
appropriate for further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 352) = 42.94, p < .001], neurocognitive disorders [F(1, 352) = 4.42, p = .04],
moderate to severe TBI [F(1, 352) = 9.20, p = .003], and cardiovascular diagnoses [F(1,
352) = 15.49, p < .001] were statistically significant. There was not a statistically
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significant interaction between the effects of using opioid combination medications and
polypharmacy, F(1, 352) < 0.01, p = .98, nor were there significant main effects of opioid
combination use, F(1, 352) = 2.13, p = .15, or polypharmacy on IIV, F(1, 352) = 1.70, p
= .19. Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no effect of opioid combination medication use,
polypharmacy, or the interaction between the two, on overall cognitive functioning as
assessed by IIV at the Bonferroni corrected alpha value of .006.
Non-Opioid Analgesics. The final two-way ANCOVA within the analgesic family
analyses evaluated the interaction and main effects of the use of non-opioid analgesics
and polypharmacy on IIV. Levene’s test was statistically significant, F(4, 373) = 3.57, p
= .007, indicating that the data violated the assumption of homogeneity of variance.
Therefore, a more stringent alpha value was used when determining whether the
univariate tests were statistically significant. Given that a Bonferroni corrected alpha of
.006 was employed due to the large number of statistical analyses conducted, an alpha
value of .001 was used for this analysis to further reduce the risk of Type I error.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 352) = 45.07, p < .001], moderate to severe TBI [F(1, 352 = 9.17, p = .003], and
cardiovascular diagnoses [F(1, 352) = 14.73, p < .001] were statistically significant.
There was not a statistically significant interaction between the effects of using nonopioid analgesics and polypharmacy, F(1, 352) < 0.01, p = .98, nor were there significant
main effects of non-opioid analgesic use, F(1, 352) = 0.20, p = .65, nor polypharmacy on
IIV, F(1, 352) = 0.01, p = .93. Overall, despite adjusting for relevant variables, such as
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the neuropsychologist conducting the evaluation, estimated premorbid functioning, age,
use of other medications, and diagnoses, there was no interaction between use of opioid
combination medications and polypharmacy on overall cognitive functioning as assessed
by IIV at the corrected alpha value of .001. There also were not independent effects of
opioid combination medication use or polypharmacy on overall cognitive functioning as
assessed by IIV at the corrected alpha value of .001.
Antiepileptic Medications
To address Aim One, a 3 (use of antiepileptics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of antiepileptic
medication and polypharmacy on the OTBM. Levene’s test was not statistically
significant, F(4, 383) = 1.55, p = .19, indicating that the data did not violate the
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for
further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 24.90, p < .001], estimated premorbid functioning [F(1, 362) = 155.96, p <
.001], use of anti-inflammatory medications [F(1, 362) = 5.09, p = 0.03], neurocognitive
disorder diagnosis [F(1, 362) = 14.75, p < .001], moderate to severe TBI [F(1, 362) =
12.613, p < .001], and cardiovascular diagnoses [F(1, 362) = 21.84, p < .001] were
statistically significant. There was a statistically significant interaction between the
effects of using antiepileptic medications and polypharmacy, F(1, 362) = 4.51, p = .03.
However, when the more stringent corrected alpha of .006 is used, this interaction is not
considered statistically significant. Neither the main effects for the use of antiepileptic
medications, F(1, 362) = 3.41, p = .07, nor polypharmacy, F(1, 362) = 0.88, p = .35, on
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OTBM were statistically significant. Therefore, despite adjusting for relevant variables,
such as the neuropsychologist conducting the evaluation, estimated premorbid
functioning, age, use of other medications, and diagnoses, there was no interaction
between use of antiepileptic medication and polypharmacy on overall cognitive
functioning as assessed by the OTBM at the Bonferroni corrected alpha value of .006.
There also were not independent effects of the use of antiepileptic medications or
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of antiepileptics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of antiepileptic
medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 0.99, p = .42, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 44.51, p < .001], use of analgesics [F(1,352) = 9.27, p = .003], moderate to
severe TBI [F(1, 352) = 8.83, p = .003], and cardiovascular diagnoses [F(1, 352) = 16.46,
p < .001] were statistically significant. There was a statistically significant interaction
between the effects of using antiepileptic medication and polypharmacy, F(1, 352) =
4.79, p = .03. However, when a more stringent corrected alpha of .006 was used, this
interaction was no longer considered statistically significant. Similarly, there was a
significant main effect of polypharmacy on IIV, F(1, 352) = 9.56, p = .002, η2 = .20.
Although, this significant main effect remained, even when compared to a more
conservative alpha of .006. No main effect of use of antiepileptic medication on IIV was
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identified, F(1, 352) = 1.87, p = .17. These results indicate that subjects without
polypharmacy showed more cognitive variability (M = 10.45, SD = 2.42) than those
taking more than 5 medications (e.g., polypharmacy; M = 8.89, SD = 2.52) and those not
taking any prescription medications (M = 7.78, SD = 2.73).
Cardiovascular Medications
To address Aim One, a 3 (cardiovascular medications) X 3 (polypharmacy)
between subjects ANCOVA evaluated the interaction and main effects of the use of
cardiovascular medications and polypharmacy on OTBM. Levene’s test was not
statistically significant, F(4, 383) = 1.57, p = .18, indicating that the data did not violate
the assumption of homogeneity of variance. Therefore, the data was deemed appropriate
for further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 23.28, p < .001], estimated premorbid functioning [F(1, 362) = 158.11, p <
.001], use of anti-inflammatory medications [F(1, 362) = 3.97, p < 0.05], neurocognitive
disorder diagnosis [F(1, 362) = 16.81, p < .001], moderate to severe TBI [F(1, 362) =
14.14, p < .001], and cardiovascular diagnoses [F(1, 362) = 22.14, p < .001] were
statistically significant. The interaction between the effects of using cardiovascular
medications and polypharmacy was not significant, F(1, 362) = 0.53, p = .47.
Additionally, neither the main effects of cardiovascular medication use, F(1, 362) = 2.48,
p = .12, nor polypharmacy, F(1, 362) = 0.13, p = .72, on OTBM were statistically
significant. Therefore, despite adjusting for relevant variables, such as the
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use
of other medications, and diagnoses, there was no interaction between use of
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cardiovascular medication and polypharmacy on overall cognitive functioning as
assessed by the OTBM at the Bonferroni corrected alpha value of .006. There also were
not independent effects of cardiovascular medication use or polypharmacy on overall
cognitive functioning as assessed by the OTBM at the Bonferroni corrected alpha value
of .006.
To address Aim Two, a 3 (use of antiepileptics) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of cardiovascular
medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 2.08, p = .08, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 43.88, p < .001], use of analgesics [F(1,352) = 8.44, p = .004], moderate to
severe TBI [F(1, 352) = 9.95, p = .002], and cardiovascular diagnoses [F(1, 352) = 16.13,
p < .001] were statistically significant. The interaction between the effects of using
cardiovascular medication and polypharmacy was not significant, F(1, 352) = 0.23, p =
.63. No main effect of use of cardiovascular medication on IIV was identified, F(1, 352)
= 0.01, p = .91. There was a significant main effect of polypharmacy on IIV, F(1, 352) =
6.76, p = .01. However, when the more stringent corrected alpha of .006 was used, this
interaction was no longer considered statistically significant. Overall, despite adjusting
for relevant variables, such as the neuropsychologist conducting the evaluation, estimated
premorbid functioning, age, use of other medications, and diagnoses, there was no
interaction between use of cardiovascular medication and polypharmacy on overall
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cognitive functioning as assessed by IIV at the Bonferroni corrected alpha value of .006.
There also were not independent effects of cardiovascular medication use or
polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni
corrected alpha value of .006.
Anti-Inflammatory Medications
To address Aim One, a 3 (anti-inflammatory medication use) X 3 (polypharmacy)
between subjects ANCOVA evaluated the interaction and main effects of the use of antiinflammatory medications and polypharmacy on the OTBM. Levene’s test was not
statistically significant, F(4, 383) = 1.83, p = .18, indicating that the data did not violate
the assumption of homogeneity of variance. Therefore, the data was deemed appropriate
for further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 24.03, p < .001], estimated premorbid functioning [F(1, 362) = 157.59, p <
.001], neurocognitive disorder diagnosis [F(1, 362) = 16.76, p < .001], moderate to
severe TBI [F(1, 362) = 14.08, p < .001], and cardiovascular diagnoses [F(1, 362) =
21.99, p < .001] were statistically significant. The interaction between the effects of using
anti-inflammatory medications and polypharmacy was not significant, F(1, 362) = 0.03, p
= .87. Additionally, neither the main effects for the use of anti-inflammatory medications,
F(1, 362) = 3.19, p = .08, nor polypharmacy, F(1, 362) = 0.18, p = .68, on OTBM were
statistically significant. Therefore, despite adjusting for relevant variables, such as the
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use
of other medications, and diagnoses, there was no interaction between anti-inflammatory
medication use and polypharmacy on overall cognitive functioning as assessed by the
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OTBM. There also were not independent effects of anti-inflammatory medication use or
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of anti-inflammatory) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of antiinflammatory medications and polypharmacy on IIV. Levene’s test was not statistically
significant, F(4, 373) = 1.38, p = .24, indicating that the data did not violate the
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for
further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 43.68, p < .001], use of analgesics [F(1,352) = 8.75, p = .003], moderate to
severe TBI [F(1, 352) = 9.78, p = .002], and cardiovascular diagnoses [F(1, 352) = 16.05,
p < .001] were statistically significant. The interaction between the effects of using antiinflammatory medication and polypharmacy was not significant, F(1, 352) = 0.29, p =
.59. No main effect of use of anti-inflammatory medication on IIV was identified, F(1,
352) = 0.34, p = .56. There was a significant main effect of polypharmacy on IIV, F(1,
352) = 5.77, p = .02. However, when the more stringent corrected alpha of .006 was used,
this interaction was no longer considered statistically significant. Overall, despite
adjusting for relevant variables, such as the neuropsychologist conducting the evaluation,
estimated premorbid functioning, age, use of other medications, and diagnoses, there was
no interaction between anti-inflammatory medication use and polypharmacy on overall
cognitive functioning as assessed by IIV. There also were not independent effects of antiinflammatory medication use or polypharmacy on overall cognitive functioning as
assessed by IIV at the Bonferroni corrected alpha value of .006.
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Hormone Medications
To address Aim One, a 3 (hormone medication use) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of hormone
medications and polypharmacy on the OTBM. Levene’s test was not statistically
significant, F(4, 383) = 1.68, p = .15, indicating that the data did not violate the
assumption of homogeneity of variance. Therefore, the data was deemed appropriate for
further analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1, 362) = 24.20, p < .001], estimated premorbid functioning [F(1, 362) = 157.55, p <
.001], neurocognitive disorder diagnosis [F(1, 362) = 16.75, p < .001], moderate to
severe TBI [F(1, 362) = 14.20, p < .001], and cardiovascular diagnoses [F(1, 362) =
22.12, p < .001] were statistically significant. The interaction between the effects of using
hormone medications and polypharmacy was not significant, F(1, 362) = 0.23, p = .63.
Additionally, neither the main effects for the use of hormone medications, F(1, 362) =
0.09, p = .77, nor polypharmacy, F(1, 362) = 0.26, p = .61, on OTBM were statistically
significant. Therefore, despite adjusting for relevant variables, such as the
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use
of other medications, and diagnoses, there was no interaction between use of hormone
medications and polypharmacy on overall cognitive functioning as assessed by the
OTBM. There also were not independent effects of hormone medication use and
polypharmacy on overall cognitive functioning as assessed by the OTBM.
To address Aim Two, a 3 (use of hormones) X 3 (polypharmacy) between
subjects ANCOVA evaluated the interaction and main effects of the use of hormone
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medications and polypharmacy on IIV. Levene’s test was not statistically significant, F(4,
373) = 1.00, p = .41, indicating that the data did not violate the assumption of
homogeneity of variance. Therefore, the data was deemed appropriate for further
analyses of variance.
In the omnibus analysis, the covariate effects of the location of the evaluation
[F(1,352) = 43.90, p < .001], use of analgesics [F(1,352) = 8.27, p = .004], moderate to
severe TBI [F(1, 352) = 10.12, p = .002], and cardiovascular diagnoses [F(1, 352) =
16.37, p < .001] were statistically significant. The interaction between the effects of using
hormone medications and polypharmacy was not significant, F(1, 352) = 0.18, p = .67.
No main effect of use of hormones on IIV was identified, F(1, 352) = 1.13, p = .29. There
was a significant main effect of polypharmacy on IIV, F(1, 352) = 6.76, p = .01.
However, when the more stringent corrected alpha of .006 was used, this interaction was
no longer considered statistically significant. Overall, despite adjusting for relevant
variables, such as the neuropsychologist conducting the evaluation, estimated premorbid
functioning, age, use of other medications, and diagnoses, there was no interaction
between use of hormone medications and polypharmacy on overall cognitive functioning
as assessed by IIV. There also were not independent effects of hormone medication use
and polypharmacy on overall cognitive functioning as assessed by IIV at the Bonferroni
corrected alpha value of .006.

Primary Analyses Aim Three
To examine the effects of medication use and polypharmacy on domain-specific
cognitive functioning, two-way MANCOVAs were used to evaluate the interactions and
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main effects of medication use and polypharmacy on the following cognitive domain
means: attention/working memory, processing speed, verbal reasoning, visual reasoning,
verbal memory, visual memory, EF, dominant motor and sensory functioning, and nondominant motor and sensory functioning.
As can be seen in Tables B.5, B.9, B.10, and B.11, linear relationships were
observed across relevant study variables. Specifically, cognitive domains correlated with
each other between .17 and .60. The covariates (estimated premorbid functioning; subject
age; location of evaluation; use of antidepressants, anxiolytics, antipsychotics, analgesics,
AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders,
neurodevelopmental disorders, seizure disorders, neurocognitive disorders, moderate to
severe TBI, cardiovascular diagnoses, respiratory disorders, and pain) were also linearly
related to cognitive domain performance, meeting the assumption of linearity of
regression. As noted above, the data also conformed to the assumption of homogeneity of
regression both at the multivariate and univariate levels.
Anticholinergic Medications
With regard to anticholinergic medications, a 3 (anticholinergic medication use)
X 3 (polypharmacy) between subjects MANCOVA evaluated the interactions and main
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1145.41, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 258.32, F(180, 16076.90) = 1.26, p = .01], suggesting
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that the matrices were not homogenous. Therefore, Pillai’s Trace was used to evaluate the
multivariate effects because it is more robust to violations of this assumption compared to
the other multivariate tests of significance.
The multivariate interaction of anticholinergic medication use X polypharmacy,
when controlling for effects of the covariates, was examined prior to the multivariate
main effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .03, F(9, 327) = 1.23, p = .27, 1 – Wilks’ lambda
= .03]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .19, F(9, 327) = 8.37, p < .001, 1-Wilks’ lambda =
.19], estimated premorbid functioning [Pillai’s Trace = .50, F(9, 327) = 35.57, p < .001,
1-Wilks’ lambda = .50], moderate to severe TBI [Pillai’s Trace = .08, F(9, 327) = 3.13, p
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 327)
= 3.20, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 327) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of anticholinergic medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .01, F(9, 327) = 0.45, p = .91, 1-Wilks’ lambda =
.01; Pillai’s Trace = .02, F(9, 327) = 0.76, p = .65, 1-Wilks’ lambda = .02, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
anticholinergic medication use and polypharmacy on cognitive functioning across
domains. There also were not multivariate main effects of anticholinergic medication use
or polypharmacy on cognitive functioning across domains.
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Antidepressant Medications
With regard to antidepressant medications, a 3 (antidepressant medication use) X
3 (polypharmacy) between subjects MANCOVA evaluated the interactions and main
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1134.32, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 226.21, F(135, 51260.58) = 1.57, p < .001],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of antidepressant medication use X polypharmacy,
when controlling for effects of the covariates, was examined prior to the multivariate
main effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.51, p = .14, 1 – Wilks’ lambda
= .04]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 7.83, p < .001, 1-Wilks’ lambda =
.18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.80, p < .001,
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.17, p
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.20, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 325) = 2.26, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of antidepressant medication use and polypharmacy, were not
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statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.85, p = .57, 1-Wilks’ lambda =
.02; Pillai’s Trace = .02, F(9, 325) = 0.73, p = .68, 1-Wilks’ lambda = .02, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
antidepressant medication use and polypharmacy on cognitive functioning across
domains. There also were not multivariate main effects of antidepressant medication use
or polypharmacy on cognitive functioning across domains.
Anxiolytic Medications
With regard to anxiolytic medications, a 3 (anxiolytic medication use) X 3
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects
of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1130.66, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 280.78, F(180, 17583.63) = 1.35, p = .001],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of anxiolytic medication use X polypharmacy, when
controlling for effects of the covariates, was examined prior to the multivariate main
effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .05, F(9, 325) = 1.70, p = .09, 1 – Wilks’ lambda
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= .05]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.37, p < .001, 1-Wilks’ lambda =
.19], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.61, p < .001,
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.17, p
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.30, p < .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of anxiolytic medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.75, p = .66, 1-Wilks’ lambda =
.02; Pillai’s Trace = .03, F(9, 325) = 0.98, p = .46, 1-Wilks’ lambda = .03, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
anxiolytic medication use and polypharmacy on cognitive functioning across domains.
There also were not multivariate main effects of anxiolytic medication use or
polypharmacy on cognitive functioning across domains.
Analgesic Medications
With regard to anxiolytic medications, a 3 (analgesic medication use) X 3
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects
of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1126.75, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
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statistically significant [Box’s M = 270.52, F(180, 17470.74) = 1.30, p = .004],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of analgesic medication use X polypharmacy, when
controlling for effects of the covariates, was examined prior to the multivariate main
effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.37, p = .20, 1 – Wilks’ lambda
= .04]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.25, p < .001, 1-Wilks’ lambda =
.19], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 34.24, p < .001,
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.27, p
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.21, p < .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of analgesic medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.66, p = .10, 1-Wilks’ lambda =
.04; Pillai’s Trace = .02, F(9, 325) = 0.81, p = .61, 1-Wilks’ lambda = .02, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
analgesic medication use and polypharmacy on cognitive functioning across domains.
There also were not multivariate main effects of analgesic medication use or
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polypharmacy on cognitive functioning across domains.
Antiepileptic Medications
With regard to antiepileptic medications, a 3 (antiepileptic medication use) X 3
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects
of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1127.40, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 283.06, F(180, 11870.59) = 1.36, p = .001],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of antiepileptic medication use X polypharmacy,
when controlling for effects of the covariates, was examined prior to the multivariate
main effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.76, p = .65, 1 – Wilks’ lambda
= .02]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.16, p < .001, 1-Wilks’ lambda =
.18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.60, p < .001,
1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.19, p
= .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.19, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 325) = 2.31, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
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independent variables of antiepileptic medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.61, p = .11, 1-Wilks’ lambda =
.04; Pillai’s Trace = .02, F(9, 325) = 0.69, p = .72, 1-Wilks’ lambda = .02, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
antiepileptic medication use and polypharmacy on cognitive functioning across domains.
There also were not multivariate main effects of antiepileptic medication use or
polypharmacy on cognitive functioning across domains.
Cardiovascular Medications
With regard to cardiovascular medications, a 3 (cardiovascular medication use) X
3 (polypharmacy) between subjects MANCOVA evaluated the interaction and main
effects of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1126.04, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 262.89, F(180, 17816.35) = 1.28, p = .008],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of cardiovascular medication use X polypharmacy,
when controlling for effects of the covariates, was examined prior to the multivariate
main effects. The multivariate interaction effect on cognitive domain scores was not
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statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.47, p = .16, 1 – Wilks’ lambda
= .04]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .19, F(9, 325) = 8.33, p < .001, 1-Wilks’ lambda =
.19], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 33.98, p < .001,
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.25, p
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.18, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,
F(9, 325) = 2.27, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of cardiovascular medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .04, F(9, 325) = 1.37, p = .20, 1-Wilks’ lambda =
.04; Pillai’s Trace = .02, F(9, 325) = 0.86, p = .57, 1-Wilks’ lambda = .02, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between
cardiovascular medication use and polypharmacy on cognitive functioning across
domains. There also were not multivariate main effects of cardiovascular medication use
or polypharmacy on cognitive functioning across domains.
Anti-Inflammatory Medications
With regard to anti-inflammatory medications, a 3 (anti-inflammatory medication
use) X 3 (polypharmacy) between subjects MANCOVA evaluated the interaction and
main effects of medication use and polypharmacy across cognitive domains. Bartlett’s
test of sphericity was statistically significant (approximate chi square = 1131.57, df = 44,
p < .001), indicating that the correlation of the dependent variables was sufficient to
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support the MANCOVA. Box’s test of the equality of the variance-covariance matrices
was also statistically significant [Box’s M = 295.76, F(180, 15030.91) = 1.36, p = .001],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of anti-inflammatory medication use X
polypharmacy, when controlling for effects of the covariates, was examined prior to the
multivariate main effects. The multivariate interaction effect on cognitive domain scores
was not statistically significant [Pillai’s Trace = .01, F(9, 325) = 0.44, p = .91, 1 – Wilks’
lambda = .01]. The multivariate main effect of the following covariates were significant:
location of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.11, p < .001, 1-Wilks’
lambda = .18], estimated premorbid functioning [Pillai’s Trace = .48, F(9, 325) = 33.78,
p < .001, 1-Wilks’ lambda = .48], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325)
= 3.17, p = .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08,
F(9, 325) = 3.15, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s
Trace = .06, F(9, 325) = 2.32, p = .02, 1-Wilks’ lambda = .06]. The multivariate main
effects of the independent variables of anti-inflammatory medication use and
polypharmacy, were not statistically significant [Pillai’s Trace = .01, F(9, 325) = 0.43, p
= .92, 1-Wilks’ lambda = .01; Pillai’s Trace = .03, F(9, 325) = 0.94, p = .49, 1-Wilks’
lambda = .03, respectively]. Overall, despite adjusting for relevant variables, such as the
neuropsychologist conducting the evaluation, estimated premorbid functioning, age, use
of other medications, and diagnoses, there was no significant multivariate interaction
between anti-inflammatory medication use and polypharmacy on cognitive functioning
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across domains. There also were not multivariate main effects of anti-inflammatory
medication use or polypharmacy on cognitive functioning across domains.
Hormone Medications
With regard to hormone medications, a 3 (hormone medication use) X 3
(polypharmacy) between subjects MANCOVA evaluated the interaction and main effects
of medication use and polypharmacy across cognitive domains. Bartlett’s test of
sphericity was statistically significant (approximate chi square = 1131.05, df = 44, p <
.001), indicating that the correlation of the dependent variables was sufficient to support
the MANCOVA. Box’s test of the equality of the variance-covariance matrices was also
statistically significant [Box’s M = 287.01, F(180, 13592.02) = 1.38, p < .001],
suggesting that the matrices were not homogenous. Therefore, Pillai’s Trace was used to
evaluate the multivariate effects because it is more robust to violations of this assumption
compared to the other multivariate tests of significance.
The multivariate interaction of hormone medication use X polypharmacy, when
controlling for effects of the covariates, was examined prior to the multivariate main
effects. The multivariate interaction effect on cognitive domain scores was not
statistically significant [Pillai’s Trace = .03, F(9, 325) = 1.18, p = .31, 1 – Wilks’ lambda
= .03]. The multivariate main effect of the following covariates were significant: location
of the evaluation [Pillai’s Trace = .18, F(9, 325) = 8.06, p < .001, 1-Wilks’ lambda =
.18], estimated premorbid functioning [Pillai’s Trace = .49, F(9, 325) = 34.01, p < .001,
1-Wilks’ lambda = .49], moderate to severe TBI [Pillai’s Trace = .08, F(9, 325) = 3.26, p
< .001, 1-Wilks’ lambda = .08], cardiovascular diagnoses [Pillai’s Trace = .08, F(9, 325)
= 3.16, p = .001, 1-Wilks’ lambda = .08], and respiratory diagnoses [Pillai’s Trace = .06,

113

F(9, 325) = 2.28, p = .02, 1-Wilks’ lambda = .06]. The multivariate main effects of the
independent variables of hormone medication use and polypharmacy, were not
statistically significant [Pillai’s Trace = .02, F(9, 325) = 0.78, p = .64, 1-Wilks’ lambda =
.02; Pillai’s Trace = .03, F(9, 325) = 0.97, p = .47, 1-Wilks’ lambda = .03, respectively].
Overall, despite adjusting for relevant variables, such as the neuropsychologist
conducting the evaluation, estimated premorbid functioning, age, use of other
medications, and diagnoses, there was no significant multivariate interaction between use
of hormone medications and polypharmacy on cognitive functioning across domains.
There also were not multivariate main effects of use of hormone medications or
polypharmacy on cognitive functioning across domains.
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CHAPTER VI
DISCUSSION

This study sought to add to and extend the literature regarding effects of
medications and polypharmacy on cognition in a broad clinical sample (e.g., TBI,
vascular/cerebrovascular accident [CVA], encephalitis, mental health diagnoses, etc.)
using a comprehensive battery of neuropsychological tests. Collaborative and
independent effects of medications and polypharmacy on cognitive functioning were
thoroughly evaluated through three broad aims: 1) examining the effects of medication
use and polypharmacy on global cognitive functioning, as assessed by OTBM; 2)
examining the effects of medication use and polypharmacy on global cognitive
functioning, as assessed by IIV; and 3) examining the effects of medication use and
polypharmacy on domain-specific cognitive functioning. Additionally, the use of
covariates in the analyses allowed for the relationships between cognitive performance
and other variables in the sample (e.g., premorbid functioning, effects of underlying
pathology related to diagnosis, effects of other prescribed medications) to be statistically
controlled for, leaving a “purer” evaluation of the medication effects, addressing some of
the limitations of previous studies (e.g., del Ser et al., 2019; Obermann et al., 2013).
To control for increased Type 1 error, and at times heterogeneity of variance,
alpha values were variously corrected to .006 (Bonferroni corrected alpha) or .001 as
appropriate. Regarding Aim One, results of the two-way ANCOVAs evaluating the
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interaction and main effects of medication use and polypharmacy on the OTBM did not
reveal a significant interaction or main effect of medication use or polypharmacy, as
hypothesized. With regard to Aim Two, results of the two-way ANCOVAs evaluating the
interaction and main effects of medication use and polypharmacy on IIV found no
significant interactions between medication use and polypharmacy. However, three
significant main effects were identified. There was a significant main effect for use of
analgesics on IIV and a significant main effect of triptan on IIV, such that those who used
these medications demonstrated higher cognitive variability (IIV) with regard to their
performance across neuropsychological tests. There was also a significant main effect of
polypharmacy on IIV, such that subjects without polypharmacy showed more cognitive
variability than those taking more than 5 medications and those who were not taking any
medications. Aim Three, which evaluated the interaction and main effects of medications
and polypharmacy on domain-specific cognitive functioning using multivariate analyses,
did not produce any significant interactions or main effects for medication use or
polypharmacy.
Overall, the significant effects are interesting in that they suggest that the use of
broad analgesics, and the use of triptans specifically, increase cognitive variability across
a neuropsychological assessment, while polypharmacy reduces cognitive variability.
While these findings may seem at odds with one another, they highlight a unique quality
of cognitive variation: it can both positively and negatively impact cognition.
Specifically, while many studies have identified associations between increased IIV and
cognitive dysfunction (e.g., Ballard et al., 2001; Hill et al., 2013; Morgan et al., 2011;
Murtha et al., 2002), some degree of cognitive variability is normal. For example, in their
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evaluation of a sample of community dwelling adults, Schretlen et al. (2003) found that
all subjects had a discrepancy of at least 1.6 SD between their highest and lowest scores
on a comprehensive neuropsychological assessment. Additionally, two-thirds of these
subjects had a discrepancy of more than three standard deviations between their highest
and lowest scores.
Similarly, across various normative samples of healthy individuals, Binder et al.
(2009) found that the median number of abnormal scores, defined as a score more than 1
SD away from the mean, was between 10 and 15% of the number of scores derived from
the test battery. Therefore, on a neuropsychological assessment with at least 20 tests, such
as that administered to participants in the current study, an individual will likely have at
least two abnormal scores. However, the probability of obtaining low scores has also
been associated with demographic characteristics, such as age and diverse ethnic and
cultural backgrounds, and inversely related to intelligence and education (Iverson et al.,
2008; Schretlen et al., 2003). Thus, those with higher intelligence are more likely to have
some low scores and likely would have higher IIVs. On the other hand, those with greater
probabilities of low scores due to various demographic characteristics will likely have an
IIV that is constricted and lower than the IIV of the general population.
This is also true when considering the relationship between low scores and
neurocognitive dysfunction. For those with severe, global cognitive impairment (e.g.,
later stages of dementia), there will likely be less variability with regard to
neuropsychological test performance. This suggests that there is a curvilinear relationship
between IIV and cognitive dysfunction. Although, additional research is needed to fully
define this relationship.

117

Regardless, with the exception of a significant effect of broad analgesics, triptans,
and polypharmacy on IIV, these findings suggest that use of anticholinergics,
antidepressants, anxiolytics, analgesics, antiepileptics, cardiovascular, anti-inflammatory,
and hormone medications, and the combination of both medication use and
polypharmacy, do not significantly impact cognition on global or domain specific levels
above and beyond effects of estimated premorbid functioning, age, other medication
effects, and disease pathology. These findings are somewhat consistent with the current
literature regarding effects of medication use on cognition.
Specifically, while fairly consistent cognitive deficits have been identified
following use of some medications (e.g., anticholinergics and analgesics), similar to the
relationship between analgesics and IIV illuminated here, many other therapeutic use
groups (e.g., antidepressants, anxiolytics, and cardiovascular) have inconsistent findings
regarding the relationship between medication use and cognition (see del Ser et al., 2019;
Marpillat et al., 2013; Nevado-Holgado et al., 2016; Picton et al., 2018; Prado et al.,
2018). Based on the literature, one factor that may lead to this variability in identifying
cognitive effects across current literature, as well as the null results in the present study,
is the demographics of the participants in the sample.
Sample Demographics
As noted above, the average age of sample subjects in the present study was
approximately 40 years old (SD = 14.6). While some studies containing younger adults
have identified cognitive deficits secondary to the use of medications (Nevado-Holgado
et al., 2016), it appears that strong or consistent cognitive findings secondary to
medication effects are most often identified in older adult populations (> 65; e.g.,
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Campbell et al., 2009; Nader & Gowing, 2020; Obermann et al., 2013; Picton et al.,
2018). This may be due to a number of reasons, including pharmacokinetic and
pharmacodynamic factors or premorbid cognitive fragility causing older adults to be at
higher risk of cognitive effects of medication use (Fulton & Allen, 2005; Kinirons &
O'Mahony, 2004).
However, the clinical nature of the sample suggests that these participants may be
more cognitively vulnerable than a sample of healthy adults. Nearly 20% of this sample
was composed of individuals with a history of traumatic brain injury, nearly 10 % of this
sample had a history of cardiovascular disorders, and approximately 6% of this sample
were diagnosed with SMI. Individuals with these diagnoses are at heightened risk of
cognitive dysfunction (Almeida et al., 2019; Huang et al., 2018; Kuller et al., 2005), like
older adults. Additionally, over 6% of the sample were diagnosed with various
neurocognitive disorders, suggesting that while the overall sample was composed of
younger adults, a majority of the sample consisted of those who may not have had
significant cognitive reserve to compensate for medication effects, if they were present.
Despite this, no significant effects of medications were identified for OTBM or domain
means and the only significant medication effects identified, above and beyond that of
disease processes, were for the use of analgesic medications, the use of triptans, and
polypharmacy, on cognitive variability.
Polypharmacy.
Older adults also have higher rates of medication use and polypharmacy (Barnett
et al., 2012; Kantor et al., 2015), which has been suggested as adding to the risk of
cognitive dysfunction in older adults (Jyrkkä et al., 2011; Maher et al., 2014; Moore &
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O’Keefe, 1999; Sordahl et al., 2019). While an effect of polypharmacy on IIV was
identified, this relationship was only significant in one analysis and no significant effects
of polypharmacy were found on overall cognition as measured by the OTBM or at the
domain level, as has been suggested in the previous literature. These mostly null findings
may have been due to the relatively low rate of polypharmacy in the current sample
(11%). However, it is also possible that the previous findings of significant effects of
polypharmacy on cognition were due to more than simply the number of medications
used.
For example, studies by Lam (2017) and Risacher et al. (2016) indicate that the
effects of polypharmacy on cognition are particularly salient when resulting from the use
of multiple anticholinergic drugs. Specifically, the use of one anticholinergic drug in the
context of other medications may not lead to cognitive impairment. Rather, it is the
overall anticholinergic burden which leads to cognitive impairment. While evaluating for
the overall burden of specific medications was beyond the scope of this study, it is
possible that low burden could have contributed to some of the null findings.
Medication.
In addition to the potential of medication burden effects, which were not able to
be evaluated in the present study, there are several other variables that may have
contributed to the present findings, despite generally findings of cognitive effects of
anticholinergics, benzodiazepine anxiolytics, opioid analgesics, and AEDs in the previous
literature. Specifically, medication dosage, duration of use, frequency of use, and when
the medication was taken in relation to the date and time of the neuropsychological
assessment would each affect a drug’s response, and subsequently the effect of the drug
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on cognition. Unfortunately, these variables were not available for study participants
given the archival nature of the data. Further, information regarding the reason for the
prescription medication use or what specific diagnosis it was prescribed to treat were also
not available in the current sample. Therefore, while classifications of medications were
based on chemical compositions, the true therapeutic use of many medications was
unknown given that many medications can be used for various purposes depending on
does and frequency of use. This further complicates the medication use classifications
and analyses of the current sample. While some of these variables were considered in
previous literature, such as long-term use of benzodiazepines (Nader & Gowing, 2020),
opioids (Allegri et al., 2019) and AEDs (Park & Kwon, 2008; Stein & Strickland,1998),
further consideration should be given to evaluation of each of these variables in the
context of effects on cognitive functioning in future studies.
Diagnoses and Estimated Premorbid Functioning.
Results of this study also underlined the importance of controlling for
neurological, psychological, and general health diagnoses, as well as estimated premorbid
functioning when evaluating the cognitive effects of medication. Specifically, significant
effects of moderate to severe TBI and the presence of a cardiovascular diagnosis on
overall cognition, as measured by OTBM and IIV, and domain-specific cognition were
identified for all univariate and multivariate analyses. Significant effects of estimated
premorbid functioning were also identified for all analyses of OTBM and domain means.
Further, many analyses also showed significant effects of neurocognitive disorders and
respiratory disorders on cognition.
Despite the clear influence of premorbid functioning and these various disease
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processes on cognitive functioning, no known studies to date have controlled for both
premorbid functioning and physical, psychiatric, and medical diagnoses when evaluating
the relationship between medication use and cognitive functioning. Therefore, in the
context of significant main effects of analgesics, triptans, and polypharmacy on IIV only,
questions remain regarding the validity of many of the previously identified relationships
between medication use and cognition. Additional studies of these effects while
controlling for these factors are necessary to fully understand the extent of the
contributions from premorbid functioning and underlying disease processes on previously
identified medication effects.
Neuropsychological Test Battery
Another factor that may have led to the variability in cognitive effects across
current literature compared to the largely null results in the present study, is the use of a
comprehensive battery of neuropsychological tests to evaluate cognitive functioning. As
previously discussed, most of the previous studies examining the cognitive effects of
medication used screening tests, such as the MMSE (Folstein et al., 1975), to evaluate
global cognitive status. While this type of measure has benefits in briefly assessing
cognition within the research setting, there are significant limitations to using such tests.
Specifically, while screening measures are ideally sensitive and specific to cognitive
dysfunction, this is not always the case. For example, in a heart failure population one
study found that at a cut value of < 24, the MMSE only correctly identified 28% of
individuals as having cognitive impairment, while nearly 10% of cognitively normal
individuals were incorrected identified as having cognitive impairment (Hawkins et al.,
2014). Using a more conservative cut-off (<29/30), Hoops et al. (2009) found that the
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MMSE correctly identified 92% of individuals with mild cognitive impairment in the
context of Parkinson’s disease. However, 58% of cognitively normal individuals were
also identified as having mild cognitive impairment. Given that many of the previous
studies evaluating the cognitive effects of medication showed small to medium effect
sizes and were plagued by small sample sizes, the use of screening measures to identify
cognitive impairment, such as the MMSE, may further explain the discrepancies.
Even when specific neuropsychological tests are utilized to examine cognitive
impairment, such as Trail Making Test (e.g., Allegri et al., 2019; Baldacchino et al.,
2012), there is significantly more risk of erroneously concluding impairment or a lack of
impairment when researchers do not use a comprehensive battery of neuropsychological
tests. This is because, as previously discussed, some degree of cognitive variability is
normal (Binder et al., 2009; Schretlen et al., 2003). When combining scores across
multiple tests from the same domain within a comprehensive test battery, such as with the
MNS used in this study, the risk of Type I error is reduced. Additionally, given the
number of analyses conducted, and at times heterogeneity of variance, corrected
significance values were used in the present study to further reduce risk of false positive
findings.
Trends
Using these criteria, the only significant effects were found for use of broad
analgesic medications, triptans, and polypharmacy on IIV at .001 and .006 alpha levels.
However, there were other effects that were trending towards significance at this higher
level. Specifically, significant interactions between use of anxiolytics and polypharmacy
on OTBM (p=.01) and on IIV (p=.03) were identified, as were significant interactions
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between AEDs and polypharmacy on OTBM (p=.03) and on IIV (p=.03). A main effect
of analgesics on OTBM, as well as main effects of polypharmacy on IIV when run with
anticholinergic drugs, antidepressants, analgesics, cardiovascular medications, antiinflammatory medications, and hormone medications were also identified at p < .05.
Overall, the pattern of these results continues to fit with the previous literature and
suggest that most medications do not have significant effects on cognitive functioning
when accounting for estimated premorbid functioning, the neuropsychologist who
supervised the evaluation, use of other medications and various diagnoses. Small
differential effects of anxiolytics and AEDs on the OTBM and IIV were identified.
Although, these differences appear to be only in the context of polypharmacy. Consistent
with the previously discussed results, a main effect of analgesic use on global cognitive
functioning appears to be present when assessed by OTBM, as well as when assessed by
IIV. This pattern also provides added support for the effects of polypharmacy on IIV
across other medication use groups.
Interestingly, when evaluating global cognitive effects, significant effects on the
OTBM were rarely identified. Rather, more often, significant interaction and main effects
for both medication use and polypharmacy were either significant for differences in both
OTBM and IIV, or IIV independently. Additionally, no significant multivariate analyses
assessing medication use and polypharmacy across cognitive domains were significant at
conservative or typical alpha values. This pattern suggests that IIV may be particularly
sensitive to the effects of medication use and polypharmacy on cognition and provide
additional support for the use of this valuable metric of cognitive functioning in the
context of neuropsychological assessment in a clinical sample of younger adults.
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Implications
While this study was exploratory in nature, the findings have clinical relevance
for physicians, neurologists, and neuropsychologists given that these physicians are often
asked to identify and differentiate cognitive “signal” from “noise” through cognitive
assessment following complaints of subjective cognitive change (Schoenberg & Scott,
2011). The current results provide evidence for small effects of analgesics, triptans, and
polypharmacy on cognitive IIV in this younger adult, clinical sample. These findings are
above and beyond the effects of premorbid functioning; neurological, psychiatric, and
general medical diagnoses; and use of other medications. However, while these effects
were statistically significant, differences in IIV only equated to negligible differences in
terms of clinical relevance across all significant results. For example, differences in IIV
for analgesics triptans, and polypharmacy were within 1-3 points of the other groups.
Given that recommendations to interpret significant discrepancies on
neuropsychological tests ranges from 1 to 2 SD (Lezak et al., 2012), the differences
identified in this study do not constitute clinically significant discrepancies in cognitive
functioning from a neuropsychological perspective. In conjunction with the otherwise
null results, this study provides support for younger adults’ relative resistance to
significant cognitive effects of the medications evaluated in the present study. Therefore,
it would be highly unlikely for most of the medications evaluated in this study to produce
any more than a mild changes to variability on neurocognitive performance for younger
adults, even those from a clinical, cognitively vulnerable sample.
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Limitations
Despite this, it is important to recognize some important limitations to the present
study. First, while the overall sample size was large and it surpassed the minimal sample
size identified by the a priori power analysis, due to the wide variety of medications
reported by study subjects, not all medication groups had sufficient data to support an
analysis. Due to this issue, a deductive approach to data analysis was employed.
However, it is possible that because analyses were first run with the therapeutic use group
category, specific effects of a drug class or specific medication were outweighed by the
effects, or lack thereof, of the other drug classes.
Additionally, given the high number of different medications reported, further
caution had to be used when running analyses with sufficiently populated groups.
Specifically, given that familywise error rate increases with the number of analyses, a
Bonferroni corrected alpha was used to reduce the chance of Type I error. The alpha was
further reduced in the event of violations of homogeneity of variance, which was not
uncommon, particularly given the distribution of medications across the sample. While
this helped reduce the risk of false positive errors, it is possible that legitimate
interactions and main effects of medications and polypharmacy on global and domain
specific cognitive functioning were not interpreted.
Finally, given the circumstances regarding neuropsychological evaluations and
the archival nature of the data, some data that would have aided in more accurate
classifications and evaluations of medication use was missing. Specifically, all
information regarding medication use and diagnoses was provided by the patient, and not
a comprehensive medical record system. Thus, it is possible that some of the reported

126

medication and diagnosis information is inaccurate or incomplete. Additionally,
information regarding why a medication had been prescribed, the dosage of medications,
frequency of medication use, when the subject last took a dose of medication in relation
to the date and time of the neuropsychological assessment, and how long the patient had
been taking their medications was not available. These missing factors limit our
understanding of the study results.

Future Directions
Further evaluation of the cognitive effects of medication use with a larger sample
size and more comprehensive medication information (e.g., dose, frequency of
administration, duration of use, reason for use, etc.) is warranted. While the present study
provides a comprehensive baseline of the effects of medications and polypharmacy on
cognition in a relatively young clinical sample, future studies should explore the effects
of medication in older clinical and non-clinical samples using this comprehensive
methodology to provide a more complete picture of the potential effects of these
medications on comprehensive neuropsychological tests. Additionally, while this study
focused exclusively on the use of prescription medications and their effects on cognition,
future studies should also explore the use and effects of over-the-counter medications and
dietary supplements on cognition. Much like the use of prescription medications, the use
of dietary supplements has increased over time (Qato et al., 2016). Given that dietary
supplements do not require FDA approval, the potential for unknown cognitive side
effects in these substances is high.
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Appendix B – Demographic and Correlation Tables

Table B.1
Frequency of Diagnoses for Study Participants
Diagnosis
Internalizing Disorders
Depression
Anxiety
PTSD
Panic Disorder
OCD
Somatic Symptom Disorder
Conversion Disorder
Impulse Control Disorder
Substance Use Disorder
Severe Mental Illness
Schizophrenia
Bipolar Disorder
Other Psychotic Disorders
Learning Disorders
Learning Disability
ADHD
Neurodevelopmental Disorders
ASD
Developmental Motor Disorders
Borderline Intellectual Functioning
Intellectual Disability
Seizure Disorder
Neurocognitive Disorders
Alzheimer’s Disease
Cerebrovascular Disease
FTLD
Parkinson’s Disease
Dementia
Multiple Sclerosis
Viral Encephalitis
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n (Valid %)
230 (46.3%)
173 (43.3%)
106 (26.5%)
8 (2.0%)
7 (1.8%)
3 (0.8%)
23 (5.8%)
14 (3.5%)
1 (0.3%)
66 (13.3%)
23 (5.8%)
5 (1.3%)
16 (4.0%)
2 (0.5%)
85 (21.3%)
59 (14.8%)
39 (9.8%)
20 (5.0%)
6 (1.5%)
3 (0.8%)
9 (2.3%)
2 (0.5%)
18 (4.5%)
25 (6.3%)
6 (1.5%)
8 (2.0%)
1 (0.3%)
1 (0.3%)
16 (4.0%)
9 (2.3%)
3 (0.8%)

Table B.1 Cont.
Diagnosis
n (Valid %)
Chiari Malformation
3 (0.8%)
Brain Tumor
7 (1.8%)
Traumatic Brain Injury
71 (17.8%)
Post Concussive Syndrome
7 (1.8%)
Mild TBI
48 (12.0%)
Moderate to Severe TBI
21 (5.3%)
Cardiovascular Disorders
37 (9.3%)
Cardiac Disease
5 (1.3%)
Stroke
19 (4.8%)
Transient Ischemic Attack
3 (0.8%)
Aneurysm
4 (1.0%)
Hyperlipidemia
7 (1.8%)
Autoimmune Disorders
10 (2.5%)
Thyroid Dysfunction
5 (1.3%)
Lupus
2 (0.5%)
Diabetes
4 (1.0%)
Hyperchloremia
1 (0.3%)
Respiratory Dysfunction
17 (4.3%)
Sleep Apnea
12 (3.0%)
Asthma
4 (1.0%)
Chronic Obstructive Pulmonary Disease
1 (0.3%)
Gastrointestinal
6 (1.5%)
Inflammatory Bowel Diseases
5 (1.3%)
Gastroesophageal Reflux Disease
2 (0.5%)
Pain
74 (18.5%)
Migraine
19 (4.8%)
Tinnitus
1 (0.3%)
Eating Disorders
2 (0.4%)
Sleep Disorders
8 (2.0%)
Sleep Disturbance
7 (1.8%)
Narcolepsy
1 (0.3%)
Note. n = 497. PTSD = Post-traumatic Stress Disorder. OCD = Obsessive Compulsive
Disorder. ADHD = Attention-Deficit/Hyperactivity Disorder. ASD = Autism
Spectrum Disorder. FTLD = Frontotemporal Lobar Degeneration. TBI = Traumatic
Brain Injury.

165

Table B.2
Frequency of Medication Use by Study Participants
Therapeutic Use
Drug Family
Drug Name (Generic) n (Valid %)
100
Anticholinergics
(20.1%)
232
Antidepressants
(46.7%)
Atypical
67(13.5%)
Antidepressants
Bupropion
37 (7.4%)
Mirtazapine
8 (1.6%)
Nefazodone
9 (1.8%)
Trazodone
19 (3.8%)
SNRI
33 (6.6%)
Desvenlafaxine
2 (0.4%)
Duloxetine
5 (1.0%)
Levomilnacipran
1 (0.2%)
Venlafaxine
25 (5.0%)
138
SSRI
(27.8%)
Citalopram
17 (3.4%)
Escitalopram
15 (3.0%)
Fluoxetine
26 (5.2%)
Fluvoxamine
2 (0.4%)
Paroxetine
30 (6.0%)
Sertraline
46 (9.3%)
Vortioxetine
2 (0.4%)
Tricyclics
43 (8.7%)
Amitriptyline
29 (5.8%)
Doxepin
1 (0.2%)
Imipramine
4 (0.8%)
Nortriptyline
4 (0.8%)
Cyclobenzaprine
5 (1.0%)
Anxiolytics
68 (13.7%)
Benzodiazepines
51 (10.3%)
Alprazolam
20 (4.0%)
Chlordiazepoxide
1 (0.2%)
Clonazepam
13 (2.6%)
Diazepam
3 (0.6%)
Eszopiclone
1 (0.2%)
Lorazepam
12 (2.4%)
Temazepam
1 (0.2%)
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Table B.2 Cont.
Therapeutic Use

Drug Family

Drug Name (Generic) n (Valid %)
Triazolam
1 (0.2%)

BenzodiazepineLike

8 (1.6%)
Zolpidem

Other Anxiolytics
Buspirone
Antipsychotics
Atypical
Antipsychotics

8 (1.6%)
13 (2.6%)
13 (2.6%)
37(7.4%)
35 (7.0%)

Aripiprazole
Brexpiprazole
Olanzapine
Risperidone
Quetiapine
Phenothiazines
Prochlorperazine
Butyrophenones
Haloperidol
Mood Stabilizers
Antimanic Agents
Lithium
Analgesics
Triptans
Almotriptan
Eletriptan
Rizatriptan
Sumatriptan
Opioids
Buprenorphine
Dextropropoxyphene
Fentanyl
Hydrocodone
Oxycodone
Tramadol
Opioid
Combinations

3 (0.6%)
2 (0.4%)
10 (2.0%)
7 (1.4%)
15 (3.0%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
4 (0.8%)
4 (0.8%)
4 (0.8%)
67 (13.5%)
6 (1.2%)
1 (0.2%)
1 (0.2%)
2 (0.4%)
2 (0.4%)
38 (7.6%)
1 (0.2%)
9 (1.8%)
2 (0.4%)
7 (1.4%)
2 (0.4%)
19 (3.8%)
20 (4.0%)

HydrocodoneAcetaminophen
Hydrocodone
BitartrateAcetaminophen
HydrocodoneChlorpheniramine
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5 (1.0%)
10 (2.0%)
1 (0.2%)

Table B.2 Cont.
Therapeutic Use

Drug Family

Non-Opioid
Addiction
Alcohol Antagonist
Opioid Agonist

Antiepileptics
Traditional AEDs

Newer AEDs

Stimulants

Drug Name (Generic) n (Valid %)
Oxycodone2 (0.4%)
Acetaminophen
Propoxyphene2 (0.4%)
Acetaminophen
11 (2.2%)
Acetaminophen
11 (2.2%)
5 (1.0%)
1 (0.2%)
Disulfiram
1 (0.2%)
4 (0.8%)
Buprenorphine1 (0.2%)
Naloxone
Methadone
3 (0.6%)
96 (19.3%)
47 (9.5%)
Carbamazepine
10 (2.0%)
Phenytoin
13 (2.6%)
Primidone
1 (0.2%)
Divalproex Sodium
24 (4.8%)
56 (11.3%)
Oxcarbazepine
3 (0.6%)
Gabapentin
33 (6.6%)
Lamotrigine
15 (3.0%)
Levetiracetam
5 (1.0%)
Topiramate
2 (0.4%)
21 (4.2%)

Amphetamine
Combinations

13 (2.6%)
DextroamphetamineAmphetamine

Centrally Acting
Sympathomimetics

12 (2.4%)
Lisdexamfetamine
Methylphenidate
Modafinil
Pemoline

Antidementia
Cholinesterase
Inhibitors
Donepezil
Memantine
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2 (0.4%)
6 (1.2%)
3 (0.6%)
1 (0.2%)
6 (1.2%)
5 (1.0%)

NMDA Antagonists
Cardiovascular

11 (2.2%)

5 (1.0%)
1 (0.2%)
1 (0.2%)
86 (17.3%)

Table B.2 Cont.
Therapeutic Use

Drug Family
ACE Inhibitors

Drug Name (Generic) n (Valid %)
29 (5.8%)
Benazepril
3 (0.6%)
Fosinopril
3 (0.6%)
Lisinopril
9 (1.8%)
Moexipril
1 (0.2%)
Quinapril
11 (2.2%)
Ramipril
2 (0.4%)

Alpha-Adrenergic
Blockers

5 (1.0%)
Doxazosin
Prazosin

Angiotensin II
Receptor Blockers

8 (1.6%)
Candesartan
Losartan
Olmesartan
Valsartan

Beta Blockers
Atenolol
Betaxolol
Labetalol
Metoprolol
Nebivolol
Propranolol
Calcium Channel
Blockers

1 (0.2%)
5 (1.0%)
1 (0.2%)
1 (0.2%)
25 (5.0%)
4 (0.8%)
1 (0.2%)
3 (0.6%)
12 (2.4%)
1 (0.2%)
4 (0.8%)
18 (3.6%)

Amlodipine
Diltiazem
Nifedipine
Verapamil
Cardiac Glycosides
Digoxin
Centrally Acting
Alpha2 Agonist

9 (1.8%)
6 (1.2%)
3 (0.6%)
1 (0.2%)
4 (0.8%)
4 (0.8%)
5 (1.0%)

Clonidine
Diuretics
Hydrochlorothiazide
Furosemide
Spironolactone
Nitrates
Isosorbide
mononitrate
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3 (0.6%)
2 (0.4%)

5 (1.0%)
23 (4.6%)
17 (3.4%)
4 (0.8%)
3 (0.6%)
3 (0.6%)
3 (0.6%)

Table B.2 Cont.
Therapeutic Use

Drug Family
Sodium Channel
Blockers

Drug Name (Generic) n (Valid %)
1 (0.2%)
Lidocaine

Lipid Modifying
Agents

1 (0.2%)
41 (8.2%)

Fibrates
Fenofibrate
Gemfibrozil
HMG-CoA
Reductase Inhibitors

4 (0.8%)
3 (0.6%)
1 (0.2%)
38 (7.6%)

Atorvastatin
Pravastatin
Rosuvastatin
Simvastatin
Antithrombotic
Agents

25 (5.0%)
3 (0.6%)
3 (0.6%)
7 (1.4%)
15 (3.0%)

Anticoagulants
Enoxaparin
Warfarin
Antiplatelet
Clopidogrel
Anti-Inflammatory
Corticosteroids
Dexamethasone
Prednisone
Second-Generation
NSAID

25 (5.0%)
Celecoxib
Rofecoxib

First-Generation
NSAID

Contraceptives
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13 (2.6%)
12 (2.4%)
57 (11.5%)

Aspirin
Diclofenac
Diflunisal
Ibuprofen
Naproxen
Relafen
Ketorolac
Sulindac
Indomethacin
Meloxicam
Hormones

10 (2.0%)
1 (0.2%)
9 (1.8%)
6 (1.2%)
6 (1.2%)
79 (15.9%)
5 (1.0%)
1 (0.2%)
4 (0.8%)

27 (5.4%)
1 (0.2%)
1 (0.2%)
21 (4.2%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
2 (0.4%)
2 (0.4%)
79 (15.9%)
14 (2.8%)

Table B.2 Cont.
Therapeutic Use

Drug Family

Non-contraceptives

Respiratory
Bronchodilators

Corticosteroids

Drug Name (Generic) n (Valid %)
Medroxyprogesterone
3 (0.6%)
Acetate
Progesterone
2 (0.4%)
69(13.9%)
Estrogens
26 (5.2%)
Levothyroxine
45 (9.1%)
Raloxifene
3 (0.6%)
27 (5.4%)
20 (4.0%)
Albuterol
15 (3.0%)
Alupent
1 (0.2%)
Salmeterol
5 (1.0%)
Theophylline
1 (0.2%)
Tiotropium bromide
1 (0.2%)
9 (1.8%)
Flunisolide
2 (0.4%)
Fluticasone
7 (1.4%)

Nonopioid
Antitussives

1 (0.2%)
Benzonatate

Leukotriene
Modifiers

1 (0.2%)
6 (1.2%)

Montelukast
Antidiabetics
Biguanides
Metformin
Incretin Mimetics
Liraglutide
Insulin Preparations
Insulin
Meglitinides
Repaglinide
SGLT-2 Inhibitor
Dapagliflozin
Sulfonylureas
Glyburide
(Glibenclamide)
Glipizide
Thiazolidinediones
Pioglitazone
Antihistamines
First-Generation H1
Antagonist
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6 (1.2%)
25 (5.0%)
10 (2.0%)
10 (2.0%)
1 (0.2%)
1 (0.2%)
10 (2.0%)
10 (2.0%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
1 (0.2%)
3 (0.6%)
1 (0.2%)
2 (0.4%)
3 (0.6%)
3 (0.6%)
24 (4.8%)
9 (1.8%)

Table B.2 Cont.
Therapeutic Use

Drug Family

Drug Name (Generic) n (Valid %)
ChlorpheniramineMethscopolamine1 (0.2%)
Phenylephrine
Diphenhydramine
1 (0.2%)
Hydroxyzine
5 (1.0%)
Meclizine
1 (0.2%)
Promethazine
1 (0.2%)

Second-Generation
H1 Antagonist

15 (3.0%)
Cetirizine
Desloratadine
Fexofenadine
Loratadine
Azelastine

Urological
Alpha-adrenergic
Antagonists

5 (1.0%)
1 (0.2%)
5 (1.0%)
3 (0.6%)
1 (0.2%)
15 (3.0%)
2 (0.4%)

Terazosin
Tamsulosin
Anticholinergic
Oxybutynin
Solifenacin
Tolterodine
Phosphodiesterase
Type 5 Inhibitor

1 (0.2%)
1 (0.2%)
12 (2.4%)
7 (1.4%)
3 (0.6%)
2 (0.4%)
1 (0.2%)

Sildenafil
5-Alpha-Reductase
Inhibitors

1 (0.2%)
1 (0.2%)

Finasteride
Gastrointestinal
Antispasmodic
Dicycloverine
Gallstone Dilution
Agents

1 (0.2%)
65 (13.1%)
3 (0.6%)
3 (0.6%)
1 (0.2%)

Ursodiol
H2-Receptor
Antagonists

1 (0.2%)
8 (1.6%)

Cimetidine
Ranitidine
Prokinetic
Metoclopramide
Proton Pump
Inhibitors

1 (0.2%)
7 (1.4%)
3 (0.6%)
3 (0.6%)
47 (9.5%)

172

Table B.2 Cont.
Therapeutic Use

Drug Family

Stool Softener
Muscle Relaxants
Centrally Acting

Peripherally Acting

Drug Name (Generic) n (Valid %)
Esomeprazole
9 (1.8%)
Lansoprazole
12 (2.4%)
Omeprazole
21 (4.2%)
Pantoprazole
5 (1.0%)
Rabeprazole
1 (0.2%)
7 (1.4%)
Docusate Sodium
7 (1.4%)
14 (2.8%)
13 (2.6%)
Baclofen
2 (0.4%)
Metaxalone
6 (1.2%)
Methocarbamol
2 (0.4%)
Tizanidine
3 (0.6%)
1 (0.2%)
Orphenadrine
1 (0.2%)

Calcium and Bone
Mineralization

5 (1.0%)
Bisphosphonates
Alendronic Acid
Risedronic Acid

Immunomodulators
Immunostimulants
Glatiramer Acetate
Interferon Beta-1a
Immunosuppressants
Etanercept
Methotrexate
Movement Disorder
Dopamine-Releasing
Agent

5 (1.0%)
2 (0.4%)
3 (0.6%)
6 (1.2%)
4 (0.8%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
1 (0.2%)
2 (0.4%)
5 (1.0%)
1 (0.2%)

Amantadine
Dopamine
Replacement

1 (0.2%)
2 (0.4%)

Levodopa-Carbidopa
Dopamine Agonist
Ropinirole
Antiglaucoma
CAI
Acetazolamide
Prostaglandin
Analogs

2 (0.4%)
2 (0.4%)
2 (0.4%)
3 (0.6%)
2 (0.4%)
2 (0.4%)
1 (0.2%)

Travoprost
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1 (0.2%)

Table B.2 Cont.
Therapeutic Use

Drug Family
Other
Antiglaucomas

Drug Name (Generic) n (Valid %)
1 (0.2%)
Dipivefrine

Dermatological
Anti-infectives
Fluconazole
Corticosteroids
Clobetasol
Antimalarial
Aminoquinolines
Hydroxychloroquine
Cytotoxic Drugs
Alkylating Agents
Temozolomide
Weight Loss Drugs
Lipase Inhibitor
Orlistat
Sympathomimetic
Amines

1 (0.2%)
3 (0.6%)
1 (0.2%)
1 (0.2%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
2 (0.4%)
1 (0.2%)
1 (0.2%)
1 (0.2%)

Phentermine

1 (0.2%)
1 (0.2%)
Uric Acid Inhibitors
1 (0.2%)
Allopurinol
1 (0.2%)
Note. N = 497. SNRI = Serotonin-Norepinephrine Reuptake Inhibitor. SSRI =
Selective Serotonin Reuptake Inhibitor. AED = Antiepileptic Drug. NMDA = NMethyl-D-aspartate receptor. ACE = Angiotensin-Converting Enzyme. HMG-CoA
= 3-hydroxy-3-methyl-glutaryl-coenzyme A. NSAID = Non-Steroidal AntiInflammatory Drug. SGLT-2 = Sodium-Glucose Co-Transporter 2. CAI = Carbonic
Anhydrase Inhibitor. Due to some participants having prescriptions for multiple
medications within the same drug family and/or therapeutic use group, frequency
of the larger groups are not always equivalent to the frequency of use identified at
the drug-name level.
Antigout Agents
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Table B.3
Medications with Strongly Anticholinergic used by Study Participants
Therapeutic Use
Drug Family
Drug Name (Generic)
Antidepressants
Atypical Antidepressants
Paroxetine
Tricyclics
Amitriptyline
Doxepin
Imipramine
Nortriptyline
Cyclobenzaprine
Analgesics
Opioid Combinations
Hydrocodone-Chlorpheniramine
Antipsychotics
Atypical Antipsychotics
Olanzapine
Phenothiazines
Prochlorperazine
Antihistamines
First-Generation H1
Antagonist
Methscopolamine-Phenylephrine
Diphenhydramine
Hydroxyzine
Meclizine
Promethazine
Urological
Anticholinergic
Oxybutynin
Gastrointestinal
Antispasmodic
Dicycloverine
Muscle
Relaxants
Peripherally Acting
Orphenadrine
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Table B.4
Meyers Neuropsychological Battery and Supplemental Tests by Domain
#
00

Test Name
Performance Validitya
1) Word Memory Test (Green, 2003)
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2) Test of Memory Malingering
(Tombaugh, 1996)
0

I

Cognitive Function
Validity and verbal
memory recall and
recognition
Validity and recognition
memory

Hypothesized
Localization(s)
Relatively
insensitive to
cognitive
impairment
Relatively
insensitive to
cognitive
impairment

Reference

Lezak et al., 2004 (p. 850851); Strauss et al., 2006
Lezak et al., 2004 (p. 849850); Strauss et al., 2006

Premorbid Functioninga

1) North American Adult Reading
Test (Strauss et al., 2006)

Premorbid intellectual
ability

2) Word Reading (WRAT-4;
Wilkinson & Robertson, 2006)

Premorbid intellectual
ability

Attention/Working Memory

Inferior occipitaltemporal cortex;
inferior longitudinal
fasciculus, and
perisylvian
language areas
Inferior occipitaltemporal cortex;
inferior longitudinal
fasciculus, and
perisylvian
language areas

Lezak et al., 2004 (p.
560); Strauss et al., 2006

Lezak et al., 2004 (p.
560); Strauss et al., 2006

Table B.4 Cont.
#

Test Name

Cognitive Function

Hypothesized
Localization(s)
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1) Arithmetic (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

Mental Calculations and
working memory

Left parietal lobe

2) Digit Span (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

Verbal recall and auditory
attention

Left hemisphere

3) Animal Naming (Spreen &
Strauss, 1998)

Word Fluency and Mental
Flexibility

4) Auditory Verbal Learning Test
(AVLT) – Trial 1 (Rey, 1964)

Auditory working
memory and immediate
recall

5) Sentence Repetition (Spreen &
Strauss, 1991)

Auditory comprehension,
verbal expression, and
articulation

6) Forced Choice (Brandt et al.,
1985)

Verbal Expression

Reference
Hom & Reitan, 1984;
Lezak et al., 2004 (p.
605); McFie, 1975;
Newcombe, 1969; Sivak
et al., 1981
Black, 1986; Hom &
Reitan, 1984; Newcombe,
1969

Left hemisphere;
inferior temporal
Damasio et al., 1996;
lobes; Broca’s area; Martin et al., 1996; Rosen,
left medial occipital
1980
lobe
Left hemisphere,
Geffen et al., 1990; Lezak
left frontal,
et al., 2004; Powell et al.,
temporal, and
1991
parietal lobes
Left hemisphere;
middle cerebral
artery infarcts;
Goodglass & Kaplan,
Broca’s;
1983; Lezak et al., 2004;
Wernicke’s; global
aphasia
Left hemisphere

Lezak et al., 2004

Table B.4 Cont.
#

Test Name
7) Arithmetic (WRAT-4; Wilkinson
& Robertson, 2006)
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II

8) Paced Auditory Serial Addition
Test (Gronwall, 1977; Gronwall &
Sampson, 1974)
9) Minute Estimation (Meyers, 2019)
10) Dementia Rating Scale – 2 Attention Index (Mattis, 2001)
11) IVA-2 CPT – Auditory and Visual
attention and sustained attention
(Sandford & Turner, 1995)
Processing Speed
1) Digit Symbol/Coding (WAIS
III/IV) (Wechsler, 1997; Wechsler,
2008)
2) Trail Making Test – Part A
(Reitan, 1958)

III

3) Brake Pedal Test (Brake Reaction
Test)
Verbal Reasoning/Verbal Comprehension

Cognitive Function
Written calculations
Attention, working
memory, and information
processing
Attention
Attention and working
memory

Hypothesized
Localization(s)
Left hemisphere;
bilateral parietal
lobes
Frontal and parietal
lobes
Frontal lobes
Left hemisphere

Reference
Lezak et al., 2004 (p. 662)
Lazeron et al., 2003;
Lezak et al., 2004 (p.
412); Strauss et al., 2006
Meyers, 2019
Lezak et al., 2004 (p.
412); Strauss et al., 2006

Vigilance and sustained
attention

Frontal lobes

Lezak et al., 2004 (p. 415416); Tinius, 2003

Psychomotor speed and
attention

b

Lezak et al., 2004 (p. 369)

Frontal lobes

Reitan, 1958; Segalowitz
et al., 1992

b

Hasegawa et al., 2020;
Zhang et al., 2007

Attention, visual scanning,
and over-learned
sequencing
Psychomotor speed and
attention

Table B.4 Cont.
#

Test Name

Cognitive Function

Hypothesized
Localization(s)

Reference
Lezak et al., 2004 (p.
572); McFie, 1975;
Newcombe, 1969;
Warrington et al., 1986
Larrabee et al., 1985;
Russell, 1987; Schoenberg
et al., 2002; Sklar, 1963;
Storandt et al., 1986

Verbal abstraction

Left temporal and
frontal lobes

2) Information (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

Long-term memory

Left hemisphere;
general ability

3) Controlled Oral Word Association
Test (Spreen & Strauss, 1998)

Mental flexibility and
abstract reason

Left and right
frontal

4) Boston Naming Test (Kaplan et
al., 1983

Ability to name objects
and language

Left hemisphere;
Broca’s area;
hippocampus

5) Token Test (Boller & Vignolo,
1966)

Receptive language,
ability to follow directions
and concentration

Left temporal and
parietal

Boller & Vignolo, 1966;
Strauss et al., 2006

6) Dichotic Listening Test – Left
sounds (Roberts et al., 1994)

Inter-hemispheric
communication

Auditory system,
ipsilateral and
contra-lateral
auditory system

Lezak et al., 2004; Meyers
et al., 2002; Roberts et al.,
1994
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1) Similarities (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

Ferret, 1974; Miceli et al.,
1981; Rothi et al., 1991
Kaplan et al., 1983; Lezak
et al., 2004; Margolin et
al., 1990; Spreen &
Strauss, 1998

Table B.4 Cont.
#
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IV

Lezak et al., 2004; Meyers
et al., 2002; Roberts et al.,
1994

Expressive language and
lexical comprehension

Hypothesized
Localization(s)
Auditory system,
more left contralateral auditory
system than right
Left hemisphere;
general ability

Verbal abstraction and
reasoning

Left temporal and
frontal lobes

Lezak et al., 2004 (p.
412); Strauss et al., 2006

Visual spatial perceptual
skills and discrimination
of essential and nonessential details

Right parietal,
temporal, and
occipital lobes

Chase et al., 1984; Lezak
et al., 2004 (p. 598)

Right posterior and
left parietal lobes

Black & Strub, 1976;
Lezak et al., 2004 (p.
560); McFie, 1975;
Newcombe, 1969;
Warrington et al., 1986

Test Name

Cognitive Function

7) Dichotic Listening Test – Right
sounds (Roberts et al., 1994)

Inter-hemispheric
communication

8) Spelling (WRAT-4; Wilkinson &
Robertson, 2006)
9) Dementia Rating Scale – 2 –
Conceptualization Index (Mattis,
2001)
Visual Reasoning/Perceptual Organization
1) Picture Completion (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

2) Block Design (WAIS III/IV)
(Wechsler, 1997; Wechsler, 2008)

Visual spatial organization

3) Judgement of Line Orientation
(Benton et al., 1983b)

Ability to perceive visual
information and judge
lines and angles

4) Rey Complex Figure Test – Copy
(Rey, 1964)

Visual Organization

Right posterior
parietal and anterior
occipital lobes
Right hemisphere;
parietal and
temporal

Reference

Lezak et al., 2004 (p.
564-565)

Benton et al., 1983b;
Tranel et al., 2009
Meyers & Meyers, 1995

Table B.4 Cont.
#

V
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VI

VII

Test Name
Cognitive Function
5) Dementia Rating Scale – 2 –
Visual-perceptual/visualConstruction Index (Mattis, 2001)
constructional
Verbal Memory/Auditory Memory and Learning
1) Rey Auditory Verbal Learning
Learning, immediate and
Test – Total learning trials,
delayed free recall, and
immediate recall, delayed recall,
recognition of verbal
and recognition (Rey, 1964)
information
Learning, immediate and
2) Dementia Rating Scale – 2 –
delayed free recall, and
Memory Index (Mattis, 2001)
recognition
3) Wide Range Assessment of
Memory and Learning – 2
Immediate and delayed
Immediate recall, delayed recall
free recall, and
and recognition Story Memory
recognition
(Sheslow & Adams, 2003)
Visual Memory/Nonverbal Memory and Learning
Visual Organization,
1) Rey Complex Figure Test –
immediate and delayed
immediate recall, delayed recall,
recall of visual
and recognition (Rey, 1964)
information
Executive Functioning

Hypothesized
Localization(s)
Subcorticial
hyperintensities

Reference
Lezak et al., 2004 (p.
412); Strauss et al., 2006

Left hemisphere

Lezak et al., 2004;
Geffen et al., 1990

Hippocampus

Lezak et al., 2004 (p.
412); Strauss et al., 2006

Left hemisphere;
hippocampus

Lezak et al., 2004 (p.
536); Strauss et al., 2006

Right hemisphere

Meyers & Meyers, 1995

Table B.4 Cont.
#

Test Name
1) Trail Making Test – Part B
(Reitan, 1958)
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2) Dichotic Listening Test– Both Left
and Right Sounds (Meyers et al.,
2002)
3) Category Test (Spreen & Strauss,
1991)
4) Wisconsin Card Sorting Test –
percent errors, perseverative
responses, and perseverative errors
(Berg, 1948)
5) Dementia Rating Scale – 2 –
Initiation/Perseveration Index
(Mattis, 2001)
6) IVA-2 CPT – Auditory and
Visual Response Control
(Sandford & Turner, 1995)
VIII Dominant Motor and Sensory

Cognitive Function

Hypothesized
Localization(s)

Reference
Greenlief et al., 1985;
Reitan & Wolfson,
1985; Ruffolo et al.,
2000; Segalowitz et al.,
1992

Attention, set switching,
eye-hand coordination,
working memory

Frontal lobes

Bilateral interhemispheric
communication

Auditory system,
more left contralateral auditory
system than right

Meyers et al., 2002;
Lezak et al., 2004;
Roberts et al., 1994

Problem solving and
reasoning abilities

Right hemisphere

Cullum & Bigler, 1986;
Goldstein & Ruthven,
1983; Halstead, 1947;
King & Snow, 1981;
Wang, 1987

Problem solving, setshifting, mental flexibility,
judgement

Frontal lobes,
dorsolateral
prefrontal

Lezak et al., 2004 (p.
637-639)

Inhibitory control and
mental flexibility

Frontal lobes,
subcortical
hyperintensities

Lezak et al., 2004 (p.
412); Strauss et al., 2006

Inhibitory
control/response
inhibition

Frontal lobes

Lezak et al., 2004 (p.
415-16); Tinius, 2003

Table B.4 Cont.
#

Cognitive Function

1) Finger Tapping Test – Dominant
(Reitan & Wolfson, 1985)

Motor speed and
persistence

2) Finger Localization Test –
Dominant (Benton et al., 1983b)

Tactile identification
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Test Name

IX

3) Grooved Pegboard Test –
Dominant (Matthews & Klove,
1964)
Non-Dominant Motor and Sensory

1) Finger Tapping Test – NonDominant (Reitan & Wolfson,
1985)

Motor Speed and Fine
Motor Dexterity

Motor speed and
persistence

Hypothesized
Localization(s)
Contralateral and
ipsilateral
motor, contralateral
premotor,
contralateral
dorsolateral
prefrontal, and
ipsilateral
cerebellum
Left posterior
perisylvian region;
right hemisphere
Contralateral and
ipsilateral
motor cortex
contralateral and
ipsilateral
motor, contralateral
premotor,
contralateral
dorsolateral
prefrontal, and
ipsilateral
cerebellum

Reference

Lezak et al., 2012;
Prigatano et al., 2004;
Strauss et al., 2006

Benton et al., 1983b;
Gainotti, & Tiacci, 1973
Lezak et al., 2012;
Strauss et al., 2006

Lezak et al., 2012;
Prigatano et al., 2004;
Strauss et al., 2006

Table B.4 Cont.
Hypothesized
Localization(s)
#
Left posterior
Benton et al., 1983b;
2) Finger Localization Test – NonTactile identification
perisylvian region;
Gainotti, & Tiacci,
Dominant (Benton et al., 1983b)
right hemisphere
1973
3) Grooved Pegboard Test – NonContralateral and
Motor Speed and Fine
Lezak et al., 2012;
Dominant (Matthews & Klove,
ipsilateral
Motor Dexterity
Strauss et al., 2006
1964)
motor cortex
a
Note. Adapted from Meyers and Rohling (2009). = tests from this domain were not included in calculations of OTBM or IIV. b =
very sensitive to brain damage and depressed regardless of location of the locus of a lesion. WRAT = Wide Range Achievement Test.
WAIS = Wechsler Adult Intelligence Scale. Integrated Visual and Auditory = IVA. Continuous Performance Test = CPT.
#

Test Name

Cognitive Function
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Table B.5
Bivariate Correlations between Cognitive Variables
4
2
3
1) OTBM
-.45*** -.27*** .54***

5
6
7
8
9
10
11
.77*** .72*** .75*** .69*** .77*** .68*** .76***

2) IIV

<-.01

-.35*** -.45*** -.21*** -.15*** -.31*** -.34*** -.26*** -.39*** -.30***

-.07

-.21*** -.13**

3) PVTs Failed

-.20***

-.11* -.14*** -.38*** -.20***

-.11*

12
.52***

13
.44***

-.10*

-.08
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4) Premorbid Est.

.41*** .23*** .66*** .54*** .36*** .31*** .50***

.12**

.13**

5) Attention/WM

.53*** .55*** .42*** .45*** .39*** .56***

.34***

.23***

6) Processing Speed
.46*** .36*** .29*** .39*** .55*** .45*** .33***
7) Verbal Reasoning
.48*** .43*** .34*** .64*** .24*** .17***
8) Visual Reasoning
.36*** .58*** .66*** .30*** .28***
9) Verbal Memory
.43*** .40*** .22*** .19***
10) Visual Memory
.49*** .30*** .31***
11) EF
.34*** .28***
12) Dom Motor
.59***
13) NonDom Motor
Note. OTBM = Overall Test Battery Mean. IIV = Intra-Individual Variability. PVT = Performance Validity Test. Est. = Estimate. WM
= Working Memory. EF = Executive Functioning. Dom Motor = Dominant Motor Functioning. NonDom Motor = Non-Dominant
Motor Functioning.
* < .05. **<.01. ***<.001.
N = 497.

Table B.6
Bivariate Correlations between Sample Diagnoses and OTBM and IIV
OTBM
IIV
Internalizing
.02
-.02
Impulse Control
.02
-.02
Substance Abuse
<-.01
.01
Years of Substance Abuse
-.02
-.05
Severe Mental Illness
.05
.01
Learning
.09
.04
Neurodevelopmental
.17***
-.06
Seizure
.03
-.08
Neurocognitive
.10*
-.05
Chiari Malformation
-.02
.06
Brain Tumor
<.01
-.07
All Types of Traumatic Brain Injury
.03
.02
Post Concussive Syndrome
.09
-.02
Mild TBI
-.03
.12*
Moderate to Severe TBI
.14**
-.14**
Cardiovascular
.16**
-.21***
Hyperlipidemia
-.06
.04
Autoimmune
.05
-.11*
Hyperchloremia
-.02
-.04
Respiratory Dysfunction
-.12**
-.05
Pain
-.09
.12**
Migraine
-.03
-.03
Tinnitus
-.02
<.01
Eating Disorders
.01
-.04
Sleep Dysfunction
<-.01
.05
Note. N = 497. * < .05. **<.01. ***<.001.
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Table B.7
Bivariate Correlations between Therapeutic Use Categories and OTBM and IIV
OTBM
IIV
Polypharmacy
.03
-.06
Anticholinergic
.06
-.02
Antidepressant
.01
-.04
Anxiolytic
.07
-.05
Antipsychotic
.10**
-.05
Mood Stabilizer
.06
-.05
Analgesic
.07
-.07
Addiction
.06
-.05
Antiepileptic
.11**
-.08
Stimulant
.05
-.05
Antidementia
.06
-.05
Cardiovascular
.07
-.06
Lipid Modifying
.04
-.04
Antithrombotic
.08
-.07
Anti-inflammatory
.01
<.01
Hormone
.03
-.01
Respiratory
.08
-.03
Antidiabetic
.10**
-.05
Antihistamine
.07
-.06
Urological
.05
-.05
Gastrointestinal
.05
-.03
Muscle Relaxants
.06
-.06
Calcium and Bone Mineralization
.06
-.05
Immunomodulator
.06
-.06
Movement Disorder
.05
-.04
Antiglaucoma
.06
-.05
Dermatological
.06
-.06
Antimalarial
.06
-.04
Cytotoxic
.06
-.05
Weight Loss
.06
-.05
Antigout
.06
-.04
Note. N = 497. * < .05. **<.01. ***<.001
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Table B.8
Bivariate Correlations between Demographic Variables and OTBM and IIV
OTBM
IIV
Age
.15**
-.05
Gender
.04
.01
Ethnicity
-.02
-.05
Neuropsychologist
-.03
.33***
Note. N = 497. * < .05. **<.01. ***<.001
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Table B.9
Bivariate Correlations between Sample Diagnoses and Cognitive Domains

189

Internalizing
Impulse Control
SA
Years of SA
SMI
Learning
Neurodevelopmental
Seizure
Neurocognitive
Chiari Malformation
Brain Tumor
All Types of TBI
PCS
Mild TBI
Mod. to Severe TBI
Cardiovascular
Hyperlipidemia
Autoimmune
Hyperchloremia
Respiratory Disorder
Pain
Migraine

Premorbid
Est.

Attn/
WM

PS

Verbal
Reasoning

Visual
Reasoning

Verbal
Memory

Visual
Memory

-.05
-.01
.07
-.05
.06
.18**
.29***
-.01
-.09
-.03
<-.01
.03
.03
.03
.03
-.04
-1.3*
-1.2*
-.09
-.17***
.04
-.02

.05
.02
<.01
<.01
.04
.12*
.12*
.06
.03
.03
-.04
-.01
.07
-.06
.10*
.11*
-.02
.10
.02
-.07
-.05
.03

-.01
<-.01
-.03
.06
<.01
.02
.01
.04
.09
-.02
.04
.10*
.11*
.02
.16**
.16**
-.06
.03
.02
-.12*
-.15**
.04

-.09
-.01
.02
<-.01
.06
.13**
.21***
.02
.01
<.01
.03
.11*
.09
.06
.12*
.07
-.06
-.08
-.04
-.14**
<.01
-.04

.07
.01
<-.01
-.06
.07
.08
.20***
.01
.02
.01
-.02
-.04
-.01
-.03
.01
.09
-.07
-.04
-.02
-.15*
<-.01
-.04

-.02
.08
.03
-.02
.09
<.01
.09
-.01
.11*
-.03
<.01
.08
.11*
<-.01
.17***
.06
-.04
-.03
-.09
-.07
-.06
-.04

.07
.01
.04
-.05
.06
.01
.10*
<.01
.12*
<.01
-.01
-.04
.09
-.07
.05
.10*
-.07
.01
-.04
-.04
-.06
.05

EF

Dom
Motor

.01
.08
<.01
.04
-.01
-.07
-.02
.05
.05
-.02
.09
-.09
.17***
.10
-.01
-.01
.06
.11*
-.02
<.01
-.02
-.02
.02
-.04
.03
.02
.02
-.08
.04
.08
.11* .22***
-.05
.11*
.06
.17**
.04
.12*
-.01
<.01
-.05
-.09
-.02
-.05

NonDom
Motor
.01
.01
-.02
.01
<.01
-.10*
.09
.02
.14**
.03
.01
-.04
.05
-.08
.08
.19***
.16**
.11*
<-.01
-.03
-.03
-.11*

Table B.9 Cont.
Premorbid
Est.

Attn/
WM

PS

Verbal
Reasoning

Visual
Reasoning

Verbal
Memory

Visual
Memory

EF

Dom
Motor

NonDom
Motor
-.05
.06
-.09
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Tinnitus
-.09
-.02
-.01
-.05
.01
-.02
-.05
.06
-.04
Eating Disorder
-.06
-.07
.05
-.02
.02
-.03
.04
.03
.06
Sleep Disorder
-.06
.02
.04
<-.01
.03
<.01
.03
-.01
-.05
Note. N = 497. SA = Substance Abuse. SMI = Severe Mental Illness. TBI = Traumatic Brain Injury. PCS = Post Concussive
Syndrome. Mod. = Moderate. Dis. = Disorder. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF
= Executive Functioning. Dom Motor = Dominant Motor Functioning. Non-Dom Motor = Non-Dominant Motor Functioning.
* < .05. **<.01. ***<.001.

Table B.10
Bivariate Correlations between Therapeutic Use Categories and Cognitive Domains
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Polypharmacy
Anticholinergics
Antidepressants
Anxiolytics
Antipsychotics
Mood Stabilizers
Analgesics
Addiction
Antiepileptics
Stimulants
Antidementia
Cardiovascular
Lipid Modifying
Antithrombotic
Anti-inflammatory
Hormones
Respiratory
Antidiabetics
Antihistamines
Urological
Gastrointestinal
Muscle Relaxants

Premorbid
Est.

Attn/WM

.05
.05
<-.01
.06
.11*
.06
.05
.07
.10*
.05
.05
.04
.03
.07
.08
.02
.09
.08
.05
.06
.05
.07

.01
.05
.02
.07
.08
.04
.06
.04
.09*
.02
.05
.03
.02
.05
-.01
.05
.06
.08
.06
.03
.04
.05

PS

Verbal
Reasoning

Visual
Reasoning

Verbal
Memory

Visual
Memory

EF

Dom
Motor

.05
.07
.01
.06
.09*
.08
.06
.08
.16***
.09*
.08
.08
.07
.10*
.03
.03
.09
.10*
.09
.07
.08
.08

.07
.05
-.01
.08
.11*
.08
.07
.08
.13**
.07
.08
.07
.06
.10*
.06
.04
.09*
.11*
.07
.08
.07
.09

-.02
.03
<.01
.03
.06
<.01
.03
.01
.02
.01
<.01
.01
.01
.02
<-.01
-.01
.01
.03
<.01
.01
.01
<.01

.02
.02
-.02
.07
.07
.04
.04
.04
.06
.01
.04
.08
.02
.05
<-.01
.03
.04
.06
.04
.02
-.01
.04

-.03
.04
.01
.02
.07
.01
.03
.01
.01
<.01
<.01
.02
.01
.02
-.01
<-.01
.02
.03
.04
<.01
.02
<-.01

-.03
-.02
-.08
<-.01
.03
-.02
-.01
-.01
.04
-.02
-.01
<.01
-.02
<.01
-.03
-.02
.02
.05
-.02
-.01
-.01
-.02

-.09
-.02
-.02
-.01
-.02
-.03
-.01
-.04
.02
-.03
-.02
<.01
-.03
<.01
-.06
-.02
-.02
-.01
-.01
-.04
-.02
-.02

NonDom
Motor
-.09
.01
<-.01
-.02
-.01
-.04
.03
-.05
.01
-.05
-.04
.01
-.02
-.03
-.02
-.05
-.03
-.02
-.01
-.02
.02
-.03

Table B.10 Cont.
Premorbid
Est.

Attn/WM

PS

Verbal
Reasoning

Visual
Reasoning

Verbal
Memory

Visual
Memory

EF

Dom
Motor

NonDom
Motor
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Calcium & Bone
.05
.03
.09*
.08
.01
.03
.01
-.01
-.03
-.03
Mineralization
Immunomodulators
.06
.05
.09*
.09
.01
.03
.01
-.01
-.02
-.03
Movement Disorder
.06
.04
.07
.08
<-.01
.04
<.01
-.02
-.03
-.04
Antiglaucoma
.06
.05
.08
.09
.01
.04
.01
-.01
-.03
-.04
Dermatological
.06
.04
.08
.09
.01
.03
.01
-.01
-.03
-.04
Antimalarial
.06
.04
.08
.09
.01
.04
.01
-.01
-.04
-.04
Cytotoxic
.06
.04
.08
.08
<-.01
.04
.01
-.02
-.03
-.04
Weight Loss
.06
.04
.08
.08
.01
.03
.01
-.01
-.03
-.04
Antigout
.06
.05
.08
.08
.01
.04
.01
-.01
-.03
-.04
Note: N = 497. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF = Executive Functioning. Dom
Motor = Dominant Motor Functioning. Non-Dom Motor = Non-Dominant Motor Functioning.
* < .05. **<.01. ***<.001.
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Table B.11
Bivariate Correlations between Demographic Variables and Cognitive Domains
Premorbid
Verbal
Visual
Verbal
Visual
Dom Non-Dom
Attn/WM
PS
EF
Est.
Reasoning Reasoning Memory Memory
Motor
Motor
Age
.14**
.14**
.18***
.15***
.09*
.01
.08
.08
.02
-.09*
Gender
.03
.12**
-.08
.03
.08
.02
.07
.05
-.03
-.04
Ethnicity
-.05
-.07
.01
-.02
-.02
-.01
-.02
<.01
.09
.07
Neuropsychologist
.34***
-.15***
-.19***
.24***
.11**
.12**
-.03
<-.01 -.16***
-.07
Note: N = 497. Est. = Estimate. Attn/WM = Attention/Working Memory. PS = Processing Speed. EF = Executive Functioning. Dom
Motor = Dominant Motor Functioning. NonDom Motor = Non-Dominant Motor Functioning.
* < .05. **<.01. ***<.001.

Appendix C – ANCOVA Tables
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Table C.1
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anticholinergic Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
43.18
5.88
45.20
5.16
Anticholinergics
0.45 < .01
(n = 77)
No
OTBM
44.48
6.18
44.22
5.79
Polypharmacy
0.25 < .01
(n = 246)
No Meds
43.86
4.66 Anticholinergic x Polypharm 3.65 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
anxiolytics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of internalizing
disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive disorders,
moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.2
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anticholinergic Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
10.04
2.96
9.38
2.39
Anticholinergics
0.65 < .01
(n = 75)
No
IIV
9.34
2.22
9.86
2.42
Polypharmacy
0.88
.01
(n = 240)
No Meds
10.03
2.73
Anticholinergic x Polypharm
3.82 < .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of anxiolytics,
AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of internalizing disorders,
substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive disorders, moderate to
severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.3
Interaction and Main Effects of 3x3 ANCOVA of Effects of Antidepressant Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
44.21
5.64
45.02
5.64
Antidepressant
0.80 < .01
(n = 180)
No
OTBM
43.00
8.07
43.81
5.65
Polypharmacy
0.04 < .01
(n = 143)
No Meds
43.86
4.66 Antidepressant x Polypharm 0.09 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.4
Interaction and Main Effects of 3x3 ANCOVA of Effects of Antidepressant Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.62
2.69
9.70
2.39
Antidepressant
0.18
< .01
(n = 175)
No
IIV
9.56
1.68
9.82
2.46
Polypharmacy
5.29
0.01
(n = 140)
No Meds
10.03
2.73
Antidepressant x Polypharm
<0.01
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of, anxiolytics,
antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and diagnoses of
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.5
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anxiolytic Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
43.05
5.39
44.48
6.78
Anxiolytics
1.99 < .01
(n = 55)
No
OTBM
44.88
6.57
44.43
5.52
Polypharmacy
0.03 < .01
(n = 268)
No Meds
43.86
4.66
Anxiolytics x Polypharm
6.48 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.6
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anxiolytic Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
10.12
2.37
9.62
2.71
Anxiolytic
1.79 < .01
(n = 54)
No
IIV
9.10
2.62
9.78
2.38
Polypharmacy
4.47 < .01
(n = 261)
No Meds
10.03
2.73
Anxiolytic x Polypharm
4.76
.01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, antipsychotics, analgesics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.7
Interaction and Main Effects of 3x3 ANCOVA of Effects of Analgesic Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
42.41
6.65
44.97
7.61
Analgesic
3.97
< .01
(n = 53)
No
OTBM
45.46
5.14
44.37
5.39
Polypharmacy
< 0.01 < .01
(n = 270)
No Meds
43.86
4.66
Analgesic x Polypharm
2.00
< .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.8
Interaction and Main Effects of 3x3 ANCOVA of Effects of Analgesic Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
10.40
2.68
9.95
2.79
Analgesic
11.29
.02**
(n = 51)
No
IIV
8.89
2.19
9.73
2.38
Polypharmacy
4.65
.01
(n = 264)
No Meds
10.03
2.73
Analgesic x Polypharm
2.89
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.9
Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Triptans and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
12.08
3.03
12.70
3.96
Triptans
12.91
.03**
(n = 6)
No
IIV
9.36
2.37
9.74
2.40
Polypharmacy
2.79
< .01
(n = 309)
No Meds
10.03
2.73
Triptans x Polypharm
0.44
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.10
Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Opioid Analgesics and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.65
2.07
9.55
2.23
Opioids
0.10
< .01
(n = 27)
No
IIV
9.60
2.68
9.77
2.43
Polypharmacy
1.87
< .01
(n = 288)
No Meds
10.03
2.73
Opioids x Polypharm
0.07
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.11
Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Opioid-Combination Analgesics and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
10.75
1.97
10.44
3.99
Opioid-Combinations
2.13
< .01
(n = 14)
No
IIV
9.43
2.57
9.74
2.36
Polypharmacy
1.70
< .01
(n = 301)
No Meds
10.03
2.73
Opioid Combos x Polypharm
<0.01
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.12
Interaction and Main Effects of 3x3 ANCOVA of Effects of Using Non-Opioid Analgesics and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
10.90
3.93
8.76
1.22
Non-Opioids
0.20
< .01
(n = 10)
No
IIV
9.44
2.31
9.78
2.43
Polypharmacy
0.01 < .01
(n = 305)
No Meds
10.03
2.73
Non-Opioids x Polypharm
1.48 < .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, AEDs, cardiovascular medications, anti-inflammatory medications, and hormones; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.005. **p<.001.
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Table C.13
Interaction and Main Effects of 3x3 ANCOVA of Effects of Antiepileptic Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
45.62
4.95
42.43
5.87
Antiepileptic
3.41 < .01
(n = 76)
No
OTBM
43.13
6.46
44.99
5.50
Polypharmacy
0.88 < .01
(n = 247)
No Meds
43.86
4.66
Antiepileptic x Polypharm
4.51 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, cardiovascular medications, anti-inflammatory medications, and hormones;
and diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.14
Interaction and Main Effects of 3x3 ANCOVA of Effects of Antiepileptic Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.13
1.96
10.47
2.41
Antiepileptic
1.83
< .01
(n = 74)
No
IIV
9.86
2.76
9.56
2.39
Polypharmacy
9.56
0.02*
(n = 241)
No Meds
10.03
2.73
Antiepileptic x Polypharm
4.79
.01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, cardiovascular medications, anti-inflammatory medications, and hormones;
and diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.15
Interaction and Main Effects of 3x3 ANCOVA of Effects of Cardiovascular Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
43.08
6.43
43.69
5.61
Cardiovascular
2.48 < .01
(n = 72)
No
OTBM
45.00
5.56
44.59
5.68
Polypharmacy
0.13 < .01
(n = 251)
No Meds
43.86
4.66 Cardiovascular x Polypharm 0.53 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, anti-inflammatory medications, and hormones; and diagnoses of
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.16
Interaction and Main Effects of 3x3 ANCOVA of Effects of Cardiovascular Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.86
2.97
10.04
2.30
Cardiovascular
0.01
< .01
(n = 69)
No
IIV
9.34
1.95
9.70
2.44
Polypharmacy
6.76
0.01
(n = 246)
No Meds
10.03
2.73
Cardiovascular x Polypharm
0.23
< .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, anti-inflammatory medications, and hormones; and diagnoses of
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.17
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
44.24
6.06
45.60
5.41
Anti-Inflammatory
3.19 < .01
(n = 63)
No
OTBM
43.80
6.14
44.23
5.70
Polypharmacy
0.18 < .01
(n = 260)
No Meds
Anti-Inflammatory x
43.86
4.66
0.03 < .01
(n = 65)
Polypharm
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and hormones; and diagnoses of
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.
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Table C.18
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.43
2.48
9.15
2.23
Anti-Inflammatory
0.34 < .01
(n = 61)
No
IIV
9.75
2.59
9.87
2.44
Polypharmacy
5.77
0.01
(n = 254)
No Meds
10.03
2.73 Anti-Inflammatory x Polypharm 0.29 < .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and hormones; and diagnoses of
internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders, neurocognitive
disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as covariates.
*p<.006. **p<.001.

212

Table C.19
Interaction and Main Effects of 3x3 ANCOVA of Effects of Hormone Medication Use and Polypharmacy on OTBM
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 46)
(n = 277)
(n = 65)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
44.88
5.12
45.09
5.53
Hormone
0.09 < .01
(n = 61)
No
OTBM
43.53
6.51
44.31
5.70
Polypharmacy
0.26 < .01
(n = 262)
No Meds
43.86
4.66
Hormone x Polypharm
0.23 < .01
(n = 65)
Note. N = 497. OTBM = Overall Test Battery Mean. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and anti-inflammatory medications; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.
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Table C.20
Interaction and Main Effects of 3x3 ANCOVA of Effects of Anti-Inflammatory Medication Use and Polypharmacy on IIV
Polypharmacy
Polypharmacy
No Polypharmacy
No Meds
(n = 44)
(n = 271)
(n = 63)
M
SD
M
SD
M
SD
Factors
F
η2
Yes
9.60
3.15
9.22
2.86
Anti-Inflammatory
1.13 < .01
(n = 60)
No
IIV
9.61
2.15
9.86
2.43
Polypharmacy
6.76
0.01
(n = 255)
No Meds
10.03
2.73 Anti-Inflammatory x Polypharm 0.18 < .01
(n = 63)
Note. N = 497. IIV = Intra-Individual Variability. Estimated premorbid functioning, age, location of evaluation; use of
antidepressants, anxiolytics, antipsychotics, analgesics, AEDs, cardiovascular medications, and anti-inflammatory medications; and
diagnoses of internalizing disorders, substance abuse, SMI, learning disorders, neurodevelopmental disorders, seizure disorders,
neurocognitive disorders, moderate to severe TBI, cardiovascular diagnoses, respiratory disorders, and pain were included as
covariates.
*p<.006. **p<.001.

BIOGRAPHICAL SKETCH

BIOGRAPHICAL SKETCH
Name of Author:

Sarah E. Taylor

Graduate and Undergraduate Schools Attended:
University of South Alabama Mobile, Alabama
James Madison University Harrisonburg, Virginia
Degrees Awarded:
Doctor of Philosophy in Clinical Psychology Expected December 2021, Mobile,
Alabama
Master of Science in Psychology 2019, Mobile, Alabama
Bachelor of Science in Psychology and a minor in Biology 2013, Harrisonburg,
Virginia

215

